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Abstract 
Prostate cancer is highly prevalent in Australia, with 17 050 cases in 2014. A common 
treatment for this disease is androgen deprivation therapy (ADT), or castration, which has 
significant side-effects hence increasing morbidity in this patient population. These side-
effects include gynecomastia, erectile dysfunction, fatigue, metabolic syndrome, and 
severe bone loss. The latter is well documented with 1.5% to 4.0% of bone loss within 12 
months of treatment initiation. This leads to osteoporosis (porous bones), which increases 
the risks of fractures. Some clinical guidelines recommend bone health monitoring and 
interventions when ADT is prescribed to the prostate cancer patient, but evidence 
suggests that these practices are not well implemented by the treating team. For example, 
lifestyle factors such as increasing calcium and vitamin D intake are not routinely 
recommended to men with prostate cancer on ADT as part of standard practice. There is 
also little evidence on the bone health of men with prostate cancer before castration, which 
demonstrates the lack of research attention given to osteoporosis in men and preventative 
strategies to minimise adverse events later on the prostate cancer continuum. This 
research program therefore aims to increase the understanding of bone health in men on 
the prostate cancer continuum, regardless of treatment. 
 
The findings from three studies demonstrate the burden of poor bone health and lack of 
interventions in men with prostate cancer and prostate cancer survivors. First, the 
evidence on the prevalence of osteoporosis in men with prostate cancer was summarised 
in two meta-analyses, where it was found that (i) men with prostate cancer experience 
poor bone health before treatment with ADT, with 4% to 38% having osteoporosis, and (ii) 
the prevalence of osteoporosis in men with prostate cancer on ADT varies between 9% 
and 53% with this variation partially explained by treatment duration, disease stage, 
ethnicity, and site of osteoporosis measurement. Secondly, data from the Dubbo 
Osteoporosis Epidemiology Study were analysed to estimate the incidence of poor bone 
health and fractures in men on the prostate cancer continuum. The incidence of 
osteoporosis after diagnosis of prostatic disease was 20.8% in men with benign prostatic 
hyperplasia, 23.1% in hormone-naïve men with prostate cancer, and 44.4% in men with 
prostate cancer on ADT. Post-diagnostic fractures were present in 18.4% of men with 
benign prostatic hyperplasia, 36.3% of hormone-naïve men with prostate cancer, and 
48.0% of men with prostate cancer on ADT. In light of the significant osteoporosis problem 
in men with prostate cancer, a pilot cross-sectional study was conducted to identify (i) the 
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bone health related health behaviours that this population engage in, and (ii) the psycho-
behavioural and psycho-social factors that drive such health behaviours. Dietary 
behaviours of a small group of men with prostate cancer and survivors were analysed and 
described in detail using an innovative approach. This dietary analysis method involved 
grouping food intake into specific food categories, which were based on the food 
categories reported in the National Nutrition and Physical Activity Survey. The results from 
this analysis were also compared with the food intake of Australian men from the 
Australian health Survey to identify typical or atypical dietary behaviours. It was found that 
men with prostate cancer generally have healthier eating behaviours than an age-matched 
sample of men from the Australian Health Survey. Men with prostate cancer did not meet 
their calcium requirements (average daily intake including supplements was 870 mg 
versus Recommended Daily Intake 1000 - 1200 mg/day) as they did not consume enough 
dairy products, revealing a problem since over 70% of the study participants had poor 
bone health. The next stage of this study involved measuring the extent of osteoporosis 
knowledge, perceived health beliefs, and self-efficacy with bone healthy behaviours in men 
with prostate cancer and survivors. Three questionnaires were used to measure these 
psycho-behavioural and psycho-social factors. Participants had inadequate osteoporosis 
knowledge with a mean score of 43.3% (SD 18%) on the Facts on Osteoporosis Quiz 
(adequate knowledge defined as a score exceeding 80%). Participants scored low on the 
subscale measuring barriers to exercise (median = 11; IQR 6.5), indicating minimal 
barriers to exercise participation, and the subscale measuring the benefits of exercise 
scored the highest (median = 24; IQR 3.5) compared with the other subscales. Men with 
prostate cancer and survivors were highly confident in their exercise and calcium self-
efficacy (83.0%, IQR 24.0% and 85.7%, IQR 27.0% respectively). Unfortunately this 
confidence did not transfer to specific dietary behaviours as they did not meet their calcium 
or dairy intake requirements. 
 
This thesis supports the extent of the osteoporosis problem in men with prostate cancer 
and outlines the gap in clinical practice, which translates into poor bone health 
management strategies among prostate cancer patients. More studies are therefore 
warranted, and the interventions need to (i) be based on health behaviour theoretical 
frameworks, (ii) use a multidisciplinary approach, (iii) include men early on the prostate 
cancer continuum as well as survivors, (iv) use tools targeted at a male audience, and (v) 
provide practical information such as specific strategies on how to increase the calcium 
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content of a meal. Since nutrition research needs to grow in this area, Dietitians will benefit 
from collaborating with exercise physiologists, who seem more active in this research 
area, in investigating a nutrition-exercise intervention for osteoporosis management in men 
with prostate cancer and survivors. There is a need to update the clinical guidelines for the 
clinical treatment of prostate cancer, in order to incorporate recommendations for bone 
health management and the importance of a multidisciplinary approach in doing so.
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CHAPTER 1 BACKGROUND AND REVIEW OF THE 
LITERATURE 
1.1 Introduction 
Prostate cancer is one of the most frequently diagnosed cancers worldwide with Australia 
and New Zealand recording the highest incidence. Locally, prostate cancer is the most 
prevalent cancer (17 050 cases in 2014), apart from non-melanoma skin cancer, and is the 
second leading cause of male cancer deaths (3 390 deaths in 2014) (1). This thesis 
focuses on the bone health of men with prostate cancer and prostate cancer survivors. 
This includes the prevalence and incidence of poor bone health in men on the prostate 
cancer/health continuum, as well as health behaviours and drivers of these behaviours 
(self-efficacy, health beliefs, and knowledge). 
 
The interplay between prostate cancer and bone health will be presented in a 
comprehensive review of the literature in the form of two meta-analyses. This is followed 
by a review of the clinical guidelines for prostate cancer, to identify the current evidence-
based recommendations on the bone health management in this patient group. CHAPTER 
2 presents the findings from the secondary analysis of one of the biggest longitudinal 
Australian study on osteoporosis (from the Dubbo Osteoporosis Epidemiology Study 
[DOES] database). This chapter presents the state of bone health in men with prostate 
cancer and benign prostatic hyperplasia (BPH). The results from the cross-sectional study 
presented in CHAPTER 3 address the role of health behaviours and their psychological 
determinants within the context of bone health in the prostate cancer patient. CHAPTER 4 
presents a comprehensive discussion and consideration of implications for future 
research. Figure 1.1 depicts the framework used to guide reporting throughout this thesis. 
Relevant parts of this diagram will be highlighted at the beginning of chapters/sections 
addressing such parts. The introduction of this thesis will address each part separately 
(implications of prostate cancer for bone health, osteoporosis, followed by health 
behaviours and their psychological determinants). The conclusion of this thesis presented 
in CHAPTER 4 integrates the discussion of how the different parts of the framework in 
Figure 1.1 are interrelated. 
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Figure 1.1 Summary of the relationship between prostate cancer, poor bone health, 
and health behaviours and their determinants.1 
1
Notes: ADT, androgen deprivation therapy; dotted line represent a positive (plus sign in grey) weak 
association supported by some evidence. 
 
The prostate cancer continuum is mentioned throughout this thesis and refers to different 
stages of prostate cancer and prostate health, all of which have different co-morbidities 
associated with treatment or lack thereof: 
 
 BPH is at the beginning of this continuum even though it does not lead to prostate 
cancer (2). The presenting symptoms of this benign prostatic disease often drive 
patients to seek medical attention, which leads to testing (including digital rectal 
examination and prostate-specific antigen [PSA] screening) to rule out prostate 
Poor Bone Health 
Determinants of health behaviours 
 Knowledge 
 Health Beliefs 
 Self-efficacy 
Health Behaviours 
(risk factors and prevention) 
 Calcium and dairy 
products intake 
 Exercise and physical 
activity 
 Smoking 
 Alcohol intake… 
ADT 
Ageing 
Treatments 
Osteoblastic 
metastases 
Prostate 
Cancer 
Others 
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cancer. Therefore it is a clinically relevant disease on the prostate cancer 
continuum that shares commonalities with prostate cancer (elevated PSA) (2) and 
has been used as a comparative group in many prostate cancer research studies. 
Men with BPH are likely to have age-related co-morbidities but none associated 
with prostate cancer treatment. 
 
 Prostate cancer not treated with androgen deprivation therapy (ADT) is next on the 
continuum based on the assumption that the disease is not advanced enough to 
require androgen ablation. Men with castrate resistant prostate cancer previously 
treated with (and no longer on) ADT are not included here or on this continuum. 
Hormone-naïve men with prostate cancer are likely to have cancer-related and/or 
cancer treatment-related adverse effects, as well as similar age-related co-
morbidities as men with BPH. 
 
 Prostate cancer treated with ADT is the third point on this continuum as this group 
needs to meet worse disease parameters to qualify for this treatment (3). Men on 
this point of the continuum are likely to have (i) ADT-related adverse effects, (ii) 
similar age-related co-morbidities as men with BPH, and (iii) co-morbidities 
experienced by men with prostate cancer not on ADT. The iatrogenic effects of ADT 
are significant and are discussed in section 1.2. 
 
 At the end of this continuum are prostate cancer survivors, who are free from 
prostate cancer and have undergone different types of treatment, including ADT. 
The men in this group may present with different co-morbidities, which can be due 
to different treatment modalities, but for the purpose of this thesis they have been 
grouped because of recruitment challenges. 
 
1.2 Implications of prostate cancer for bone health 
A feature of prostate cancer is its propensity to metastasise to bone as demonstrated by 
the identification of skeletal involvement at autopsy of up to 90% of prostate cancer 
patients with metastases (4, 5). Bone provides an ideal environment (a niche) for prostate 
cancer cells as demonstrated by the “seed-and-soil” theory by Stephan Paget (6). Prostate 
cancer cells generally niche to the axial bone and long bones where there is an increased 
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marrow cellularity as well as increased active bone remodelling (discussed in section 
1.3.1) (7, 8). Bone resorption and formation are both increased in prostate cancer 
metastasis as demonstrated by elevation of their respective biomarkers (9) but as the 
disease progresses bone formation predominates (10). This is indicated by an increase in 
osteoid surface area, osteoid volume, and bone mineral apposition rate (11). Moreover, 
one of the receptors involved in normal osteoclastogenesis (formation of bone resorbing 
cells), osteoprotegerin, has been found to be elevated among prostate cancer patients 
(12-15), thus indicating a disruption in bone homeostasis where osteoclastic bone 
resorption is reduced. 
 
The skeletal metastases are characteristically ‘blastic’ (osteo-dense), with increased local 
bone density demonstrable on imaging and increased number of osteoblasts (bone-
forming cells) adjacent to prostate cancer cells (16, 17). Despite the locally increased 
osteoblastic activity leading to increased bone mass at the metastatic site, the associated 
bone architecture is abnormal, with altered volumetric and strength characteristics (18). 
This complication adds to the morbidity and mortality of prostate cancer whereby 54% of 
patients with metastases may experience skeletal related events including pathological 
fractures, bone pain, and spinal cord compression (19). 
 
Treatment options for prostate cancer vary depending on the stage and grade of the 
disease. Active surveillance involves no pharmacological or surgical intervention, and is 
recommended for men with low risk prostate cancer with a life expectancy of less than 20 
years (3). Active surveillance involves closely monitoring the disease progression through 
6-monthly PSA testing, yearly digital rectal examination, and repeat prostate biopsy if 
needed (3). This treatment, or perceived absence of treatment, is also associated with 
uncertainty in men with prostate cancer (20), despite active surveillance being safe (21, 
22). During that time some men feel pressured, by themselves or their families, to initiate a 
treatment to combat the cancer (23). 
 
If the disease progresses then other forms of treatment are initiated. Radical 
prostatectomy is recommended for men with localised disease and involves the removal of 
the prostate gland (3). Another treatment modality for localised or metastatic disease is 
radiation therapy, which is used alone or with ADT (for patients with high risk prostate 
cancer) (3). ADT is unique to this disease, and is commonly used to manage metastatic 
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prostate cancer (3). Because of the iatrogenic effects of ADT, this treatment needs to be 
weighed against the potential benefits, short-term and long-term side effects, and the 
impact on the patient’s quality of life (3). According to a survey of the Pharmaceutical 
Benefits Schedule in Australia (conducted for the purpose of this thesis), about 43 350 
claims for ADT were made in 2013-14 (see Figure 1.2), which is a considerable increase 
since 2003 (24). It is however important to note that patients may claim more than once in 
a year as they may have received multiple prescriptions of ADT during that time. (see 
Appendix I for detailed use of ADT in Australia). 
 
 
Figure 1.2 Summary of the Pharmaceutical Benefits Schedule statistics on the 
number of androgen deprivation therapy (Goserelin, Leuprolide Bicalutamide, and 
Degarelix) claims made since 2003. 
Sources from (24). 
 
ADT can be surgical, via bilateral orchiectomy, or pharmacological ((25); see Table 1.1). 
The former type of castration involves removal of the testes hence inhibiting the production 
of testosterone and oestradiol from the testicles (26). The other type of castration results in 
reduced production of testosterone or competitively binding with the androgen receptor 
inhibiting its activation (27). Under normal conditions oestrogen is produced from 
0
5000
10000
15000
20000
25000
30000
35000
40000
45000
50000
N
u
m
b
e
r 
o
f 
P
h
a
rm
a
c
e
u
ti
c
a
l 
B
e
n
e
fi
ts
 S
c
h
e
m
e
 
c
la
im
s
 
Financial year 
26 
 
 
aromatization of androgens (28); therefore during treatment with ADT, circulating 
oestrogen levels are low (29). Deficiencies in androgens and oestrogen are responsible for 
the side effects of ADT (30). Intermittent-ADT offers similar prostate cancer management 
outcomes as continuous ADT while impacting less on quality of life (31). This cyclical 
administration of ADT is based on PSA levels, where ADT is stopped when PSA levels are 
low and re-started when PSA rises to a predetermined level (no current consensus on the 
levels of PSA) (31). 
 
Table 1.1 Common drugs used in pharmacological androgen deprivation therapy. 
Drug class Drugs Mechanism of action Side effects 
Gonadotropin-
releasing hormone 
(GnRH) agonists 
and antagonists 
Leuprolide 
Goserelin 
Abarelix® 
Luteinizing hormone receptor 
down-regulation to 
decrease luteinizing 
hormone, FSH and 
testosterone 
Hot flashes 
Reduced lean bone 
mass 
Anaemia 
Osteoporosis 
Cardiovascular 
events 
Adrenal ablating 
drugs 
Ketoconazole   
Androgen receptor 
antagonists 
Flutamide 
Bicalutamide 
Nilutamide 
Binds to androgen receptor 
Hot flashes 
Reduced lean body 
mass and energy 
Anaemia 
Osteoporosis 
Cardiovascular 
events 
5-α-reductase 
inhibitor 
Finasteride 
Decreases conversion of 
testosterone to DHT 
 
FSH: follicle-stimulating hormone, DHT: dihydrotestosterone; Sourced from (27). 
 
ADT leads to significant morbidity such as leading to Metabolic Syndrome (32), sexual 
dysfunction (33), gynecomastia, depression (34), and significant bone loss (35, 36)  and 
muscle loss (37). The bone-specific side effects of ADT are mediated through deficiency of 
both androgens and oestrogen (38); where deficiency of the former reduces bone 
formation, and deficiency of the latter increases bone resorption (38). As a result net bone 
loss predominates during ADT, resulting in osteoporosis and low bone mass (39). Given 
the large economic burden of osteoporosis (40) and given the increasing number of men 
being treated with ADT, there is a need for more research in the prevention and 
management of osteoporosis in men with prostate cancer. There are many studies 
investigating and reporting on the effects of ADT on metabolic health, mental health, 
sexual health, and bone health. This thesis focusses on the latter, but also includes men 
not on ADT as they have not been as extensively studied.   
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1.3 Osteoporosis and bone biology 
Osteoporosis is a common bone condition that affects older people, including both men 
and women (41). This disease is characterised by porous weak bones that break easily, 
and often goes undiagnosed due to the lack of symptoms (42, 43). Osteopenia, or low 
bone mass, is also a state of reduced bone density but not as severe as in osteoporosis 
((44); see Table 1.2). Peak bone mass is generally attained in early adulthood, through 
bone mineral deposition in the skeleton since childhood (45). Bone maintenance is the 
next phase, where bone formation and bone resorption are in equilibrium. Menopause and 
old age, among other risk factors, are responsible for a disruption in this balance leading to 
net bone loss (46). Osteoporosis is a result of long term bone loss and its underlying 
mechanism has been explained in section 1.3.1. 
 
Currently osteoporosis and osteopenia affect 4.72 million of Australians over 50 years of 
age, of which 22% have osteoporosis and the rest have osteopenia (40). This is a 
significant problem, as the number of Australian affected by poor bone health is estimated 
to increase to 6.2 million by 2022 (40). In 2012, it was estimated that 3.2% of men aged 50 
years to 69 years and 12.9% of men aged over the age of 70 years were diagnosed with 
osteoporosis (40). The major clinical outcomes of poor bone health (osteoporosis and 
osteopenia) are osteoporotic fractures (47), which affected 140 822 Australians in 2012 
(40). Osteoporosis and fractures are often associated with women but also affects men, 
with 30% of osteoporotic fractures, and associated costs, occurring in the latter group (40). 
A report by Osteoporosis Australia (40) found that the total direct and indirect cost of poor 
bone health and associated fractures was $2.75 billion in 2012 and will cost over $33.6 
billion over the next 10 years. 
 
Osteoporosis is diagnosed from bone mineral density (BMD), which is measured using 
dual X-ray absorptiometry (DXA) and compared with the average BMD of young males 
(44). This is expressed as the T-score, which is the number of standard deviations above 
or below the mean BMD of young adult males (44). Table 1.2 outlines the classification for 
the diagnosis of osteoporosis. The World Health Organization (WHO) recommends 
measuring BMD at the femoral neck (44), forearm, or lumbar spine when diagnosing 
osteoporosis (46). The latter region of interest (ROI) is a common site for osteoarthritis in 
men, which leads to the formation of osteophytes (48). These bone formations are dense 
28 
 
 
in nature, resulting in erroneously elevated BMD that is not representative of overall bone 
health; hence it may not be suitable to assess overall bone health in men (48). 
 
Table 1.2 WHO densitometric classification for the diagnosis of osteoporosis. 
Cut off value Bone health status 
T-score ≥ -1 Normal bone mass 
-1 <T-score < -2.5 
Low bone mass (formerly known 
as osteopenia) 
T-score ≥ -2.5 Osteoporosis 
Sourced from (47). 
 
Osteoporosis and low bone mass (osteopenia) increase the risks of fragility fractures, but 
so do other risk factors (49). This is why low BMD alone cannot be used when assessing 
fracture risk. Fracture algorithms or risk assessment tools, more specifically the FRAX® 
algorithm has been validated and endorsed by the WHO for fracture risk assessment (50). 
Such tool takes into account BMD, and other risk factors, for example, previous fractures, 
body mass index (BMI), family history of fractures, smoking status, and glucocorticoid use 
(51). The FRAX® algorithm calculates the 10-year probability of major fractures (including 
hip fractures and other fractures) and hip fractures only (52). This tool has been used to 
identify patients needing pharmacological interventions for osteoporosis (53). For men 
over the age of 60, pharmacological intervention for osteoporosis is recommended for a 
10-year probability of major fractures exceeding 20% threshold (54) (see Appendix II for 
an example of FRAX® algorithm) 
 
 Bone biology explained 1.3.1
In order to understand the interplay between bone health and disease, such as prostate 
cancer, it is important to understand bone biology. The integrity of bones is maintained 
through the process of bone remodelling. It involves the coupling of bone formation and 
resorption. These respective functions are carried out by osteoblasts, the bone forming 
cells; and osteoclasts, the bone resorbing cells (55). In adulthood bone remodelling is 
essential to repair micro-damage to the skeleton and for calcium homeostasis (56). Figure 
1.3 summarises the main processes involved in bone remodelling. 
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Figure 1.3 Bone remodelling cycle and the interplay between receptor activator of 
nuclear factor- B ligand (RANKL) and osteoprotegerin (OPG). 
Osteoblasts express RANKL, which binds to its receptor (RANK) on the surface of osteoclasts precursors. 
These precursors then fuse to form the multinucleated osteoclasts. This binding also triggers differentiation, 
activation, and survival of osteoclasts. The binding of OPG to RANKL, blocks the differentiation and 
activation of new osteoclasts. (30) adapted from (38). 
 
During this process osteoclasts, which are multinucleated cells formed through fusion of 
mononuclear precursors, dissolve bone mineral and enzymatically degrade the 
extracellular matrix to form bone resorbing pits (55). These pits are then lined with 
osteoblasts that produce collagen and other proteins to create a scaffold called the 
osteoid. This flexible surface is then mineralised, through deposition of hydroxyapatite, 
which results in rigid bone (55). Some osteoblasts become embedded in the bone matrix 
(55). The functions of osteoblasts and osteoclasts are regulated by many hormones, such 
as parathyroid hormone, androgens, vitamin D, and oestrogen (47). The regulation of bone 
remodelling by androgens and oestrogen is summarised in Figure 1.4. 
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Figure 1.4 Hormonal regulation of bone remodelling. 
Androgens promote bone formation while estrogen inhibits bone formation. During androgen or estrogen 
deficiency (e.g., during treatment with ADT or menopause) bone resorption predominates over bone 
formation, resulting in net bone loss. (30) adapted from (28). 
 
 Health behaviours and risk factors for osteoporosis 1.3.2
According to National Library of Medicine controlled vocabulary for PubMed citations 
indexing (MeSH terms), health behaviours are: 
“behaviours expressed by individuals to protect, maintain, or promote their health 
status. For example, proper diet, and appropriate exercise are activities perceived 
to influence health status. Lifestyle is closely associated with health behaviour and 
factors influencing lifestyle are socioeconomic, educational, and cultural” (57). 
 
There are many lifestyle factors and health behaviours associated with osteoporosis and 
are presented in Table 1.3. The role of some of these health behaviours are discussed 
here. 
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Table 1.3 Risk factors for osteoporosis. 
Modifiable risk factors Non-modifiable risk factors 
Poor calcium intake Age 
Vitamin D deficiency Being female 
Lack of weight-bearing exercise Menopause 
Low body weight Hypogonadism
1
 
Current cigarette smoking Genetic predisposition 
Excessive alcohol intake (≥ 3 
standard drinks/day) 
Diseases such as 
hyperparathyroidism, 
inflammatory bowel disease 
Long term use of corticosteroids History of diabetes 
Sourced from (58) 
1
Androgen deficiency or suppression to castrate levels are referred to as hypogonadism. 
 
Calcium is an essential bone nutrient as it is the major constituent of bone mineral (56). 
Vitamin D is needed for the absorption of calcium in the small intestines, for calcium 
homeostasis, and for bone remodelling (59). A constant supply of this mineral and vitamin 
are therefore needed for bone growth and remodelling, among other functions in the body. 
In childhood and early adulthood calcium in needed to optimise peak bone mass (60, 61) 
and in the remaining years this mineral is needed for bone maintenance rather than 
building new bone (62). Dairy products are an important source of calcium and contribute 
to bone health as evidenced by higher hip BMD observed in men with higher intakes of 
dairy products (63). Low levels of calcium intake are associated with increased risk of 
osteoporosis in men (64). A similar effect has been observed with calcium supplements or 
calcium with vitamin D supplements (800 IU) with a 12% reduction in fracture risk and 
reduced rate of bone loss (65). While this evidence supports the positive role of calcium on 
bone health, there are also studies reporting on the lack of effect of calcium on fracture 
risk (66). A meta-analysis by Bischoff-Ferrari, Dawson-Hugheset al. (66) reports that 
calcium (supplemental and dietary) was not associated with risk of fractures in prospective 
studies and randomised controlled trials. These authors attribute this apparent lack of 
effect to the flaws in calcium intake assessment tools, notably the food frequency 
questionnaire which poorly correlates with the gold standard in dietary data collection tools 
(r = 0.4) (67). The Women’s Health Initiative study sheds more light on the discrepancy in 
the fracture risk reduction of calcium and vitamin D. This study reports on the reduced 
risks of hip fracture following long-term supplementation with calcium and vitamin D (HR 
0.62), and a further risk reduction (HR 0.24) among women who were compliant in taking 
the supplements (68). The effect of greater fracture risk reduction in studies with higher 
compliance was also seen in the meta-analysis by Tang, Eslicket al. (65).  
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Exercise and physical activity are important lifestyle factors in bone health, with regular 
exercise recognised to maximise peak bone mass in childhood and reduce bone loss in 
adulthood (69). While more research is needed on the type of exercise and the long-term 
effects on bone health and fractures, the current evidence suggests that multi-modal 
exercise programs reduce the risks of osteoporosis and fractures (69, 70). It is also noted 
that the relationship between dietary calcium intake or physical activity and bone health is 
not linear and should not be considered in isolation from other environmental factors (64). 
 
Current and/or past smoking increases the risks of low bone mass and is predictive of 
bone loss at the hips (71, 72). BMI and body weight are positively associated with hip BMD 
(72), while weight loss of >1% of body weight per year increases the risks of lower BMD 
(73). A study by Hannan, Felson et al. (74) found that weight gain slowed down bone loss, 
therefore indicating the loading effect that may be responsible for the positive association 
between body weight and BMD. 
 
1.4 Significance of this thesis 
There is ample evidence supporting poor bone health in men with prostate cancer, 
especially men on ADT, but less is known about the osteoporosis-related health 
behaviours that these men partake in. Before undertaking lifestyle interventions it is 
important to gather information about current health behaviours and practices, and 
psycho-behavioural and psycho–social factors driving such behaviours. This information 
can be used to underpin and tailor intervention programs targeted at managing poor bone 
health in specific groups. As such, the findings from this research program describe the 
determinants of health behaviours and current health behaviours (e.g. dietary), which are 
crucial to bone health, in men with prostate cancer and survivors. 
 
1.5 Purpose of this thesis 
This research program consists of two meta-analyses, a review of the prostate cancer 
clinical guidelines (with a focus on bone health management recommendations), one study 
reporting on the secondary analysis of a large longitudinal dataset (DOES), and a cross-
sectional study. The purpose of these studies is: 
1. To explore the literature on the prevalence of osteoporosis and/or low bone mass 
(osteopenia) in men with prostate cancer, whether treated with ADT or not on ADT. 
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2. To explore bone health management recommendations for men with prostate 
cancer. The research questions addressed are: 
a. What are the bone-health management recommendations made in evidence-
based guidelines for the management of prostate cancer? 
b. Do the recommendations include lifestyle management strategies, such as 
increasing dietary calcium and exercise/physical activity? 
c. If such recommendations are made, how detailed and comprehensive are 
they? 
3. To determine the incidence of osteoporosis, osteopenia, and post-diagnostic 
fractures in men with BPH, men with prostate cancer not on ADT, and men with 
prostate cancer on ADT. The research questions addressed are: 
a. What is the post-diagnostic incidence of osteoporosis and/or low bone mass 
in men with BPH, men with prostate cancer on ADT, and hormone-naïve 
men with prostate cancer? 
b. What is the rate of post-diagnostic fractures in the population mentioned 
above? 
4. To identify and describe the health behaviours and determinants of such behaviours 
in men with prostate cancer and survivors. The research questions addressed are: 
a. What is the extent of osteoporosis knowledge, osteoporosis-related health 
beliefs, and self-efficacy in men with prostate cancer and survivors? 
b. What are the health behaviours, notably dietary behaviours, that men with 
prostate cancer and survivors participate in? And are they adequate for 
optimum bone health? 
c. What is the association between determinants of health behaviours (psycho-
behavioural and psycho–social factors), and bone health; and dietary 
behaviours in men with prostate cancer and survivors? 
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1.6 Review of the literature on the prevalence of osteoporosis in 
men with prostate cancer 
 
 
 
Osteoporosis in men with prostate cancer is recognised and well-documented especially 
among men with prostate cancer on ADT. Unfortunately less attention has been paid to 
those not undergoing this treatment. This section therefore presents a review of the 
literature that synthesises the evidence on the prevalence of osteoporosis in men with 
prostate cancer, regardless of treatment. This section comprises two meta-analyses 
previously published in Endocrine (75, 76).  
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 Prevalence of osteoporosis in men with prostate cancer on ADT 1.6.1
This meta-analysis compiles the evidence on the prevalence of osteoporosis in men with 
prostate cancer on ADT. The studies were also mined to identify factors that could explain 
the pattern of prevalence observed here. The PhD candidate presented the results of this 
meta-analysis at The Prostate cancer World Congress 2013 as a moderated poster. 
 
Citation: Lassemillante A-CM, Doi SA, Hooper JD, Prins JB, Wright OR. Prevalence of 
osteoporosis in prostate cancer survivors: a meta-analysis. Endocrine. 2014;45(3):370-81. 
 
Date submitted: 2nd July 2013 
Date accepted: 11th October 2013 
 
Please note that the reference style for this manuscript is that appropriate for the journal. 
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Abstract 
Purpose: Androgen deprivation therapy (ADT), which is used in the treatment of prostate 
cancer (prostate cancer), is associated with increased morbidity. Severe bone loss is a 
major consequence of androgen ablation and with an increasing number of patients 
undergoing this treatment, the incidence of osteoporosis and fractures can be expected to 
increase with a significant impact on healthcare. To evaluate the prevalence of 
osteoporosis we conducted a review of the literature on bone health in men with prostate 
cancer undergoing ADT. Method: A meta-analysis was conducted using the quality effects 
model and sources of heterogeneity were further explored by consideration of discordant 
effect sizes of included studies in the meta-analysis and examining reasons thereof. 
Results: Our analyses indicate that the prevalence of osteoporosis varies between 9 and 
53% with this variation partially explained by treatment duration, disease stage, ethnicity 
and site of osteoporosis measurement. Conclusion: While it is well known that a rapid 
decline in bone health among men with prostate cancer on ADT occurs, this meta-analysis 
documents the high prevalence of osteoporosis in this population and reinforces the need 
of preventative approaches as part of usual care of prostate cancer patients. 
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Introduction 
Androgen deprivation therapy (ADT) is used in the management of locally advanced and 
metastatic androgen-dependent prostate cancer [1,2]. As a result there are an increasing 
number of males living with hypogonadal levels of testosterone making ADT a 
contemporary cause of severe male hypogonadism [3]. Unfortunately ADT has been 
associated with adverse effects such as gynecomastia, sexual dysfunction, increased fat 
mass, metabolic syndrome and bone loss [4,5] all of which have a significant impact on the 
quality of life of prostate cancer patients [4]. 
 
Of particular concern is the fact that ADT has been shown to significantly decrease bone 
mineral density (BMD) by 1.5-4.0% annually [6], which exceeds that of healthy ageing 
males [6] and that of postmenopausal women, who experience an annual bone loss of 
2.5% [6,7]. The estimated lifetime risk of experiencing an osteoporotic fracture in men 
aged over 50 years is 13.0% [8] while prostate cancer patients exhibit a 21.0-37.0% 
increase in this risk [6]. Although it is well-accepted that hypogonadism is responsible for 
severe bone loss in prostate cancer patients on ADT [9], there has been less emphasis on 
the burden of this problem or associated factors. Therefore this meta-analysis aims to 
compile evidence from the literature on the impact of ADT on the bone health of prostate 
cancer patients while identifying other factors that may help explain patterns in 
osteoporosis prevalence. 
 
Methods 
A systematic review was carried out using the guidelines published by Littell et al. [10] and 
the PRISMA statement [11] was used to guide reporting. A protocol has not been 
previously registered. 
 
Data sources 
We conducted a systematic literature search of EMBASE, PUBMED and SCOPUS for 
studies published until December 2012. The databases were searched using the 
respective controlled vocabulary of terms for “prostate cancer” and “osteoporosis” or “bone 
loss” (see Appendix III for more details) except for Scopus. Studies were limited to those 
carried out in humans and published in English. 
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Study selection and eligibility criteria 
Prospective longitudinal and cross-sectional studies were considered for review and 
exclusions were made if studies were case reports, conference abstracts, letters to editors, 
did not report on the prevalence of osteoporosis, did not differentiate between 
osteoporosis and osteopenia and did not categorize men by ADT status. 
 
Data extraction and eligibility criteria 
The data extracted included study year and study type, number of participants, type and 
duration of prostate cancer treatment, cancer stage and grade, metastatic status, 
prevalence of osteoporosis, osteopenia and normal bone mass, method used to determine 
bone health, region of interest (ROI) scanned, country where study was conducted and 
ethnicity. Each study was assessed using a quality assessment checklist developed from 
the “Risk of bias tool” from Hoy et al. [12] with a maximum score of 10. This tool allowed 
for checking of ten items that protect against bias in prevalence studies with four items 
relating to external validity and six to internal validity. Shortfalls in any of the two validity 
domains are known to lead to bias in prevalence studies [12]. Therefore, studies with up to 
four protective measures (score ≤ 4) had a high risk of bias (ROB), those with 5 to 7 
measures had a moderate ROB and those with eight or more measures (score ≥ 8) had a 
low ROB. Methodological quality was also evaluated using this checklist. Additionally, the 
meta-analysis model redistributed the inverse variance weights of individual studies based 
on the quality information, with the higher quality studies having less re-distribution of 
weight (final weights reported in Figure 1.6, Figure 1.7, and Figure 1.8). Thus quality 
stratification or sensitivity analysis by quality was not required. Finally, the funnel plot, a 
common method of checking for publication bias, could not be used due a high degree of 
heterogeneity between the studies; hence asymmetry on the latter plot would be attributed 
to heterogeneity rather than publication bias [13]. Furthermore, it is expected that 
asymmetry resulting from distinct subgroups will no longer be seen when a plot is done for 
each subgroup [14]. 
 
Statistical methods 
The primary outcome was prevalence of normal bone mass, osteopenia and osteoporosis 
as defined by World Health Organization osteoporosis diagnostic criteria [15]. This 
prevalence was stratified into more homogenous subgroups by classifying the studies into 
low (<15.0%), moderate (15.0-45.0%) and high (>45.0%) osteoporosis based on the data 
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reported within the studies. All analyses were performed on the double arcsine square root 
transformed proportion and results were back transformed to the natural scale. 
Heterogeneity was determined to be present when the value of 
2 was greater than zero 
and/or the Q-statistic was significant at a P < 0.1 [16]. Although the standard approach for 
handling heterogeneity between studies is to use the random effects  model [17], the 
present study used bias adjustment via the quality effects model [18,19] as the random 
effects model estimates have been shown to lack real interpretability [20]. The results from 
the random effects model were however noted for comparative purposes in online 
resource material 2. Robustness of our meta-analysis was explored using sensitivity 
analyses created through altering selection criteria of the studies. Sources of 
heterogeneity were further explored by consideration of discordant effect sizes of included 
studies in the meta-analysis and examining reasons thereof. All analyses were done using 
MetaXL version 1.32 (www.epigear.com). 
 
 
Figure 1.5 Flow diagram of study selection used in this meta-analysis. 
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Results 
Characteristics of the studies 
The search from EMBASE, PUBMED and SCOPUS identified 3809 unique abstracts. After 
elimination of irrelevant articles, case studies and conference abstracts, 33 articles were 
reviewed. Of these, only 13 reported on osteoporosis and osteopenia prevalence and have 
been included in this meta-analysis (Table 1.4). 
 
The studies reviewed here were published between 1999 and 2012, were all cross-
sectional except for two studies [21,22]. Studies were from Japan [23,24], China [25], 
Australia [26], USA [27,28,21,29,22] and Europe [30-33]. The total number of men with 
prostate cancer on ADT was 1394 with a median age of 72.9 years (range 64.5-80.0 
years) and median ADT duration of 28.5 months (range 16.0-53.2 months). All the studies 
used dual-energy X-ray absorptiometry (DXA) to determine BMD and the World Health 
Organization osteoporosis diagnostic criteria, with some studies accounting for race [23-
25] by using an ethnic appropriate normative database rather than using the National 
Health and Nutrition Examination Survey (NHANES) reference database (a Caucasian 
population [34]). The ROIs used in the studies were hip (femoral neck; FN), lumbar spine  
and distal third of the radius. Most studies included here reported osteoporosis as present 
if observed at any of the reviewed sites [21-27,29-31,33]; therefore the exact ROI affected 
could not be differentiated. Only two studies reported osteoporosis at FN only [28] or distal 
third of the radius only [32]. Primary gonadal ablation therapy (bilateral orchiectomy [25] or 
treatment with gonadotropin-releasing hormone (GnRH) agonists [21,27,29,32]) or 
combined androgen blockade (CAB; the latter in conjunction with androgen receptor 
antagonists [22-24,26,28,30,31,33]) were the two main ADT modalities. Disease stage or 
grade was not well described across studies but all reported on the presence or inclusion 
of soft tissue or bone metastases in their analyses. 
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Table 1.4 Characteristics of studies reviewed. 
Study name 
Study 
subjects 
(N) 
Study design 
Population description 
Age (mean±SD or median (range)), 
Ethnicity, Country, disease stage/grade, 
recruitment year if available 
Exclusion criteria 
Types of treatments 
received 
Quality 
score 
Sieber, 
Rommel et 
al. 2012 [21] 
343 Retrospective 
80 years (54-95 years), Caucasian, 
USA, No details on disease stage/ grade 
Prior hip replacement 
GnRH agonists with or 
without non-steroidal anti-
androgens, and 
orchiectomy 
6 
Yu, Kuo et al. 
2012 [22] 
56 Prospective trial 
64.5years (49.8- 80.9 years), mostly, 
Caucasian, USA, Stage A2-D1 
(American Urological Association 
system), 1996-2006 
Presence of  bone 
metastases, prior 
bisphosphonates 
treatment, no DXA scan at 
baseline 
GnRH agonists and non-
steroidal anti-androgens 
(initiated 2 weeks prior to 
GnRH agonists) for 9 
months 
 
This cycle re-initiated upon 
disease progression. 
6 
Wang, Yuasa 
et al. 2008 
[23] 
58 Cross-sectional 
68.5±7.7 years and 72.8±7.1 years (for 
patients with and without bone 
metastases respectively), Asian, Japan, 
Gleason 8.1±1.3 and 7.4±1.5  (for 
patients with and without bone 
metastases respectively), 2006-2007 
Presence of bone 
metastases at hip or 
lumbar spine 
GnRH agonists and/or 
orchiectomy and non-
steroidal anti-androgens or 
both modalities alone 
7 
Yuasa, Maita 
et al. 2010 
[24] 
70 Cross-sectional 
71.1±7.7 years and 74.1±6.2  years (for 
patients with and without bone 
metastases respectively), Asian, Japan, 
Gleason 8.0±1.3 and 7.7±1.4 (for 
patients with and without bone 
metastases respectively), 2006-2009 
Presence of bone 
metastases at hip or 
lumbar spine 
GnRH agonists and/or 
orchiectomy and non-
steroidal anti-androgens or 
both modalities alone 
7 
Deng, Yang 
et al. 2004 
[25] 
28 Cross-sectional 
71 years (65-83 years), Asian, Taipei,  
Stage C or D (Whitmore-Jewett Staging 
system), 1999-2002 
Secondary cause of 
osteoporosis, drugs 
affecting bone metabolism 
GnRH agonists or 
orchiectomy 
6 
Spry, Galvao 
et al. 2009 
[26] 
72 
Prospective 
Longitudinal 
73.5±8.8 years (44.4-88.4 years), 
Caucasian, Australia, locally and distally 
advanced disease (excluding bone 
metastases), 1999-2002 
Presence of bone 
metastases 
GnRH agonists depot at 
baseline, 3 and 6 months 
and non-steroidal anti-
androgens for 9 months. 
7 
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prostate cancer, prostate cancer; ADT, androgen deprivation therapy; GnRH, gonadotropin releasing hormone. 
 
This cycle re-initiated upon 
disease progression. 
Bruder, Ma 
et al. 2006 
[27] 
89 Retrospective 
77±7 years, mostly Caucasian and 
Hispanic, USA, No details on disease 
stage/grade 
Prior bone disease 
GnRH agonists or 
orchiectomy 
8 
Chen, 
Maricic et al. 
2002 [28] 
62 Cross-sectional 
74.3years, mostly Caucasian, USA, 
Stage C or D (Whitmore-Jewett Staging 
system) 
Intermittent-ADT, active or 
hormonally refractive 
prostate cancer, presence 
of bone metastases at hip 
or lumbar spine, prior 
surgery at hip or lumbar 
spine 
GnRH agonists and non-
steroidal anti-androgens 
6 
Wei, Gross 
et al. 1999 
[29] 
24 Cross-sectional 
73 years (71-76 years), Caucasian and 
African American, USA, No details on 
disease stage/grade 
Documented secondary 
cause of osteoporosis, 
drugs affecting bone 
metabolism 
GnRH agonists or 
orchiectomy 
7 
 
Bernat, 
Pasini et al. 
2005 [30] 
18 Cross-sectional 
53-78 years, Caucasian, Croatia, No 
details on disease stage/ grade, 1999-
2002 
Prior treatment with ADT 
or bisphosphonates, or 
treatment with drugs 
affecting bone metabolism 
GnRH agonists and non-
steroidal anti-androgens 
4 
Morote, 
Morin et al. 
2007 [31] 
266 Cross-sectional 
68.9±7.3 years, Mediterranean, Spain, 
mean Gleason 6.8±1.6 
Prior radiotherapy, 
presence of bone 
metastases, treatment 
with drugs affecting bone 
metabolism 
GnRH agonists and non-
steroidal anti-androgens 
7 
 
Peters, 
Fairney et al. 
2001 [32] 
42 Cross-sectional 
76.7±0.98 years, No details on ethnicity, 
UK,median Gleason 5 
Presence of bone 
metabolic diseases 
GnRH agonists 4 
Planas, 
Morote et al. 
2007 [33] 
266 Cross-sectional 
71.0 years (53.0-89.0 years), 
Mediterranean, Spain, mean Gleason 7 
Presence of bone 
metastases, secondary 
causes of osteoporosis 
GnRH agonists 
7 
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a. Normal 
 
b. Osteopenia 
 
c. Osteoporosis 
 
Figure 1.6 Stratum of low prevalence of osteoporosis - range 6.0-12.0%; pooled 
9.0%. 
  
Prev
0.80.60.40.2
Study 
Bernat, Pasini et al. 2005 
Yuasa, Maita et al. 2010 
Chen, Maricic et al. 2002 
Overall 
Q=17.59, p=0.00, I2=72%
Spry, Galvao et al. 2009 
Wang, Yuasa et al. 2008 
Yu, Kuo et al. 2012 
    Prev (95% CI)          % Weight
   0.22  (  0.06,  0.45)      5.98
   0.37  (  0.26,  0.49)     21.21
   0.40  (  0.28,  0.53)     16.76
   0.47  (  0.38,  0.56)    100.00
   0.49  (  0.37,  0.60)     21.62
   0.53  (  0.40,  0.66)     18.73
   0.66  (  0.53,  0.78)     15.70
Prev
0.80.60.40.2
Study 
Yu, Kuo et al. 2012 
Wang, Yuasa et al. 2008 
Spry, Galvao et al. 2009 
Overall 
Q=17.59, p=0.00, I2=72%
Yuasa, Maita et al. 2010 
Chen, Maricic et al. 2002 
Bernat, Pasini et al. 2005 
    Prev (95% CI)          % Weight
   0.30  (  0.19,  0.43)     15.70
   0.38  (  0.26,  0.51)     18.73
   0.42  (  0.30,  0.53)     21.62
   0.45  (  0.36,  0.53)    100.00
   0.51  (  0.40,  0.63)     21.21
   0.52  (  0.39,  0.64)     16.76
   0.72  (  0.49,  0.91)      5.98
Prev
0.20.150.10.050
Study 
Yu, Kuo et al. 2012 
Bernat, Pasini et al. 2005 
Chen, Maricic et al. 2002 
Wang, Yuasa et al. 2008 
Overall 
Q=17.59, p=0.00, I2=72%
Spry, Galvao et al. 2009 
Yuasa, Maita et al. 2010 
    Prev (95% CI)          % Weight
   0.04  (  0.00,  0.10)     15.70
   0.06  (  0.00,  0.22)      5.98
   0.08  (  0.02,  0.16)     16.76
   0.09  (  0.03,  0.17)     18.73
   0.09  (  0.06,  0.12)    100.00
   0.10  (  0.04,  0.18)     21.62
   0.11  (  0.05,  0.20)     21.21
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a. Normal 
 
b. Osteopenia 
 
c. Osteoporosis 
 
Figure 1.7 Stratum of moderate prevalence of osteoporosis - range 28.0-38.0%; 
pooled 33.0%. 
  
Prev
0.30.250.20.150.10.05
Study 
Wei, Gross et al. 1999 
Sieber, Rommel et al. 2012 
Overall 
Q=4.78, p=0.09, I2=58%
Bruder, Ma et al. 2006 
    Prev (95% CI)          % Weight
   0.13  (  0.02,  0.29)     15.60
   0.13  (  0.09,  0.17)     55.21
   0.15  (  0.09,  0.23)    100.00
   0.22  (  0.14,  0.32)     29.19
Prev
0.70.60.50.40.3
Study 
Wei, Gross et al. 1999 
Bruder, Ma et al. 2006 
Overall 
Q=4.78, p=0.09, I2=58%
Sieber, Rommel et al. 2012 
    Prev (95% CI)          % Weight
   0.50  (  0.30,  0.70)     15.60
   0.51  (  0.40,  0.61)     29.19
   0.52  (  0.46,  0.57)    100.00
   0.53  (  0.47,  0.58)     55.21
Prev
0.50.40.30.2
Study 
Bruder, Ma et al. 2006 
Overall 
Q=4.78, p=0.09, I2=58%
Sieber, Rommel et al. 2012 
Wei, Gross et al. 1999 
    Prev (95% CI)          % Weight
   0.27  (  0.18,  0.37)     29.19
   0.33  (  0.28,  0.38)    100.00
   0.34  (  0.29,  0.40)     55.21
   0.38  (  0.19,  0.58)     15.60
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a. Normal 
 
b. Osteopenia 
 
c. Osteoporosis 
 
Figure 1.8 Stratum of high prevalence of osteoporosis - range 48.0-57.0%; pooled 
53.0%. 
 
Quantitative synthesis by osteoporosis stratum  
Low prevalence of osteoporosis  
Six studies reported a prevalence of osteoporosis under 15.0% [23,24,26,28,22,30]. The 
pooled prevalence of osteoporosis was 9.0% (95% CI: 6.0%-12.0%) and normal bone 
mass was the predominant group at 47.0% (95% CI: 38.0%-56.0%). The exact ADT 
duration in this subgroup could not be quantified due to two studies [26,22] reporting on 
intermittent ADT. This latter treatment involved a number of cycles of androgen ablation 
interspersed with cessation of therapy until PSA rose above 20ng/mL. Hence, the number 
of months on treatment was different across participants in these studies, and the authors 
Prev
0.350.30.250.20.150.10.05
Study 
Morote, Morin et al. 2007 
Planas, Morote et al. 2007 
Overall 
Q=2.17, p=0.54, I2=0%
Deng, Yang et al. 2004 
Peters, Fairney et al. 2001 
    Prev (95% CI)          % Weight
   0.14  (  0.10,  0.18)     40.39
   0.14  (  0.10,  0.19)     40.39
   0.15  (  0.12,  0.18)    100.00
   0.18  (  0.06,  0.35)     10.98
   0.21  (  0.10,  0.35)      8.25
Prev
0.50.40.30.2
Study 
Peters, Fairney et al. 2001 
Planas, Morote et al. 2007 
Overall 
Q=2.17, p=0.54, I2=0%
Morote, Morin et al. 2007 
Deng, Yang et al. 2004 
    Prev (95% CI)          % Weight
   0.29  (  0.16,  0.43)      8.25
   0.31  (  0.25,  0.37)     40.39
   0.32  (  0.29,  0.36)    100.00
   0.34  (  0.28,  0.40)     40.39
   0.36  (  0.19,  0.55)     10.98
Prev
0.60.50.40.3
Study 
Deng, Yang et al. 2004 
Peters, Fairney et al. 2001 
Overall 
Q=2.17, p=0.54, I2=0%
Morote, Morin et al. 2007 
Planas, Morote et al. 2007 
    Prev (95% CI)          % Weight
   0.46  (  0.28,  0.65)     10.98
   0.50  (  0.35,  0.65)      8.25
   0.53  (  0.48,  0.57)    100.00
   0.53  (  0.47,  0.59)     40.39
   0.55  (  0.49,  0.61)     40.39
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also noted that BMD recovered during the treatment cessation periods. Men in this 
subgroup were younger (median 71.0 years, IQR 5.7) than the moderate osteoporosis 
subgroup (median 75.7 years, IQR 3.7). Interestingly, CAB was quite frequent among 
studies in this subgroup [24,26,22,30]. The median ROB score for this subgroup was 6.5 
(range 4-7), and was found to be similar to the scores of the high osteoporosis subgroup. 
 
Moderate prevalence of osteoporosis  
Three studies reported a prevalence of osteoporosis between 15.0-45.0% [27,21,29]. 
Pooled prevalence of normal bone mass was now much lower than the previous subgroup 
at 15.0% (95% CI: 9.0%-23.0%) while osteopenia and osteoporosis were much higher at 
52.0% (95% CI: 46.0%-57.0%) and 33% (95% CI: 28%-38%) respectively. The ROB 
scores for these studies ranged between 6 and 8 (median 7). The duration of ADT varied 
between 16.0 months and 43.0 months (median 32.4 months) and studies reported on use 
primary gonadal androgen ablation only. All these studies also used radial BMD in addition 
to hip or lumbar spine, in the diagnosis of osteoporosis. 
 
High prevalence of osteoporosis 
Four studies reported a prevalence of osteoporosis over 45.0 % [25,31-33]. Here the 
prevalence of normal bone mass remained similar to the previous group (15.0%; 95% CI: 
12.0%-18.0%) while the prevalence of osteoporosis was higher (53.0%, 95% CI: 48.0%-
57.0%) and of osteopenia was lower. An even number of studies reported on the use of 
primary gonadal androgen deprivation and CAB. All except Deng et al. [25], used the 
NHANES database when diagnosing osteoporosis. All the studies in this subgroup only 
included men with metastatic disease demonstrating advanced prostate cancer. 
 
Sensitivity analyses and publication bias 
There was a trend towards worse bone health with longer ADT duration, as osteoporosis 
prevalence increased. An inverse trend could be seen in the prevalence of normal bone 
mass with ADT duration and studies investigating ADT for <24months (or intermittent-
ADT) reported the highest prevalence of normal bone mass (see Table 1.5). 
 
Studies reporting on non-Asian males reported a higher prevalence of osteoporosis than 
those reporting on their Asian counterparts (34.7%; 95% CI: 23.3%-44.9% versus 15.8%; 
95% CI: 4.3%-30.9%). Studies measuring osteoporosis at a site that included the radius 
also reported a higher prevalence of osteoporosis and osteopenia (34.3% and 49.6% 
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versus 31.4% and 40.0% respectively) than studies measuring osteoporosis at sites 
excluding the radius. Therefore the addition of this ROI led to a higher detection of poorer 
bone health.  
 
The prevalence of osteoporosis and osteopenia were similar in studies investigating the 
impact of primary gonadal androgen ablation or CAB. Also, studies of younger prostate 
cancer participants reported a similar prevalence of osteoporosis as subjects aged 70 
years and over (see Table 1.5). 
 
In terms of risk of bias, two studies were deemed high risk [30, 32], ten were deemed 
moderate risk [21-26, 28, 29, 31, 33] and one low risk [27] on the “Risk of bias tool” as 
defined in the methods section [12]. The most common deficiency among the moderate 
group was selection bias as most authors recruited participants from local health care 
centres, which may not be representative of the prostate cancer population at large. The 
two studies [30,32] classified as high ROB, mainly had poor external validity and thus 
exhibited deficiencies on the following items: the target population, randomisation, 
reporting of the sampling frame and non-response bias. Consequently under the meta-
analysis model used, these studies contributed much less to their respective subgroup’s 
pooled estimate. Numbers of non-deficient items (quality score) for each study are listed in 
Table 1.4. 
 
Discussion 
The results presented here quantify the prevalence of osteoporosis and osteopenia in 
prostate cancer patients on ADT, with the majority of these patients experiencing poor 
bone health (up to 85.0%). The variation in the prevalence of osteoporosis (9.0%-53.0%) 
observed in this paper seems to be influenced by ADT duration, disease stage, ethnicity 
and skeletal site used to diagnose osteoporosis. The effects of ADT on bone mass are 
well recognized in the literature and a prior meta-analysis by Neto et al. [9] reported an 
increase in the risk of developing osteoporosis in prostate cancer patients on ADT. Our 
meta-analysis is the first to compile the prevalence of osteoporosis from the literature and 
to document the extensive disparity in prevalence of osteoporosis in this population, 
therefore revealing an important clinical heterogeneity worthy of further investigation. 
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Table 1.5 Sensitivity analyses. 
Studies selected if: 
Osteoporosis 
prevalence 
(95% CI) 
Osteopenia 
prevalence 
(95% CI) 
Normal bone 
mass prevalence 
(95% CI) 
Age  
≥70 years 
[19, 21-27,30]  
0.270 
(0.176-0.361) 
0.485 
(0.420-0.526) 
0.245 
(0.158-0.331) 
<70 years 
[20,28,29,31]  
0.436 
(0.233-0.612) 
0.361 
(0.261-0.434) 
0.204 
(0.074-0.351) 
Publication year  
<2007 
[23,25-28,30] 
0.270 
(0.156-0.391) 
0.487 
(0.387-0.573) 
0.244 
(0.172-0.316) 
≥2007 
[19-22,24,29,31] 
0.329 
(0.193-0.450) 
0.416 
(0.317-0.482) 
0.255 
(0.141-0.362) 
Ethnicity 
Asian population 
[21-23] 
0.158 
(0.043-0.309) 
0.444 
(0.338-0.530) 
0.398 
(0.241-0.546) 
`Non-Asian population 
[19,20,24-31] 
0.347 
(0.233-0.449) 
0.432 
(0.345-0.495) 
0.221 
(0.137-0.302) 
Median ADT duration  
<24 months / intermittent 
[19,20,24,28] 
0.198 
(0.067-0.346) 
0.506 
(0.367-0.594) 
0.297 
(0.114-0.485) 
24-30 months 
[21,23,26,30] 
0.202 
(0.067-0.363) 
0.416 
(0.307-0.500) 
0.381 
(0.236-0.510) 
>30 months 
[22,25,27,29,31] 
0.427 
(0.279-0.568) 
0.395 
(0.301-0.480) 
0.179 
(0.110-0.253) 
ROI 
Hip / lumbar spine 
[20-24,26,28,29,31]  
0.314 
(0.187-0.426) 
0.400 
(0.320-0.445) 
0.287 
(0.179-0.381) 
Third distal radius (alone or with 
hip/lumbar spine) 
[19,25,27,30] 
0.343 
(0.270-0.420) 
0.496 
(0.420-0.588) 
0.161 
(0.108-0.222) 
ADT 
Primary gonadal ablation 
therapy 
[19,23,25,27,30] 
0.355 
(0.287-0.426) 
0.482 
(0.397-0.567) 
0.164 
(0.119-0.214) 
Combination androgen 
blockade 
[20-22,24,26,28,29,31]  
0.302 
(0.170-0.422) 
0.402 
(0.317-0.452) 
0.295 
(0.179-0.396) 
 
Disease stage: Metastasis 
This meta-analysis demonstrated that the highest prevalence of osteoporosis occurred in 
men with metastatic disease probably as a result of disease pathophysiology. This can be 
due to an increase in bone resorption, as evidenced by elevated N-telopeptide levels seen 
upon disease progression [35]. There are suggestions that bone resorption is necessary to 
release growth factors that allow prostate cancer bone metastases to appear in the 
skeleton [36]. This is a complex process, whereby prostate cancer cells secrete pro-
osteolytic factors that increase bone resorption and the release of various growth factors 
from the bone [37,38]. These factors are believed to modify the bone microenvironment 
and the prostate cancer cells phenotype [37] leading to the development of osteoblastic 
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metastases. Therefore it is hypothesized that an increase in skeletal metastatic foci, is 
preceded by an increase in bone resorption to allow prostate cancer cells to niche to active 
resorption sites. Unfortunately, this model is based on in vitro and animal models and such 
research involving prostate cancer patients remains challenging due to the confounding 
effects of treatments, such as ADT, on bone metabolism. Besides, the high osteoporosis 
prevalence can also be associated with longer duration of ADT in such cases as a result of 
a longer life with prostate cancer. While it is well accepted that ADT will lead to severe 
bone loss in men with localized prostate cancer [6], the longitudinal effects of ADT on bone 
resorption in men with metastatic prostate cancer are confounded by the disease stage 
[35,39,40] therefore limiting the conclusions that can be drawn. 
 
ADT duration 
Testosterone is known to affect bone cells through the androgen receptor (AR), for 
instance androgens will increase osteoblast proliferation while inhibiting osteoblast 
apoptosis [41]. Therefore upon androgen deprivation, there is an imbalance between bone 
formation and degradation resulting in net bone loss as indicated by elevated levels of 
bone resorption biomarkers [42]. Additionally, decreases in testosterone levels also lead to 
a decrease in aromatization to estrogen and while both hormones seem to be important for 
bone formation, it seems that estrogen is the major sex steroid regulating bone resorption 
even in men [43]. This change in bone metabolism with ADT leads to the decrease of bone 
mass over time [42] and was demonstrated in the sensitivity analyses that revealed an 
increase in the prevalence of osteoporosis with ADT duration. Although there is a link 
between ADT, body composition changes [44] and bone resorption biomarkers, this could 
not be quantified here due to lack of reporting of these parameters in the studies reviewed. 
 
Type of ADT 
Our results indicated that the type of ADT used impacted less on bone loss, whereby 
patients on primary gonadal ablation or CAB seem to experience a similar prevalence of 
osteoporosis and osteopenia. This is consistent with a previously published review on the 
long-term side effects of ADT by Alibhai et al. [45], where the authors could not 
differentiate between the impact of the two ADT modalities on bone loss. Androgen 
ablation is associated with an increase in bone resorption, as evidenced by increased 
levels of N-telopeptide [46], therefore is also associated with a higher mean percentage 
yearly decrease in BMD [6], as a result of an increase in cortical porosity and decrease 
trabecular number [47]. Increases in clinical fractures after treatment with GnRH agonists 
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or CAB have been documented [48]. The latter study reported a higher hazard of fractures 
among men treated with CAB than GnRH agonists [48] while Smith et al. [49] reported 
elevation in fracture risk when prostate cancer patients are treated with GnRH agonists for 
at least one year. It is important to note that about 15.0% of fractures seen in men with 
prostate cancer are pathologic in nature suggesting that any differences in osteoporosis 
prevalence may be due to variations in disease characteristics (and associated co-
morbidities) than treatment per se [48]. 
 
Osteoporosis site and age 
There may be erroneously elevated BMD at the lumbar spine as a result of osteoarthritis 
rendering the spine unsuitable, or after hip replacement rendering the FN unsuitable. 
Therefore, BMD measurement practices and age of subjects will also impact on the 
prevalence of osteoporosis as outlined by some studies reviewed here [21,29]. The 
inclusion of distal third radius T-scores, which is only recommended when other ROIs are 
not suitable, has led to a slight increase in the prevalence of osteoporosis and osteopenia 
in prostate cancer patients on ADT [27]. This increase in prevalence when adding distal 
third radius to other ROIs can be explained by the fact that the trabecular content of the 
distal third radius is known to increase with age [50]. Besides, bone loss is more severe at 
trabecular sites, with a higher remodelling surface, than cortical sites [51]. Evidence from 
high-resolution peripheral quantitative computed tomography has shown that increased 
porosity at cortical bone, trabecularization of cortical bone and loss of trabecular bone all 
occur in androgen deprived prostate cancer patients [47]. Age had a minimal impact on the 
prevalence of osteoporosis probably because of the small difference in median ages 
between the two groups while ADT may have masked the typical longitudinal changes in 
BMD in elderly males [6]. 
 
Ethnicity 
The use of race appropriate reference groups in determining T-scores also affected the 
prevalence of osteoporosis in the current population and is likely to be similar in other 
populations [52]. The International Society for Clinical Densitometry (ISCD) recommends 
to use the NHANES III database when diagnosing osteoporosis rather than accounting for 
race [53]. Sensitivity analysis by ethnicity demonstrates that non-Asian prostate cancer 
patients are more prone to osteoporosis but an explanation cannot be offered as studies 
investigating both ethnicities used different normative database to diagnose osteoporosis. 
This finding outlines the importance of consistent bone health monitoring while following 
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current ISCD guidelines. It may also warrant early pharmacological management of 
osteoporosis [6] in certain ethnic groups. 
 
Limitations and conclusions 
The studies included in this meta-analysis did not report on any co-morbidity data, dietary, 
exercise or lifestyle factors that are known to affect bone mass. Although these would 
impact on bone health of prostate cancer patients, we cannot make any conclusions 
whether differences in these may help explain the variation that is seen in the current 
prevalence of osteoporosis. This evident gap in the literature warrants further research on 
these factors and their impact on osteoporosis in prostate cancer patients. Additional 
limitations include the possible exclusion of data from studies not published in English and 
studies which did not differentiate between osteopenia and osteoporosis. We suspect that 
such data would have a minimal effect on the pooled estimates while narrowing the 
confidence intervals. The funnel plot was excluded due to its inherent flaws with 
interpretability given the high degree of heterogeneity between the studies in this meta-
analysis; therefore publication bias could not be determined. However, adjustment for 
other possible biases has been undertaken through the use of the quality effects model. 
 
prostate cancer patients now live longer [54] and are increasingly treated with ADT. This 
meta-analysis suggests that over 50.0% of patients will suffer from osteoporosis if treated 
with ADT for approximately 3 years. Unfortunately, there is evidence suggesting that DXA 
scanning and interventions, such as promotion of healthy bone behaviours, are poorly 
implemented at initiation of ADT  [55] despite the presence of other osteoporosis risk 
factors and co-morbidities [56]. Moreover, it was found that such patients lack basic 
osteoporosis knowledge and do not engage in healthy bone behaviours such as 
participating in physical exercise and consuming adequate calcium and vitamin D [57]. 
There is thus a real need to initiate the bone health conversation between the prostate 
cancer patient and treating health professional as this issue is currently overlooked 
[56,58]. Finally, current recommendations do not include the addition of an osteoclast 
inhibitor therapy (bisphosphonates, RANKL inhibitor) in men without bone metastases who 
are treated with long-term ADT unless the 10-year probability of hip fracture is ≥3.0% or 
the 10-year probability of a major osteoporosis-related fracture is ≥20.0% [59]. Recent 
reviews on the cotemporary management of osteoporosis have outlined the superiority of 
RANKL inhibitors over bisphosphonates in reversing the impact of ADT on BMD as well as 
the reductions in skeletal related events in prostate cancer patients [60,61]. The evidence 
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presented here therefore reinforces the need for preventative strategies such as calcium 
and vitamin D supplementation [6], and early osteoporosis pharmacological interventions, 
prior to ADT initiation to avoid the deleterious effects of osteoporosis related morbidity in 
prostate cancer patients. 
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 Prevalence of osteoporosis in prostate cancer not on ADT and survivors 1.6.2
This meta-analysis is a continuation of the one presented in section 1.6.1 and compiles the 
evidence on the prevalence of osteoporosis in hormone-naïve men with prostate cancer. 
The results from this analysis were compared with the pooled prevalence of osteoporosis 
of men with prostate cancer on ADT (presented in the section 1.6.1). The studies in this 
second meta-analysis were mined to identify factors, other than ADT status, that could 
explain the differences observed in the prevalence of osteoporosis between the two 
populations. 
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Abstract 
The prevalence of osteoporosis in men with prostate cancer (prostate cancer) on 
androgen deprivation therapy (ADT) is well documented, with up to 53% affected by this 
bone condition. However, there has been less emphasis on the burden of severe bone 
loss in men with prostate cancer but not undergoing ADT. Therefore the purpose of this 
meta-analysis is to compile evidence from the literature on the bone health of hormone-
naïve prostate cancer patients and to compare it the bone health of men with prostate 
cancer on ADT. Three databases were searched for relevant literature published from 
1990 January 2014. The pooled prevalence of osteoporosis, low bone mass and normal 
bone mass were estimated for this patient group and compared with similar subgroups 
from a previously published meta-analysis. The prevalence of osteoporosis varies from 4-
38% in hormone-naïve prostate cancer patients, and men with more advanced disease 
have a higher prevalence of osteoporosis. Men with prostate cancer on ADT have poorer 
bone health than their hormone-naïve counterparts, but the trend towards poorer bone 
health with metastatic disease remains. In conclusion, it was found that men with prostate 
cancer experience poor bone health prior to treatment with ADT. These results suggest 
that all men with prostate cancer should have regular bone health monitoring, whether 
they commence ADT or not, in order to prevent or indeed minimise the morbidity that 
accompanies osteoporosis.  
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Introduction 
Prostate cancer (prostate cancer) is highly prevalent in Western countries with strong 
evidence reporting on the deleterious side effects of one of its treatment modalities, 
notably androgen deprivation therapy (ADT) [1,2]. It is well-accepted that ADT leads to 
severe bone loss [2,3], but bone health management and osteoporosis screening are 
poorly implemented by doctors in this population [4]. Androgen deprivation therapy is not 
the first line treatment for prostate cancer [5] but the number of men receiving such 
treatment is increasing [6]. Such ADT candidates include men on active surveillance who 
are not currently receiving any medical or pharmacological treatments. Therefore 
ascertaining and managing their bone health early on the prostate cancer continuum has 
the potential to decrease their risk of future fractures. Adopting osteoporosis preventative 
behaviours, if needed, during active surveillance gives men with prostate cancer the 
opportunity to self-manage their overall health which may help in managing uncertainty 
that is common during this treatment modality [7,8]. Consequently this meta-analysis aims 
to synthesize evidence from the literature on the bone health, notably osteoporosis, of men 
with prostate cancer not on ADT. The secondary aim is to compare the bone health of 
these men to the bone health of men with prostate cancer on ADT thereby examining the 
burden of osteoporosis across the prostate cancer continuum. 
 
Methods 
A systematic review was carried out using the guidelines published by Littell et al. [9] and 
the PRISMA statement [10] was used to guide reporting. The meta-analysis protocol is 
similar to that used in a study focussing on the prevalence of osteoporosis in men with 
prostate cancer treated with ADT published by our group [11]. Therefore, a brief 
description of the methodology and its differences to the previously published protocol are 
given below. 
 
Data sources and study selection 
Studies, published from 1990 until January 2014, were identified through a systematic 
literature search of EMBASE, PUBMED and SCOPUS. The databases were searched 
using the respective controlled vocabulary of terms for “prostate cancer” and 
“osteoporosis” or “bone loss” (see Online resource material 1 for more details) except for 
SCOPUS. Studies were limited to those carried out in humans and published in English. 
The meta-analysis was limited to prospective longitudinal and cross-sectional studies 
involving hormone-naïve men with prostate cancer (not treated with ADT). Further 
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exclusions were made if studies did not differentiate between osteoporosis and low bone 
mass (osteopenia) among other exclusion criteria [11]. 
 
Data Extraction and Quality assessment 
The data extracted were identical to that described in our previous study [11], with the 
addition of prostate cancer treatment plan, calcium intake and serum biomarkers 
representative of bone health. Each study was assessed using a methodological quality 
assessment checklist developed from the “Risk of bias tool” suggested by Hoy et al. [12] 
with a maximum score of 10. 
 
Statistical methods 
Prevalence of normal bone mass, low bone mass and osteoporosis as defined by World 
Health Organization (WHO) and/or the International Society for Clinical Densitometry 
(ISCD) osteoporosis diagnostic criteria [13,14] were the primary outcomes for this study. 
This prevalence was stratified into more homogenous subgroups by classifying the studies 
into low (<5%), moderate (8-30%) and severe (>30%) osteoporosis based on the 
prevalence reported within the studies. All analyses were performed using bias adjustment 
via the quality effects model [15,16] as the estimates from the random effects model have 
been shown to underestimate the statistical error [17,18] and are based on assumptions 
about random effects that may not be valid in practice [19]. The quality effects model does 
not assume bias can be quantified through quality scores. Rather it introduces a 
differential synthetic bias variance to improve the estimator performance. In meta-analyses 
of proportion studies, funnel plots were found to be an inaccurate method of assessing 
publication bias [20] therefore a Doi plot [21] was presented in addition to the funnel plot 
for comparison. This plot is similar to the funnel plot in that it resembles an inverted funnel 
when there is symmetry, but the studies define the limbs of the funnel instead of being 
confined within the funnel. To explain differences in bone health status within each 
stratum, the respective studies were mined for characteristics, other than ADT status, that 
could contribute to such discrepancy. The findings of this meta-analysis were directly 
compared with those from our meta-analysis investigating men with prostate cancer on 
ADT [11]. All analyses were done using MetaXL version 2.0 [22]. 
 
Results 
Characteristics of the studies and participants 
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The systematic search generated 5812 articles, of which only 15 [23-37] met the inclusion 
criteria and have been discussed in this meta-analysis (see Figure 1.9). 
 
 
Figure 1.9 Flow diagram of study selection used in this meta-analysis. 
 
The studies reviewed here were published between 1999 and 2013, and originated from 
Europe [27,30,32,33,37], USA [28,31,29], Asia [23,24,29] Canada [26,36] and Australia 
[35]. The total number of hormone-naïve men with prostate cancer included in this meta-
analysis was 1267 (median age 69.5 years, IQR: 5.7). Nine studies [26,28,29,31-35,37] 
reported on men with prostate cancer eligible for ADT, and five studies [23-25,27,30] 
5812 articles retrieved 
from initial search 
4720 articles 
1092 duplicates 
286 articles 
4434 irrelevant titles 
and abstracts 
36 articles 
15 articles for final 
review 
250 conference 
proceedings, case 
studies and poor 
characterisation of 
study population 
21 articles not using 
WHO/ISCD 
osteoporosis definition, 
with missing results, 
reporting on ADT only 
or inappropriate effect 
size 
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compared the bone health of men with prostate cancer not requiring ADT, to their ADT 
counterparts. Alibhai et al. [36] reported on men about to commence ADT and men not 
eligible for ADT (separate values for age and PSA for these groups are presented in Table 
1.6), with the bone health data of both groups combined in this meta-analysis. Alibhai et al. 
[36], Berruti et al. [32], Cheung et al. [35], Panju et al. [26], Ziaran et al. [37] and Yu et al. 
[28] were longitudinal studies investigating the effects of ADT on bone mineral density with 
baseline measurements collected prior to ADT initiation. The study by Conde et al. [31] 
was nested within a longitudinal ADT trial and these authors reported only on the baseline 
characteristics of the participants. Therefore the baseline measurements from all these 
studies were used in this meta-analysis. 
 
Hussain et al. [33] were the only authors to measure bone mass at the forearm while all 
the other studies measured bone mass at the lumbar spine and/or hip. All the studies used 
dual energy x-ray absorptiometry (DXA) to measure bone mineral density and the WHO or 
ISCD definitions for osteoporosis. The three studies composed solely of Asian participants 
[23,24,29] utilised a culturally-specific normative database for determining osteoporosis 
status, rather than the National Health and Nutrition Examination Survey reference 
database that is predominantly Caucasian [38]. 
 
Disease stage was reported in all studies reviewed, with two studies [29,33] including men 
with metastatic disease and the rest including men with local (T1-T4N0M0) or locally 
advanced disease (T1-T4N1M0). Prostate cancer grade using the Gleason histological 
grading was reported in five studies [23,25,27,30,31], with a median score of 7 (range 6.3-
7.4). Eleven studies [23-25,27,29-31,33,34,36,37] measured and reported mean or median 
prostate-specific antigen (PSA) levels, ranging from 0.99ng/mL to 41.4ng/mL. The mean or 
median PSA levels from three studies [24,30,33] could not be included here because such 
levels for hormone-naïve patients only could not be distinguished from the rest of the 
sample. The median dietary calcium intake, as reported in four studies [27,31,32,34], was 
879.0mmg (range 651.3-1107.0mg). Serum calcium reported in three studies [29,33,34] 
ranged from 9.2mg/dL to 9.4mg/dL (2.3-2.35mmol/L). Conde et al. [31] collected vitamin D 
intake data via a food frequency questionnaire and found that the mean intake was 
4.80±5.57μg/day (192IU/day). The respective serum vitamin D (25-hydroxyvitamin D) 
measured in two studies [34,35] was 22±8ng/mL and 25.24±8.81ng/mL 
(54.91±19.97nmol/L and 63±22nmol/L). 
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Quality of studies 
All the studies were deemed to be at moderate risk of bias, with five studies 
[24,26,28,33,37] scoring the lowest as they lacked four bias protective measures. Overall 
the studies reviewed in this meta-analysis had flaws in external validity mostly due to poor 
reporting on selection criteria and narrow sampling frame. The lack of reporting on 
sampling data is common and has been documented before [39]. In this meta-analysis, 
most participants were recruited from medical centres rather than the general population, 
therefore allowing for more accurate reporting of primary outcome and detailed medical 
information. The study by Panju et al. [26] had an internal validity issue where some of the 
data were not collected directly from participants, although it is important to note that such 
flaw did not apply to bone mineral density but rather to other aspects of this study. 
 
Comparison of bone health across two hormonally diverse prostate cancer groups 
Three distinct subgroups, based on osteoporosis severity, were identified among 
hormone-naïve prostate cancer patients (See Table 1.7). Five studies reported a low 
prevalence of osteoporosis [23,25,26,28,34], with a pooled prevalence of 3.9% (95% CI: 
0.7%-9.1%) and seven studies reported a moderate prevalence of osteoporosis 
[24,29,31,32,35-37] (pooled prevalence 12.6%, 95% CI: 7.8%-18.1%). The remaining 
three studies [27,30,33] reported osteoporosis in more than one-third of the participants 
(pooled prevalence 37.8%, 95% CI: 31.5%-44.4%). A comparison of these three 
subgroups with similar subgroups identified in a previously published meta-analysis on 
prostate cancer patients treated with ADT [11] is presented in Table 1.7. Seven studies 
[26,31-36] included here were not included in our previous meta-analysis as these either 
(i) did not meet the inclusion criteria [26,31-34] or (ii) were published after our first meta-
analysis [35,36]. We conducted our meta-analysis both with and without these seven 
studies  to determine whether their inclusion affected the results. Since their inclusion did 
not affect to the pooled prevalence of normal bone mass, osteopenia or osteoporosis, we 
included them for all subsequent analyses. 
 
Overall, hormone-naïve prostate cancer patients have better bone health than their ADT 
treated counterparts. Table 1.7 outlines heterogeneity in the prevalence of osteoporosis in 
hormone-naïve prostate cancer patients similar to that of prostate cancer patients on ADT. 
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Low osteoporosis prevalence: defining characteristics other than hormone status 
Hormone-naïve prostate cancer patients in this subgroup were younger (median 68 years, 
IQR: 4.6) than the men with prostate cancer on ADT (median 71.0 years, IQR: 5.7). The 
inclusion criteria based on prostate cancer stage varied within the studies of both hormone 
status groups. The majority of men in the ADT group (about 95%) appeared to be 
diagnosed with metastatic prostate cancer compared with none in the hormone-naïve 
group. While median prostate cancer aggressiveness was similar between the two patient 
groups, studies investigating men treated with ADT also included patients with more 
aggressive disease (Gleason score 7.4-8.1 v/s Gleason score 7.2-7.4).  
 
Moderate osteoporosis prevalence: defining characteristics other than hormone status 
The prevalence of osteoporosis and normal bone mass was significantly different between 
the two groups of men with prostate cancer (see Table 1.7). Ethnicity was heterogeneous 
in the hormone-naïve group, while the ADT group mostly comprised Caucasian males. 
The trend in age was similar to the previous osteoporosis subgroup, but the hormone-
naïve prostate cancer patients included here were older than the other two subgroups 
(median 71 years, IQR: 5.9 versus median 68 years, IQR: 4.6 and 68.9 years, IQR: 7.6). 
Disease stage and grade could not be ascertained in the studies included here. 
 
High osteoporosis prevalence: defining characteristics other than hormone status 
The age trend observed here was similar to the low osteoporosis subgroup (ADT median 
age 71 years, IQR: 1.95; No ADT median age 68.9 years, IQR: 7.6). Around half of the 
hormone-naïve men were of Mediterranean descent (56.9%) compared with almost 90% 
of men on ADT. Additionally, all of the men on ADT had metastatic disease and 
moderately to highly aggressive prostate cancer, whereas 32.7% hormone-naïve had 
suspected metastases and intermediate aggressive disease (Gleason score 6.3-6.8). 
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Table 1.6 Details and characteristics of studies included in this meta-analysis. 
Study name 
(Country) 
Number of 
hormone-naïve 
patients 
(Recruitment 
year, Ethnicity) 
Study 
design 
Hormone-naïve prostate cancer 
patient description 
Age (mean±SD or median [range])* 
Disease stage/grade 
PSA level (mean ±SD or median 
(range))* 
Prevalence of 
osteoporosis 
and low bone 
mass (%) 
Exclusion criteria 
Types of 
treatments 
received 
Quality 
score 
Yuasa, Maita 
et al. 2010 [23] 
(Japan) 
88 
(2006-2009, 
Asian) 
Cross-
sectional 
65.1±9.7 years 
Gleason 7.4±1.2 
PSA 12.6±10.3ng/mL 
Osteoporosis 
4.5% 
Low bone mass 
29.5% 
Presence of bone 
metastases at hip or 
lumbar spine 
None specified 7 
Deng, Yang et 
al. 2004 [24] 
(Taipei) 
21 
(1999-2002, 
Asian) 
Cross-
sectional 
71 years (65-83 years) 
Stage C or D (Whitmore-Jewett 
Staging system 
Mean/median PSA level could not be 
determined 
Osteoporosis 
28.6%  
Low bone mass 
33.3% 
Secondary cause of 
osteoporosis, drugs 
affecting bone 
metabolism 
Participants 
due to 
commence 
ADT 
6 
Wang, Yuasa 
et al. 2008 [25] 
(Japan) 
43 
(2006-2007, 
Asian) 
Cross-
sectional 
68.1±7.3 years 
Gleason 7.2±1.2 
PSA 10.3±24.2ng/mL 
Osteoporosis 
2.3%  
Low bone mass 
44.1% 
Presence of bone 
metastases at hip or 
lumbar spine 
None specified 7 
Panju, Breunis 
et al. 2009 [26] 
(Canada) 
66 
(Caucasian) 
Prospective 
longitudinal 
70.6 years 
Non-metastatic disease 
No details on PSA level 
Osteoporosis 
4.5% 
Low bone mass 
50.3% 
Prior ADT treatment, 
presence of metastases 
Participants 
due to 
commence 
ADT 
6 
Planas, 
Morote et al. 
2007 [27] 
(Spain) 
106 
(Mediterranean) 
Cross-
sectional 
67 years (54.-80 years) 
Localized disease only and Gleason 
6.3 
PSA 7.8ng/mL (2.9-13.2 ng/mL) 
Osteoporosis 
34.9% 
Low bone mass 
47.2% 
Presence of bone 
metastases, secondary 
causes of osteoporosis 
Radical 
prostatectomy 
7 
Yu, Kuo et al. 
2012 [28] 
(USA) 
56 
(1996-2006, 
mostly 
Caucasian) 
Prospective 
trial 
64.5years (49.8- 80.9 years) 
Stage A2-D1 (American Urological 
Association system) 
No details on PSA level 
Osteoporosis 
17.9% 
Low bone mass 
33.4% 
Presence of  bone 
metastases, prior 
bisphosphonates 
treatment, no DXA scan 
at baseline 
Participants 
due to 
commence 
intermittent-
ADT 
GnRH agonists 
6 
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and non-
steroidal anti-
androgens 
(initiated 2 
weeks prior to 
GnRH 
agonists). 
This cycle re-
initiated upon 
disease 
progression. 
Wei, Gross et 
al. 1999 [29] 
(USA) 
8 
(Caucasian and 
African American) 
Cross-
sectional 
76 years (75-78 years) 
All participants with metastases 
PSA 41.4±32.4ng/mL 
Osteoporosis 
25.0% 
Low bone mass 
37.5% 
Documented secondary 
cause of osteoporosis, 
drugs affecting bone 
metabolism 
Participants 
due to 
commence 
ADT 
7 
Morote, Morin 
et al. 2007 [30] 
(Spain) 
124 
(Mediterranean) 
Cross-
sectional 
68.9±7.3 years 
Gleason 6.8±1.6 
Mean/median PSA level could not be 
determined 
Osteoporosis 
35.5% 
Low bone mass 
45.2% 
Prior radiotherapy, 
presence of bone 
metastases,  treatment 
with drugs affecting 
bone metabolism 
Radical 
prostatectomy 
7 
Conde, Sarna 
et al. 2004 [31] 
(USA) 
34 
(mostly African 
American) 
Cross-
sectional 
(Nested 
within a 
prospective 
longitudinal 
trial) 
69.1±7.6 years 
T1NxM0-T3NxM0 and Gleason 
6.3±1.3 
PSA 15.5±11.7ng/mL 
Osteoporosis 
17.6 % 
Low bone mass 
57.9% 
Presence of bone 
metastases, prior 
treatment with ADT or 
chemotherapy,  
documented secondary 
cause of osteoporosis, 
drugs affecting bone 
metabolism 
Participants 
due to 
commence 
ADT or on 
watchful 
waiting 
7 
Berruti, 
Dogliotti et al. 
2002 [32] 
(Italy) 
35 
(Mediterranean) 
Longitudinal 
75 years (60-85 years) 
T2N0/N1 and T3N0/N1 
No details on PSA level 
Osteoporosis 
14.3% 
Low bone mass 
45.7% 
Presence of bone 
metastases, 
documented secondary 
causes of osteoporosis, 
prior treatment with 
bisphosphonates and 
other drugs known to 
Participants 
due to 
commence 
ADT 
7 
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affect bone metabolism 
Hussain, 
Weston et al. 
2003 [33] 
(UK) 
174 
(1999-2002, 
Caucasian) 
Cross-
sectional 
74.6 years 
T1-T4 and M0-Mx 
Mean/median PSA could not be 
determined (PSA range 0.4-2148) 
Osteoporosis 
42.0% 
Low bone mass 
36.8% 
Prior treatment with 
ADT 
Participants 
due to 
commence 
ADT 
6 
Smith, 
McGovern et 
al. 2001 [34] 
(USA) 
41 
(mostly 
Caucasian) 
Cross-
sectional 
68±9 years 
Locally advanced and/or lymph node 
positive or recurrent disease 
PSA 15±21ng/mL 
Osteoporosis 
4.9% 
Low bone mass 
29.3% 
Presence of bone 
metastases, 
documented secondary 
causes of osteoporosis, 
prior treatment with 
bisphosphonates and 
other drugs known to 
affect bone metabolism 
Participants 
due to 
commence 
ADT 
7 
Cheung, 
Pattison et al. 
2013 [35] 
(Australia) 
216 
(2007-2011, 
Ethnicity not 
specified) 
Longitudinal 
69.8±7.1 years 
Non-metastatic disease 
No details on PSA level 
Osteoporosis 
10.6% 
Low bone mass 
39.8% 
Presence of bone 
metastases 
Participants 
due to 
commence 
ADT 
7 
Alibhai, 
Mohamedali et 
al. 2013 [36] 
(Canada) 
160 
(Ethnicity not 
specified) 
Longitudinal 
69.1±6.7 years and 69.8±6.7 years
#
 
T1NxM0-T3NxM0 
PSA 10.0 ng/mL (5.7-21.4 ng/mL) 
and 0.99 ng/mL (<0.05-4.5 ng/mL)
 #
 
Osteoporosis 
8.1% 
Low bone mass 
52.5% 
Not proficient in English, 
presence of another 
malignancy, life 
expectancy <1 year, 
major neuropsychiatric 
abnormality and inability 
to ambulate without 
assistance 
Participants 
about to 
commence 
ADT and men 
prostate cancer 
not eligible for 
ADT 
7 
Ziaran, 
Goncalves et 
al. 2013 [37] 
(Slovakia) 
95 
(Caucasian) 
Longitudinal 
73.5±6.3 years 
cT3a 
PSA 15.4±7.5 ng/mL 
Osteoporosis 
18.9% 
Low bone mass 
41.1% 
Presence of bone 
metastases, prior 
treatment with ADT or 
chemotherapy, drugs 
affecting bone 
metabolism 
Participants 
due to 
commence 
ADT 
6 
*Mean or median (for age and PSA level) are presented here as reported in the studies reviewed. 
#Separate results presented for men with about to commence ADT and men not eligible for ADT respectively. 
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Table 1.7 Results of the multi-category meta-analysis: comparing bone health status between men with prostate cancer on ADT 
and hormone-naïve patients. 
Osteoporosis 
prevalence stratum 
No ADT ADT* 
Normal bone 
mass 
Low bone mass Osteoporosis 
Normal bone 
mass 
Low bone mass Osteoporosis 
Low, % 
(95% CI) 
59.5 
(49.3-69.5) 
36.6 
(27.0-46.8) 
3.9 
(0.7-9.1) 
46.8 
(38.5-55.3) 
44.6 
(36.4-53.1) 
8.6 
(4.4-14.0) 
Moderate, % 
(95% CI) 
42.6 
(35.0-50.2) 
44.9 
(37.2-52.5) 
12.6 
(7.8-18.1) 
15.5 
(10.2-21.7) 
51.7 
(43.8-59.6) 
32.7 
(25.5-40.3) 
High, % 
(95% CI) 
19.7 
(14.7-25.3) 
42.4 
(36.0-49.1) 
37.8 
(31.5-44.4) 
15.1 
(12.2-18.2) 
32.4 
(28.6-36.5) 
52.5 
(48.5-56.8) 
*Prevalence presented in this column has been published previously [11]. 
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Sensitivity analyses 
There was a trend towards increasing prevalence of osteoporosis in older studies (≤ 
2004), in men aged over 70 years of age and in studies reporting on dietary calcium and/or 
vitamin D intakes (see Table 1.8). The only statistically significant difference, and of most 
clinical significance, was the increase in prevalence of osteoporosis in men with metastatic 
disease compared with those with localized or locally advanced disease (40.1%, 95% CI: 
28.4-52.3% v/s 13.7%, 95% CI: 6.6-22.0%). 
 
Publication bias 
Study asymmetry was not as clear as expected using the funnel plot. The Doi plot depicted 
in (Figure 1.10) was slightly asymmetrical, which is indicative of a preponderance of lower 
prevalence studies. However, this asymmetry could also result from study heterogeneity 
rather than publication bias. This heterogeneity has been addressed by stratification of 
studies into three homogeneous subgroups by prevalence as presented above. 
 
 
Figure 1.10 Doi plot (left) and funnel plot (right) to assess study asymmetry. 
 
Discussion 
Major findings 
This meta-analysis is the first to compile evidence on the prevalence of osteoporosis in 
hormone-naïve men with prostate cancer. Significant bone loss is experienced by 80% of 
hormone-naïve men with prostate cancer, of whom 3.9-37.8% have osteoporosis. This 
prevalence is lower than that of men with prostate cancer on ADT (9.0-53.0%) [11], but 
higher than that of healthy older males (6-10%) [38,40]. A study investigating advanced 
prostate cancer prior to ADT [33], which is included in this meta-analysis, reported similar 
Double arcsine prevalence 
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prevalence figures to our high prevalence group. The prostate cancer-free age-matched 
controls included in this study also had prevalence figures comparable with our moderate 
prevalence group. This suggests that advanced prostate cancer itself serves as a risk 
factor for osteoporosis independent of ADT or age. This is not surprising since prostate 
cancer with skeletal metastases is associated with increased bone resorption [41,42] as 
illustrated by elevated markers of bone resorption when compared with localized prostate 
cancer or benign prostatic hyperplasia [43]. This supports the findings from our sensitivity 
analysis that showed a three-fold increase in the prevalence of osteoporosis in hormone-
naïve men with metastatic prostate cancer compared to those with localized or locally 
advanced disease. While increased bone resorption clearly occurs in advanced metastatic 
prostate cancer, its mechanism is less clear. One possible contributing factor is the 
osteoblastic metastases [44-47] driving the mild hyperparathyroidism seen in men with 
prostate cancer [48]. This may lead to parathyroid hormone-driven systemic osteoclastic 
bone resorption to restore the bone/serum calcium equilibrium [49]. Regardless of the 
putative mechanism, it seems clear that in clinical practice, metastatic status can be used 
in the decision-making process about bone health management. 
 
The prevalence of osteoporosis in the moderate prevalence subgroup, which did not 
include men with metastatic prostate cancer, may reflect the burden of age or of additional 
prostate cancer related radiation therapy [50]. The latter leads to some degree of 
hypogonadism [51,52], probably due to testicular damage [53]. This decline in testosterone 
is seen in the year following radiation therapy to the prostate [52] but has also been found 
to persist three to eight years post-radiation [51]. Such low levels of androgens are likely to 
affect bone health similarly to ADT but the rate of bone loss may not be as rapid. The 
interplay between a greater burden of such treatment and of age may explain the 
difference in prevalence of osteoporosis in our moderate prevalence group compared with 
our low prevalence group. 
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Table 1.8 Sensitivity analyses in studies investigating osteoporosis in hormone-
naïve men with prostate cancer. 
Studies selected if 
Normal bone 
mass 
prevalence, 
% (95 % CI) 
Low bone mass 
prevalence, 
% (95% CI) 
Osteoporosis 
prevalence, 
% (95% CI) 
Publication year 
>2004 
42.2 
(28.6-53.9) 
44.3 
(30.5-56.1) 
13.5 
(5.5-23.2) 
≤ 2004 
32.7 
(12.7-53.8) 
40.0 
(18.2-61.1) 
27.3 
(8.9-48.1) 
Reporting of dietary calcium and/or vitamin D intake 
Yes 
31.6 
(8.5-56.9) 
46.8 
(19.3-71.3) 
21.6 
(2.9-46.0) 
No 
41.8 
(27.0-54.6) 
42.8 
(27.9-55.6) 
15.4 
(6.1-26.5) 
ADT focus of research* 
Yes 
42.1 
(28.0-54.9) 
43.2 
(29.0-55.9) 
14.7 
(5.9-25.3) 
No  
34.6 
(9.0-60.4) 
44.4 
(15.5-69.4) 
21.0 
(1.8-46.2) 
Median age 
<70yrs 
42.8 
(26.9-56.7) 
43.8 
(27.8-57.7) 
13.3 
(4.2-24.9) 
≥70yrs 
33.0 
(14.4-52.3) 
42.3 
(21.7-61.6) 
24.7 
(8.5-43.5) 
Disease stage 
Localized or locally advanced disease 
only 
42.4 
(30.6-52.6) 
43.9 
(32.0-54.1) 
13.7
#
 
(6.6-22.0) 
Metastatic disease 
23.0 
(13.4-34.0) 
36.9 
(25.5-49.0) 
40.1
#
 
(28.4-52.3) 
*Although ADT was the focus of these studies, only data on controls or prior to ADT initiation have been 
included here; 
#
These values are statistically different. 
 
Implications in the monitoring of bone health in the prostate cancer patient 
Androgen deprivation therapy has been associated with higher fracture risks in men with 
prostate cancer [54], but there is increasing evidence suggesting poor implementation of 
bone health monitoring and management in men with prostate cancer initiating ADT [55]. 
This meta-analysis reveals that the majority of men who are potential ADT candidates 
already have low bone mass or osteoporosis. We concluded that these patients did not 
meet their calcium requirements (879.0 mg/day against RDA 1000-1200mg [56]), nor did 
they meet their vitamin D requirements (192 IU/day against RDA 600-800IU [56]), and 
some of them were vitamin D insufficient based on the Endocrine Society Vitamin D 
insufficiency definition [57]. Therefore these patients are at even greater risk of 
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pathological fractures, upon treatment initiation, due to baseline elevated fracture risks. As 
a result, osteoporosis preventative strategies and/or pharmacological management will 
likely come too late in delaying pathological fractures. It is recommended that newly 
diagnosed men with prostate cancer be educated about osteoporosis preventative 
behaviours such as increasing calcium and vitamin D intake (via diet alone or 
supplements) and weight bearing exercise [58]. The timing of DXA scanning in men with 
prostate cancer on ADT differs internationally [5,59,60], but it may be useful to scan 
prostate cancer patients at baseline and 1-2 yearly thereafter [61] to identify whether 
pharmacological management is needed even before ADT. The WHO-endorsed fracture 
assessment tool, FRAX [62,63], should also be used prior to ADT initiation to determine 
the treatment plan [5]. While this tool can still be used once ADT has started, and is 
recommended by National Osteoporosis Foundation [62,63] and National Comprehensive 
Cancer Network [5], it may underestimate fracture risk in men with prostate cancer on ADT 
[64,65]. The FRAX tool does not take into account the increase in fracture risk with 
increasing duration of ADT [54]. Clinical judgment is paramount when managing bone 
health in prostate cancer patients, regardless of hormone status, hence awareness of the 
magnitude of poor bone health in this population is essential. 
 
Limitations and conclusion 
This meta-analysis aims at informing health professionals on the burden of osteoporosis in 
hormone-naïve men with prostate cancer, who are potential ADT candidates. The level of 
detail included in the studies reviewed by us dictated the information presented in this 
meta-analysis. We note that additional clinical data may have been valuable in assisting 
the understanding of heterogeneity in the prevalence of osteoporosis. For example, the 
potential impact of some clinically relevant treatments, such as radiation therapy, could not 
be explored here, and this represents a limitation of this meta-analysis. 
 
In conclusion, it has been found that hormone-naïve men with prostate cancer and 
potential ADT candidates have a high prevalence of low bone mass and osteoporosis but 
these remain lower than those of men with prostate cancer on ADT. This reinforces the 
idea that osteoporosis also affects men, but more importantly affects a sub-population 
which is at potential risk of increased pathological fractures. The disastrous resulting 
effects, notably fractures, therefore call for changes in the management of bone health in 
men with prostate cancer. A multidisciplinary approach is essential to reduce the added 
workload on the treating physician.  
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1.7 Psychological determinants of health behaviours 
 
 
 
The meta-analyses outlined the extent of the bone health problem in men with prostate 
cancer; however, there is evidence suggesting that DXA scanning and interventions, such 
as promotion of bone healthy behaviours, are poorly implemented at initiation of ADT (77). 
Evidence also suggests that men with prostate cancer lack basic osteoporosis knowledge 
and do not engage in bone healthy behaviours such as physical activity/exercise, and 
consuming adequate calcium and vitamin D (78). It is imperative to increase men’s 
awareness and understanding of this bone condition in order to promote the uptake of 
such bone healthy behaviours. Many theoretical frameworks have been used in 
osteoporosis research to investigate the psycho-behavioural and psycho-social drivers of 
Poor Bone Health 
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 Knowledge 
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 Self-efficacy 
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health behaviours. To understand bone healthy behaviours in men and women, two main 
theories have been used namely the Health Belief Model (HBM) and the Orem’s self-care 
deficit nursing theory. 
 
The HBM was first introduced in the 1950s (79) and encompasses several primary 
concepts that predict why individuals will take action to prevent, to screen for, or to control 
illness conditions. Self-efficacy was not incorporated in the earlier formulations of the HBM 
and was added in 1988 by Rosenstock, Strecher et al. (80). The constructs of this model 
include susceptibility, seriousness, barriers and benefits to behaviours, cues to action, and 
self-efficacy (81) as outlined in Figure 1.11. According to the HBM, the likelihood of 
engaging in health behaviours is associated with an individual’s health beliefs (82) and its 
constructs have been coined as “important contributors to the explanation and prediction 
of individuals’ health behaviours” (83). According to the HBM in the context of 
osteoporosis, bone healthy behaviours are more likely to change if an individual believes 
in personal susceptibility to osteoporosis and, at the same time, perceives that having 
osteoporosis would have serious consequences. This model also recognises the 
perceived barriers and benefits of behavioural change. 
 
The definition of the constructs of the HBM is as follows: 
 “Perceived susceptibility” is the belief about the chances of experiencing a risk or 
getting a condition. For example: whether men with prostate cancer perceive to be 
at risk of osteoporosis and/or fractures. 
 
 “Perceived severity” is the belief about how serious a condition and its sequelae 
are. For example: the perception that osteoporosis and/or fractures are serious or 
not. 
 
 “Perceived benefits” is the belief in efficacy of the advised action to reduce risk or 
seriousness of impact. For example: whether men with prostate cancer perceive 
that increased physical activity and calcium intake would decrease the risks of 
osteoporosis and/or fractures. 
 
 “Perceived barriers” is the belief about the tangible and psychological costs of the 
advised action. For example: whether men with prostate cancer identify barriers to 
increasing physical activity and/or calcium intake.  
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 “Cues to action” are the strategies to activate “readiness”. 
 
 “Self-efficacy” is the confidence in one’s ability to take action. For example: how 
confident are men with prostate cancer in increasing physical activity and/or dietary 
calcium? 
Sourced from (79-81). 
 
 
Figure 1.11 The Health Belief Model. 
The constructs are highlighted in the shaded area (79-81) 
 
Self-efficacy is derived from the social cognitive theory and has been defined as “the 
conviction that one can successfully execute the behaviour required to produce the 
outcomes” (84). An individual is motivated to engage in a behaviour based on the belief 
that it will result in a favourable outcome (outcome expectation) and on the capacity to 
execute the behaviour (efficacy expectation). This capacity is related to behaviour by the 
conviction that an individual has the ability to initiate the activity, maintain it, and persist in 
the activity despite obstacles (85). 
 
Another psychological determinant of health behaviours that has been researched, 
especially among women, is osteoporosis knowledge (86). Knowledge falls under Orem’s 
Self-Care Deficit Nursing Theory, which is one aspect of the Self-Care Theory (87). Self-
care is defined as: 
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“the practice of activities that mature and maturing persons initiate and perform, 
within time frames, on their own behalf in the interests of maintaining life, healthful 
functioning, and development” (88). 
Knowledge is an important aspect of chronic health awareness efforts as it informs 
decisions about health practices (86). In chronic disease management, increased 
knowledge leads to improved patient’s compliance through increased identification and 
awareness with the decision-making process (89). Disease knowledge, especially 
symptom knowledge is important as it can facilitate early detection of disease (90).  
 
Health beliefs, self-efficacy, and osteoporosis knowledge are modifiable, therefore they are 
important to take into consideration when designing osteoporosis interventions (91). There 
is still much work to do in bone health education because women are more likely to 
perceive themselves at risk of osteoporosis and perceive more benefits of calcium intake 
than men (83). This is a concern as perceived susceptibility is one of the most influential 
HBM construct on health behaviour (92). It was demonstrated that women were more 
likely to take calcium supplements if they perceived themselves at risk/susceptible to 
osteoporosis and if they perceived the benefits of taking calcium (83). The body of 
literature on these psycho-behavioural and psycho-social factors are scarce in men (83) 
despite the fact that osteoporosis and low bone mass are common in this gender. 
 
1.8 Review of prostate cancer clinical guidelines: a focus on bone 
health management strategies 
In light of the deleterious effects of ADT on bone health of men with prostate cancer, a 
review of the clinical guidelines for the management of prostate cancer, with a focus on 
bone health, was conducted. The aims were to identify the range and breadth bone health 
recommendations made; and to determine their relevance against the latest evidence and 
adequacy of translating this evidence into practice recommendations. Guidelines from the 
European Association of Urology (93), the UK (94), the USA (National Comprehensive 
Cancer Network) (3), and Australia (95) are included here. The Australian guidelines (95) 
for the management of advanced prostate cancer are available in a wiki format and were 
first published in 2010, therefore are not considered current by the NH&MRC. Although the 
new wiki format has allowed for some recent updates, the evidence on which the bone 
health recommendations are based on is at least 10 years old. Despite being outdated, 
these guidelines are included here as they reflect Australian evidence-based practice in 
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prostate cancer management up to now. The four guidelines were mined for 
recommendations specific to osteoporosis, bone health, and/or fractures, regardless of 
prostate cancer treatment. All recommendations on bone health monitoring, calcium, 
vitamin D, and/or exercise were appraised for their relative adequacy. Summary of such 
recommendations are included in Table 1.9. 
 
The Australian clinical guidelines for the Management of Locally Advanced and Metastatic 
Prostate Cancer (95) include a comprehensive review of studies, albeit at least 10 years 
old, investigating bone loss secondary to ADT. This evidence (BMD loss, fractures, and 
frailty) is subsequently discussed in the context of ADT. The guidelines (i) recommend to 
consider the prostate cancer patient with his co-morbidities before prescription of ADT, 
and (ii) state that ADT “may not be desirable” for men with low bone mass (osteopenia). 
The bone health-related recommendations are Grade C, based on the NH&MRC levels of 
evidence and grades for recommendations, as most of the studies were observational. 
The guidelines recommend taking into consideration the side effects of ADT, especially 
osteoporosis and the increased risk of pathological fractures, before treatment is initiated. 
These guidelines are patient-centred as they recommend discussing the iatrogenic effects 
of ADT with the patients in order to tailor the treatment plan to the patient’s needs. BMD 
monitoring is mentioned briefly as a footnote but not included in the many 
recommendations made in these guidelines. This footnote also includes some information 
about preventative strategies such as calcium and vitamin D supplementation, and 
exercise. In summary these guidelines offer limited recommendations on the management 
of bone health in the prostate cancer patient, and are inadequate in light of the extent of 
the osteoporosis problem exposed in sections 1.6.1 and 1.6.2. 
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Table 1.9 Summary of bone health-related recommendations in clinical guidelines for the management of prostate cancer 
Guideline 
Prescriptive 
in nature 
Room for 
clinical 
judgement 
Patient-
centred 
Osteoporosis 
and/or fractures 
discussed as side 
effects of ADT 
Includes exercise 
recommendations 
Recommends 
dietetic input 
Calcium and 
vitamin D 
recommendations 
DXA 
monitoring 
Australian 
Guidelines 
(95) 
 
    
 
 
Considered to be 
part of clinical 
judgement 
 
Considered to 
be part of 
clinical 
judgement 
EAU 
guidelines 
(93) 
  
 
  
 
  
NICE 
guidelines 
(94) 
 
   
 
For the 
management of 
fatigue not 
osteoporosis 
   
NCCN 
guidelines 
(3) 
 
  
 
 
   
NCCN, National Comprehensive Cancer Network; NICE, National Institute for Health and Care Excellence; EAU, European Association of Urology. 
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The guidelines from the European Association of Urology acknowledge bone problems as 
systemic side effects of ADT. These guidelines promote a holistic approach, whereby the 
prostate cancer patient needs an overall health assessment similarly to the geriatric 
patient. This document also discusses the increase in bone turnover and decrease in BMD 
secondary to treatment with ADT. They recommend pharmacological treatment as well as 
encouraging patients to adopt bone healthy lifestyle changes, such as increasing physical 
activity, smoking cessation, reduction of alcohol intake, and normalising BMI. Calcium and 
vitamin D supplementation are recommended only if blood levels are low. These 
guidelines give detailed information on (i) how to identify patients at increased risk of 
fractures, including the WHO-endorsed FRAX®, and (ii) how to identify patients with 
behaviours that could be detrimental to their overall health. Bone health management 
recommendations include BMD measurement before initiation of long-term treatment, with 
repeated measures every year for the osteoporotic patient or very second year for the 
osteopenic patient. These guidelines offer a holistic and integrated approach in the 
management of bone health in prostate cancer patients, but the recommendations on 
fracture prevention need to be updated. 
 
The Prostate Cancer: Diagnosis and Treatment guidelines from the National Institute for 
Health and Care Excellence (NICE) (94) were recently reviewed, with the updated version 
published in 2014 (previous version 2010). The discussion of the iatrogenic effects of ADT 
in the current guidelines is not as detailed as the other guidelines reviewed here. The 
updated NICE guidelines include a new, but only one, recommendation on the 
management of fracture risks in men with prostate cancer on ADT. Assessment of fracture 
risks is recommended in line with the NICE Osteoporosis guidelines; hence implying that 
other bone health management strategies need to be applied to this population. 
 
The Clinical Practice Guidelines in Oncology – Prostate Cancer from the National 
Comprehensive Cancer Network (NCCN) (3) are the most up-to-date guidelines and 
provide the most comprehensive recommendations on the management of bone health in 
men with prostate cancer. These guidelines include a short review of the literature on 
prostate cancer and bone health, and the related clinical trials. All of the adverse effects of 
ADT are enumerated, but most of the related recommendations address osteoporosis and 
fractures. As with most of the prostate cancer guidelines, the NCCN recommends 
discussing all the side effects of ADT with the patient prior to treatment. The NCCN 
guidelines summarise recommendations for the screening and management of 
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osteoporosis, and refer to another document (from the National Osteoporosis Foundation) 
for further details. Fracture risk assessment is recommended using the WHO-endorsed 
FRAX® algorithm, with detailed instructions on how to use this algorithm in men with 
prostate cancer on ADT (see Appendix II for the FRAX® algorithm). Recommendations on 
the management of patients at increased risks of fractures, using the above-mentioned 
tool, are (i) supplementation with calcium (1200 mg/day) and vitamin D3 (800 – 1000 
IU/day), and (ii) following a detailed pharmacological protocol. Bone health monitoring 
(using DXA scanning) is recommended before treatment with ADT and one year after 
treatment initiation, as recommended by the ISCD. The current guidelines also 
acknowledge the lack of consensus on the “optimal approach to monitor the effectiveness 
of drug therapy” (meaning bone-targeted therapy). Most interestingly the NCCN guidelines 
are the only ones to mention the need for a nutritionist on the bone health management of 
men with prostate cancer. Assessment of dietary calcium intake and serum 25-hydroxy 
vitamin D levels should be used by this allied health professional when tailoring the bone 
health treatment plan. 
 
The guidelines from the NCCN offer the most comprehensive recommendations with a 
strong emphasis on preventative strategies such as calcium and vitamin D 
supplementation; however, reviewing these four guidelines revealed a high level of 
inconsistency in the bone health recommendations and depth between the guidelines. 
Given the high prevalence of osteoporosis in men with prostate cancer, the high risk of 
fractures that ensues, and the strength of the evidence supporting the fracture-
preventative effects of calcium and vitamin D, bone health management recommendations 
need to be updated. There is a clear gap between the ‘gold standard’ of clinical practice 
and bone healthy behaviours that needs to be addressed; however, it is paramount to 
understand current bone healthy behaviours in men with prostate cancer to better target 
future recommendations and interventions. 
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CHAPTER 2 BONE HEALTH ON THE PROSTATE CONTINUUM 
 
 
 
The previous chapter summarised the prevalence of osteoporosis in men with prostate 
cancer, whether treated with ADT or not. This chapter attempts to explore the bone health 
of men with prostate cancer in greater details, including osteoporosis status and risk of 
post-diagnostic fractures, and comparing three groups of men with diseased prostates. 
This was achieved through the secondary analysis of DOES, from the Garvan Institute, 
Sydney. Data collection for this longitudinal study started in 1989 and is ongoing, with 
main aim to investigate the risk factors of osteoporosis in a town that was believed to be 
representative of the Australian population (96, 97).  
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The initial aim of this chapter was to identify the longitudinal changes in BMD and bone 
health status, starting before prostatic disease diagnosis and ending after diagnosis. This 
dataset comprises over 2000 men, therefore men with prostate cancer or BPH diagnosed 
after baseline measurement and cancer-free controls were selected for this analysis. The 
longitudinal changes in BMD and evolution of bone health status could not be explored 
due to violations of statistical assumptions, hence interfering with the reliability of the 
results. As a result, the focus for this manuscript evolved and aimed to investigate the 
effects of prostatic disease (prostate cancer and BPH) on fracture risk. 
 
This manuscript has been submitted to The Prostate, and is currently under review. 
 
Date submitted: 7th June 2015 
 
Please note that the reference style for this manuscript is that appropriate for the journal. 
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Abstract 
Background: The poor bone health of men with prostate cancer on ADT is well-
documented but this is not the case for other patient groups with prostatic diseases. The 
present study aims at investigating the bone health of men on the prostate cancer 
continuum; hence presented here is the secondary analysis of the Dubbo Osteoporosis 
Epidemiology Study, focussing on men with diseased prostates. Methods: We identified 
484 prostate cancer-free controls, and 53 men with BPH and 53 men with prostate cancer 
(27 on ADT and 26 hormone-naïve) who were diagnosed after enrolment in this study. We 
conducted logistic regression analysis to determine the association between prostatic 
disease and the incidence of post-diagnostic osteoporosis. Cox proportional regression 
was also used to determine the impact of prostatic disease on post-diagnosis fracture risk. 
Results: The incidence of osteoporosis after diagnosis of prostatic disease was 20.8% in 
men with BPH, 23.1% in hormone-naïve men with prostate cancer, and 44.4% in men with 
prostate cancer on ADT. The odds ratio for incident osteoporosis/osteopenia at the lumbar 
spine was 0.32 (95% CI: 0.11-0.92; p=0.04) for men with BPH when compared with men 
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with prostate cancer on ADT. Post-diagnostic fractures were present in 18.4% of men with 
BPH, 36.3% of hormone-naïve men with prostate cancer, and 48.0% of men with prostate 
cancer on ADT. Conclusion: This paper thus reveals that poor bone health is a significant 
problem in men with diseased prostates, and not just men on ADT. It is therefore important 
to implement bone health management strategies and preventative behaviours even 
before treatment with ADT. 
 
Keywords 
Osteoporosis, prostatic neoplasm, benign prostatic hyperplasia, osteoporosis, bone 
fractures 
 
Introduction 
Benign prostatic hyperplasia (BPH) and prostate cancer are highly prevalent in elderly 
men (1,2). There are many treatment modalities for prostate cancer including active 
surveillance, radiation therapy and androgen deprivation therapy (ADT), all of which 
impact on the physical and psychological wellbeing of these patients. Severe 
hypogonadism, as a result of treatment with ADT, and its related side-effects have been 
extensively researched (3-5). A well-accepted adverse effect of ADT is severe bone loss 
that leads to osteoporosis, which affects 9-53% of men with prostate cancer on ADT (6). 
On the other hand, only 4-38% of hormone-naïve men with prostate cancer have 
osteoporosis (7), which could be age-related and/or secondary to treatment such as 
radiation therapy. There is evidence to suggest that external beam radiation therapy leads 
to hypogonadism (8,9), which may impact the bone health of hormone-naïve men with 
prostate cancer in similar fashion to their ADT counterparts. Osteoporosis has devastating 
outcomes that increases morbidity and mortality (10). 
 
Osteoporosis and low bone mass (osteopenia) increase the risks of fragility fractures (11). 
In men with prostate cancer fractures are a result of osteoporosis, which is secondary to 
ADT (12), or fractures are pathological, which is secondary to metastases (13). In those 
treated with ADT, fractures have been associated with a decrease in overall survival (13). 
A large proportion of the literature on male bone health focusses on ADT in prostate 
cancer. There are some studies investigating the bone health of hormone-naïve men with 
prostate cancer and even fewer studies investigating men with BPH. Since prostatic 
diseases (prostate cancer and BPH) are age-related diseases, it is important to expand 
the research focus beyond ADT. Therefore this paper aims to investigate the bone health 
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of men on a prostatic disease continuum, including two hormonally diverse groups. The 
secondary aims of the study are to identify the effect of the diagnosis of a prostatic disease 
on the incidence of osteoporosis and/or osteopenia; and the incidence of fractures. Men 
with BPH and hormone-naïve men with prostate cancer are hypothesized to have a lower 
incidence of osteoporosis and fractures than men with prostate on ADT. 
 
Materials and methods 
The present secondary analysis is based on the data collected in the Dubbo Osteoporosis 
Epidemiology Study (DOES), which was initiated in 1989 and is an ongoing prospective 
longitudinal population-based epidemiological investigation. The main objective of DOES 
was to evaluate the clinical risk factors for fractures among an elderly Australian sub-
population (14,15). In brief, all elderly men and women from the city of Dubbo were invited 
to participate in this study, with follow-up conducted every two years. The study details 
have been reported previously (14,15). Data collected between 1989 and 2012, at two 
year intervals between each visit, have been used here. The St Vincent’s Campus 
Research Ethics Committee approved this study, and written informed consent was 
obtained for all study participants. 
 
By the end of 2012, 1479 men had been recruited in DOES. Men reporting a diagnosis of 
prostate cancer or BPH were classified as cases. The cases were further grouped based 
on reports of treatment with ADT. Controls were remaining prostate cancer-free males. 
Men with data collected at one time point only were excluded from this analysis. Only 
incident cases of prostate cancer and BPH were included in this study while men with 
prevalent disease were excluded as pre-diagnostic changes in bone health could not be 
ascertained. Participants in this study have therefore been divided into 4 groups: men with 
prostate cancer on ADT, hormone-naïve men with prostate cancer, men with BPH and 
prostate cancer-free controls (see Figure 2.1). Pre-diagnostic data were defined as data 
collected at enrolment of DOES (baseline) while post-diagnostic data were defined as data 
collected closest to year of prostatic diseases diagnosis. 
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Figure 2.1 Flowchart representing participants included and excluded from the 
secondary analysis of Dubbo Osteoporosis Epidemiology Study on the bone health 
of men with BPH or prostate cancer. 
BPH, benign prostatic hyperplasia; ADT, androgen deprivation therapy; DOES, Dubbo Osteoporosis 
Epidemiology Study. 
 
Baseline and follow-up data (at year of prostatic disease diagnosis), including age, medical 
history, medication and supplement use, and smoking status, were collected by the nurse 
coordinator during a structured interview. Weight (to the nearest 0.1 kg) and height (to the 
nearest 0.1 cm) were measured in light clothing and without shoes using an electronic 
scale and wall-mounted stadiometer, respectively. Calcium intake was determined using a 
calcium-specific food frequency questionnaire (98) and smoking was defined as past or 
1479 
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270 
Men with BPH or 
prostate cancer 
53 
Men with BPH 
26 
Men with  prostate 
cancer not on ADT 
27 
Men with prosate 
cancer on ADT 
164 excluded 
- BPH or prostate cancer 
diagnosed before enrolment in 
DOES 
- Lack of follow-up data 
1209 
Prostate cancer-
free elderly men 
484 
Prostate cancer-
free controls 
725 exlcuded 
- Lack fo follow-up 
data 
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present tobacco intake. Dietary calcium was measured at baseline and every five years, 
with the latter not coinciding with prostatic disease diagnosis time point for many 
participants. Only dietary calcium intake at baseline was included here, since it was the 
most complete dietary variable available for all participants. 
 
Dual energy x-ray absorptiometry (Lunar DPX and Prodigy densitometers; Lunar Radiation 
Corporation, Madison, Wisconsin, USA) was used to measure bone mineral density (BMD 
in g/cm2) at lumbar spine (LS), femoral neck (FN), Ward’s triangle and trochanter. BMD 
was measured at baseline and at multiple times during the follow-up period at 
approximately 2-year intervals. In all cases the right hip was scanned unless a hip fracture 
or hip replacement had occurred in which case the left hip was scanned. Because of 
differences between BMD measured on the two DXA scanners (16), BMD was stratified 
based on the WHO osteoporosis diagnostic criteria (17), where a T-score ≤ -2.5 was 
classified as osteoporosis, -2.5 < T-score ≤ -1 was classified as low bone mass 
(osteopenia), and T-score > -1 was classified as normal bone mass. In multivariate 
analyses osteoporosis and osteopenia were grouped together as the number of 
osteopenic cases was too small. The number of non-trauma fractures for all participants 
was recorded. For cases only, the prevalence of non-trauma fractures before and after 
diagnosis was calculated. 
 
Statistical analyses 
To determine the difference between participants’ characteristics at enrolment of DOES, 
continuous variables were compared using one-way between-groups ANOVA with Post 
Hoc comparisons using Tukey HSD test. For non-normally distributed continuous variables 
the Kruskal-Wallis test was used. For categorical variables, Chi-square test was used. 
Significant difference was determined at p < 0.05. The same univariate tests were applied 
on outcome variables collected at time of prostate cancer or BPH diagnosis. 
 
To determine whether the diagnosis of prostate cancer (ADT or not on ADT) or BPH 
affected the incidence osteoporosis/osteopenia, a logistic regression model for each 
skeletal site (LS and FN) was conducted. Dietary calcium, age, BMI, and years since 
diagnosis were associated with incidence of osteoporosis/osteopenia in univariate models, 
hence were included in the logistic regression models. For the LS model, the predictors 
forced in the models were age, BMI, prostate health, and years since diagnosis. For the 
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FN model, the predictors forced in the model were age, BMI, prostate health, number of 
years since diagnosis, and calcium intake at baseline for the FN. 
 
Cox proportional hazards regression analysis was used to determine the risk of fractures 
occurring between time diagnosis of a prostatic disease and last follow up visit recorded, 
while adjusting for number of fractures before diagnosis and incidence of osteoporosis at 
the LS and FN. The computer software used for all statistical analyses was Statistical 
Package for the Social Sciences (SPSS; version 22, IBM Corporation). Participants with 
missing data on prostate health and BMD were excluded from all analyses. 
 
Results 
Characteristics at baseline 
The DOES dataset comprised 1479 men (1989 - 2012), of which 270 were diagnosed with 
BPH or prostate cancer. Over half (n = 164) were excluded as they were either diagnosed 
with a prostatic disease before enrolment in the study or because they did not complete 
the first follow-up visit. A total of 53 men with BPH, 27 men with prostate cancer on ADT 
and 26 hormone-naïve men with prostate cancer were included in this study (see Figure 
2.1). Controls who were lost at follow-up were also excluded leaving a total number of 484. 
The characteristics of study participants at baseline are presented in Table 2.1. Age was 
significantly different between the groups with hormone-naïve men with prostate cancer 
being younger than controls (p = 0.004). The median time from enrolment (baseline 
measurement) and year of prostatic disease diagnosis was 6 years (range 0 - 21). 
 
Characteristics at year of prostatic disease diagnosis 
The incidence of LS osteoporosis/osteopenia was 20.8% (n = 11) in men with BPH, 23.1% 
(n = 6) in hormone-naïve men with prostate cancer, and 44.4% (n = 12) in men with 
prostate cancer on ADT (p = 0.068). At the FN, the incidence of osteoporosis was 59.2% 
(n = 29) in men with BPH, 50.0% (n = 12) in hormone-naïve men with prostate cancer, and 
51.9% (n = 14) in men with prostate cancer on ADT (p = 0.706). Multinomial logistic 
regression was performed to assess the impact of the respective prostatic diseases, 
calcium intake at baseline, age, BMI, and/or time since diagnosis on the incidence of 
osteoporosis/osteopenia at the FN and LS (Table 2.2 and Table 2.3). The odds of having 
LS osteoporosis/osteopenia are 3.2 times lower in men with BPH than men with prostate 
cancer on ADT (p = 0.035). Increasing calcium intake slightly reduces the odds (OR = 
0.998, p = 0.013) of having osteoporosis/osteopenia at the FN.  
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Table 2.1 Characteristics of study participants at enrolment in this study 
 
Prostate 
cancer no 
ADT 
Prostate 
cancer ADT 
BPH Controls p-value 
Total (n) 26 27 53 484 
 
Age (yrs)
1
 64.5 (3)
a
 68 (7) 67 (5.5) 68 (7) 0.004 
Weight (g) 86.2 (12.2) 79.5 (11.7) 81.2 (12.3) 81.1 (13.1) 0.22 
Height (cm) 175.3 (6.3) 174.8 (6.0) 174.5 (5.9) 173.4 (6.7) 0.23 
BMI (kg/cm
2
) 28.1 (4.1) 26.1 (3.9) 28.7 (4.0) 29.9 (3.8) 0.25 
Dietary Calcium 
Intake (mg) 
720 (300) 675 (590) 650 (260) 680 (565) 0.96 
Alcohol intake (g)
1
 40 (43) 15 (133) 10 (40) 12 (46) 0.10 
LS BMD (g/cm
2
) 1.29 (0.20) 1.21 (0.26) 1.29 (0.25) 1.27 (0.20) 0.36 
FN BMD (g/cm
2
) 0.98 (0.11) 0.95 (0.15) 0.93 (0.13) 0.93 (0.14) 0.42 
WT BMD (g/cm
2
) 0.81 (0.13) 0.75 (0.17) 0.74 (0.15) 0.75 (0.15) 0.22 
TR BMD (g/cm
2
) 0.96 (0.14) 0.93 (0.16) 0.92 (0.12) 0.92 (0.15) 0.44 
LS Z-score 0.55(1.54) 0.28 (2.20) 0.92 (2.20) 0.68 (1.60) 0.47 
LS T-score 0.38 (1.65) -0.22 (2.21) 0.48 (1.67) 0.21 (1.18) 0.41 
FN Z-score 0.12 (0.75) 0.22 (0.99) 0.01 (1.01) 0.13 (1.02) 0.84 
FN T-score -0.81 (0.87) -0.93 (1.09) -1.13 (1.06) -1.05 (1.11) 0.67 
Osteoporosis/ 
Osteopenia at LS, % (n) 
25.0 (6) 50.0 (13) 24.5 (13) 22.6 (100) 0.02 
Osteoporosis/ 
Osteopenia at FN, % (n) 
34.8 (8) 46.2 (12) 52.8 (28) 56.2 (246) 0.18 
Fracture prevalence pre-
diagnosis, % (n) 
9.1 (2) 8.0 (2) 10.2 (5)  0.95 
DXA Machine   
   Prodigy, % (n) 
   Lunar, % (n) 
26.9 (7) 
73.1 (19) 
7.4 (2) 
92.6 (25) 
9.4 (5) 
90.6 (48) 
14.5 (70) 
85.5 (414) 
0.14 
Bisphosphonates, % (n) 0 (0) 0 (0) 5.7 (3) 3.3 (16) 0.43 
Calcium Supps, % (n) 3.8 (1) 0 (0) 5.7 (3)  3.7 (18) 0.66 
Current Steroid use, % (n) 0 (0) 0 (0) 3.8 (2) 0.6 (3) 0.10 
Beta Blocker, % (n)      
Current Smoker, % (n) 4.2 (1) 4.5 (1) 2.3 (1) 4.6 (19) 0.90 
Past Smoker, % (n) 75.0 (18) 57.9 (11) 54.8 (23) 60.2 (189) 0.43 
BPH, benign prostatic hyperplasia; LS BMD, Lumbar spine bone mineral density; FN BMD, femoral neck 
bone mineral density ; WT BMD, Ward’s triangle bone mineral density; TR BMD, trochanter bone mineral 
density; DXA, dual x-ray absorptiometry 
Mean (SD) presented for continuous variables and 
1
median (inter-quartile range) for non-normally distributed 
variables 
Percentage (n) for categorical variables 
a
Kruskal-Wallis test for comparison between with prostate cancer no ADT and controls, p=0.004 
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Table 2.2 Multivariable relationships between incidence of osteoporosis (at lumbar 
spine) and the diagnosis of prostatic diseases 
 
Number 
of men 
Incidence 
osteoporosis, 
% (n) 
Crude 
OR
a
 
Adjusted
b
 
OR
a
 
95% CI
c
 Sig.
d
 
Prostatic 
disease 
group 
Prostate 
cancer ADT 
27 7.4 1.00 1.00 Referent  
Prostate 
cancer no 
ADT 
25 0 0.38 0.54 
0.15-
1.98 
0.35 
BPH 53 1.9 0.33 0.32 
0.11-
0.92 
0.04 
Age at diagnosis, years   1.02 1.00 
0.92-
1.08 
0.93 
BMI, kg/m
2
   0.84 0.84 
0.73-
0.96 
0.01 
Years since prostatic 
disease diagnosis, years 
  1.24 1.21 
0.82-
1.79 
0.34 
a Odds ratio of fracture incidence 
b Odds ratio adjusted for all other variables in the table 
c Confidence interval for estimate of adjusted odds ratio 
d Statistical significance of the adjusted odds ratio 
 
Post-diagnostic fractures 
The numbers of years between diagnosis and incidence of first fracture varied between 
zero and 17 years (mean 1.8 years, SD = 3.6 years). Post-diagnostic fractures occurred in 
18.4% of men with BPH, 36.3% of hormone-naïve men with prostate cancer, and 48% of 
men with prostate cancer on ADT. The hazard of post-diagnostic fractures was lower in 
men with BPH when compared with men with prostate cancer on ADT (HR: 0.284, 95% CI 
= 0.091 - 0.892; p = 0.031) when adjusting for number of fractures pre-diagnosis and 
incidence of osteoporosis (at LS and FN) at baseline. This difference in hazard was no 
longer seen when adjusting for incidence of osteoporosis (at LS and FN) at diagnosis.  
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Table 2.3 Multivariable relationships between incidence of osteoporosis (at femoral 
neck) and the diagnosis of prostatic diseases 
 
Number 
of men 
Incidence 
osteoporosis, 
% (n) 
Crude 
OR
a
 
Adjusted
b
 
OR
a
 
95% CI
c
 Sig.
d
 
Prostatic 
disease 
group 
Prostate 
cancer ADT 
27 4.2 1.00 1.00 Referent  
Prostate 
cancer no 
ADT 
23 7.4 0.93 1.56 
0.422-
5.781 
0.504 
BPH 48 12.2 1.35 1.77 
0.60-
5.23 
0.301 
Age at diagnosis, years   1.02 1.00 
0.93-
1.08 
0.937 
BMI, kg/m
2
   0.87 0.90 
0.79-
1.01 
0.076 
Years since prostatic 
disease diagnosis, years 
  0.76 0.72 
0.46-
1.13 
0.154 
Ca intake at baseline, mg   0.998 0.998 
0.996-
1.00 
0.013 
a Odds ratio of fracture incidence 
b Odds ratio adjusted for all other variables in the table 
c Confidence interval for estimate of adjusted odds ratio 
dStatistical significance of the adjusted odds ratio 
 
Discussion 
The prevalence of osteoporosis is comparable in men with prostate cancer on ADT and 
not on ADT at time of diagnosis, suggesting that any differences in the progression of this 
bone disease can be due to treatment side-effects. For example, the lack of difference 
between men on ADT and the hormone-naïve group was likely due to recent treatment 
with ADT, less than one year, whereby bone loss had not lead to osteoporosis yet. This is 
in line with previous studies reporting on the deleterious effects of ADT on BMD over time 
(18,19). There is also evidence supporting the negative impact of localized treatments on 
bone health of men with prostate cancer, notably radiation therapy (8,9). The mechanism 
underlying this effect is the testicular damage secondary to radiation, resulting in low 
testosterone levels for up to 8 years (9). Such low levels in testosterone may be 
responsible for some degree of bone loss but not to the same extent as ADT. In other 
words men with prostate cancer have poor bone health that is likely to worsen upon 
treatment.   
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Men with BPH were less likely to have osteoporosis at the LS than men with prostate 
cancer on ADT at time of diagnosis. As mentioned previously, this is not likely to be due to 
pharmacological management as these would have been prescribed for long enough to 
exert such effects. This finding, more specifically the potential mechanism for such effect is 
unclear. Further investigations into the various circulating growth factors and BMD will help 
identify pathophysiological candidates associated with this protective/adverse effect. 
 
The difference in post-diagnostic fractures was expected between men with BPH and men 
with prostate cancer on ADT, as the latter treatment leads to porous bone that is more 
prone to fragility fractures (18,20). Metastases are also responsible for pathological 
fractures in men with prostate cancer, whether on ADT or not (21); therefore it explains the 
difference between men with BPH and men with prostate cancer on ADT, who might have 
metastatic disease. The lack of difference between hormone-naïve prostate cancer and 
their ADT counterparts was surprising. This could be a result of our inability to control for 
certain confounders that were not collected as part of this study. The confounders that 
impact on fracture risk in men with prostate cancer include presence of metastases, time 
since ADT initiation, disease stage and grade, and radiation therapy (12). 
 
A strength of this study was the comparison of the bone health of men with BPH with the 
bone health of men with prostate cancer (on ADT and not). This is a novel approach as 
most studies to date have compared healthy men to those with prostate cancer (6, 7). The 
current analysis has greater clinical implications, as it supports bone health monitoring of 
patients presenting with BPH rather than only focussing on the cancer patients on ADT. 
While bone health monitoring of the latter group is critical, a preventative approach may be 
more effective in men with BPH. 
 
Because of inherent challenges in longitudinal studies, we could not evaluate the 
longitudinal effects of prostatic diseases on the progression of poor bone health. For 
example, longitudinal statistical modelling could not be applied here due to the 
inconsistencies in the number of follow-up visits across the study participants. Exclusions 
of study participants to meet such criteria would lead to small number of cases (prostate 
cancer and BPH) that would compromise statistical power. Post-hoc sample size 
calculations revealed that a minimum of 202 hormone-naïve men with prostate cancer and 
those on ADT would have been needed to conclude that the current incidences of 
osteoporosis (at LS) were statistically different. This study reports on poor bone health in 
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men with diseased prostates and adds to the growing body of evidence that osteoporosis 
is a disease that affects men as well as women. 
 
Conclusions 
This paper thus reveals that poor bone health is a significant problem in men with 
diseased prostates, and not just men on ADT. It is therefore important to implement bone 
health management strategies and preventative behaviours even before treatment with 
ADT. The current prostate cancer guidelines (22) recommend bone health management 
strategies upon ADT initiation but there is evidence that it has not been translated to 
practice (23,24). It is possible that early lifestyle changes on the prostate cancer 
continuum (or even BPH) might reduce the bone-related burden of future ADT treatment. 
There are also benefits beyond prostate cancer treatments, as prostate cancer survivors 
can live many years post-treatment. 
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CHAPTER 3 BONE HEALTHY BEHAVIOURS AND PSYCHO-
BEHAVIOURAL AND PSYCHO-SOCIAL FACTORS 
 
 
 
The previous chapters have demonstrated the extent of the osteoporosis problem among 
men with prostate cancer, regardless of hormonal status. While poor bone health is a well-
known side-effect of ADT, less is known about preventative strategies and drivers of such 
strategies that are specific to men with prostate cancer. Deficits in osteoporosis knowledge 
have been identified in this population and are likely to result in poor uptake of 
osteoporosis preventative health behaviours. To confirm this the following studies were 
performed.  
Poor Bone Health 
Determinants of health behaviours 
 Knowledge 
 Health Beliefs 
 Self-efficacy 
Health Behaviours 
(risk factors and prevention) 
 Calcium and dairy 
products intake 
 Exercise and physical 
activity 
 Smoking 
 Alcohol intake… 
ADT 
Ageing 
Treatments 
Osteoblastic 
metastases 
Prostate 
Cancer 
Others 
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The drivers of healthy bone behaviours are well-research post-menopausal women (99-
102), while elderly men at risk of osteoporosis are often ignored (103). Men with prostate 
cancer are at increased of poor bone health as demonstrated in the previous sections; 
therefore it is important to understand their health behaviours specific to osteoporosis. This 
will help inform future interventions, side-effects management strategies, and bone health 
education programs. There has been recent interest in understanding the drivers of health 
behaviours in men with prostate cancer (78). A pilot cross-sectional study was conducted 
to build on such evidence and further explore dietary health behaviours, which may impact 
on the bone health of men with prostate cancer. Men with prostate cancer and survivors 
previously participating in a student-led exercise clinic were recruited in this study. A total 
of 54 men were invited, with 41 consenting and eligible men participating. 
 
The results are presented in the form of two manuscripts, which are currently under review 
in American Journal of Men’s Health and Nutrition and Dietetics. Section 3.1 focusses on 
the specific drivers of health behaviours including osteoporosis knowledge, osteoporosis-
related health beliefs, and osteoporosis-related self-efficacy. The relationship between 
these drivers, dietary intake, and bone health status has also been explored. This is 
followed by section 3.2, which addresses the dietary behaviours of men with prostate 
cancer and survivors. 
 
3.1 Osteoporosis-related health behaviours in men with prostate 
cancer and survivors: Exploring osteoporosis knowledge, 
health beliefs and self-efficacy. 
This manuscript describes the psycho-behavioural and psycho-social factors that drive 
osteoporosis preventative health behaviours in men with prostate cancer and survivors 
and has been submitted to the American Journal of Men’s Health. 
 
Date submitted: 9th June 2015 
 
Please note that the reference style for this manuscript is that appropriate for the journal. 
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Abstract 
Purpose: This descriptive study aimed to (i) determine the extent of osteoporosis 
knowledge, perceived health beliefs, and self-efficacy with bone healthy behaviors in men 
with prostate cancer and survivors, and (ii) identify how dietary bone healthy behaviors are 
associated with these psycho-behavioural and -social factors. Methods: Three different 
questionnaires were used to measure osteoporosis knowledge, health beliefs, and self-
efficacy in a group of men with prostate cancer and survivors. Bone health was assessed 
via dual-energy X-ray absorptiometry and calcium intake using a diet-history. Results: The 
prevalence of osteoporosis and low bone mass was high at over 70%. Participants had 
inadequate osteoporosis knowledge with a mean score of 43.3% (SD 18%) on the Facts 
on Osteoporosis Quiz .Participants scored low on the subscale measuring barriers to 
exercise (median = 11; IQR 6.5), indicating minimal barriers to exercise participation, and 
the subscale measuring the benefits of exercise scored the highest (median = 24; IQR 3.5) 
compared with the other subscales. Men with prostate cancer and survivors were highly 
confident in their exercise and calcium self-efficacy (83.0%, IQR 24.0% and 85.7%, IQR 
27.0% respectively). Participants did not meet their calcium requirements or consume 
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enough dairy products for optimum bone health. Conclusion: Men with prostate cancer and 
survivors have poor osteoporosis knowledge, but are confident in their self-efficacy of 
undertaking bone healthy behaviors. This confidence did not translate to specific dietary 
behaviors as they did not meet their calcium or dairy intake requirements. Implications for 
cancer survivors: There is a need for bone health education programs among prostate 
cancer survivors. These programs should go beyond education and empowerment to 
provide practical guidance to maximize uptake of bone healthy behaviors. 
 
Introduction 
Men with prostate cancer are increasingly being treated with androgen deprivation therapy 
(ADT) (Grossmann et al., 2011), which has resulted in better survival rates than a decade 
ago (National Cancer Institute). Androgen deprivation therapy is associated with increased 
bone loss leading to a high prevalence of osteoporosis, with up to 53% of men with 
prostate cancer being diagnosed with the disease (A. C. Lassemillante, Doi, Hooper, 
Prins, & Wright, 2014). Since osteoporosis has traditionally been seen as a “women’s 
disease”, there has been less emphasis on educating men about this bone condition 
resulting in men feeling less susceptible to this disease (McLeod & Johnson, 2011). ). A 
meta-analysis (Laliberté, Perreault, Jouini, Shea, & Lalonde, 2011) on osteoporosis 
interventions in primary care identified six published studies conducted in men and women 
(Ashe et al., 2004; Majumdar, Beaupre, Harley, & et al., 2007; Majumdar et al., 2004; D. 
Solomon et al., 2007; D. H. Solomon et al., 2007; Yuksel, Majumdar, Biggs, & Tsuyuki, 
2010), five in women only (Bessette et al., 2008; Cranney et al., 2008; Feldstein et al., 
2006; Lafata et al., 2007; Pencille et al., 2009), and none in men only.  Evidence suggests 
that bone health monitoring and interventions, such as promotion of bone healthy 
behaviors, are poorly implemented at initiation of ADT (Pradhan et al., 2012) despite the 
presence of other osteoporosis risk factors and co-morbidities (Tanvetyanon, 2005). Such 
behaviors include adequate intake of calcium (Recommended Dietary Intake is 1000 – 
1200 mg per day depending on age (National Osteoporosis Foundation, 2014)) and 
calcium-containing foods, exercise, smoking cessation, and minimising alcohol intake 
(National Osteoporosis Foundation, 2014). Calcium is essential to bone health and vitamin 
D is needed for calcium homeostasis in the body (Lips & van Schoor, 2011). Calcium 
supplementation, alone or in conjunction with vitamin D supplements, is associated with 
decreased risk of osteoporotic fractures (Tang, Eslick, Nowson, Smith, & Bensoussan, 
2007). The exact role of vitamin D in bone physiology is currently under debate (Peterlik, 
Kállay, & Cross, 2013; Takahashi, Udagawa, & Suda, 2014), but cross-sectional studies 
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and clinical trials have demonstrated the protective effects of this vitamin on fracture risk 
(Lips & van Schoor, 2011). Exercise, notably resistance-training and high-impact loading 
activities, has a positive impact on hip and/or spine bone mineral density (BMD) of middle-
aged and older men (Bolam, van Uffelen, & Taaffe, 2013). Because the epidemiological 
evidence suggests that diet and exercise have a positive role, many osteoporosis 
intervention/education studies have included various lifestyle modifications in their protocol 
(Jean M. Gaines & Marx, 2011; Ryan, Schlidt, & Ryan, 2013). ). Clinical guidelines for the 
management of prostate cancer from the National Comprehensive Cancer Network 
(2015), make comprehensive recommendations for screening, preventing, and managing 
poor bone health in men with prostate cancer (especially ADT candidates and users). 
These include fracture risk assessment; bone density monitoring; calcium and vitamin 
supplementation; exercise regimes; and allied health involvement (National 
Comprehensive Cancer Network, 2015). 
 
Nadler et al. (2013) have reported have shown that men with prostate cancer on ADT lack 
basic osteoporosis knowledge and do not engage in bone healthy behaviors such as 
participating in exercise, or consuming adequate calcium and vitamin D as measured by 
food frequency questionnaire (Nadler et al., 2013). A framework that has been used to 
investigate such phenomenon in osteoporosis research is the Health Belief Model (Janz & 
Becker, 1984). The Health Belief Model encompasses several primary concepts that 
predict why individuals will take action to prevent, to screen for, or to control illness 
conditions. Knowledge, health beliefs, and self-efficacy are modifiable, hence are ideal 
targets when planning interventions and education programs. This framework has been 
extensively used in osteoporosis descriptive and intervention studies focussing on women 
(McLeod & Johnson, 2011). Nadler et al. (2013) are one of the few who have used this 
framework in men with prostate cancer, and have found that men with prostate cancer on 
ADT lack basic osteoporosis knowledge and do not engage in bone healthy behaviors. 
This study therefore aims to add to this small body of literature by determining the extent 
of osteoporosis knowledge, and perceived health beliefs and self-efficacy related to 
osteoporosis in men with prostate cancer and survivors. Men with prostate cancer 
undergoing treatment and survivors are included in this study to replicate the 
heterogeneity of this population as encountered in clinical practice, thus contributing to the 
clinical relevance of the findings presented here. The secondary aim of this study is to 
identify whether dietary bone healthy behaviors and biological markers of bone loss are 
associated with health beliefs, osteoporosis knowledge, and self-efficacy. The dietary 
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methodology used in the current study is more robust than the one used by Nadler et al. 
(2013), therefore providing more accurate information about dietary bone healthy 
behaviors (Kristal, Peters, & Potter, 2005). Based on the osteoporosis literature and lack of 
bone health education in men with prostate cancer, we hypothesise that this population 
has inadequate osteoporosis knowledge and poor dietary behaviors. 
 
Methods 
Study Participants 
This cross-sectional study was conducted at The University of Queensland, Australia, 
(September 2013 to June 2014) and included men with prostate cancer and prostate 
cancer survivors, who attended an exercise clinic. Men with prostate cancer, either 
undergoing active treatment or not; and prostate cancer survivors (regardless of treatment) 
were included in this study. Eligible participants were: prostate cancer survivors or men 
with a current prostate cancer diagnosis; aged over 60 years; either currently undergoing 
active treatment or not treated; not diagnosed with a bone-related disease; free of 
cardiovascular, musculoskeletal or metabolic disorders that would have prevented safe 
participation in exercise; and a body mass less than 150kg. The study was approved by 
the University of Queensland Medical Research Ethics Committee (2013001160). 
Informed consent was obtained from all individual participants included in the study. 
 
Instruments 
The extent of osteoporosis knowledge was measured using the 26-item Facts on 
Osteoporosis Questionnaire (FOOQ) that has been validated in men (see Appendix IV). It 
comprises 20 items from the FOOQ (R. L. Ailinger, Harper, & Lasus, 1998), and 6 items 
from the Men’s Osteoporosis Knowledge Quiz (MOKQ) (Jean M Gaines et al., 2011). The 
psychometric properties of this 26-item tool were determined in an elderly male population 
(validity r = 0.076 and Crobach’s ɑ = 0.9) (Jean M Gaines et al., 2011). This tool was 
scored based on the percentage of correct answers, with adequate osteoporosis 
knowledge defined as a total score of 80% or more (Rita L Ailinger, Braun, Lasus, & Whitt, 
2005). The Osteoporosis Self-Efficacy Scale (OSES) was used to measure osteoporosis-
specific self-efficacy and consists of 21 items in a visual analogue format (possible score 
range 0 - 100%; see Appendix V). This tool comprises two subscales measuring 
confidence for initiating and maintaining calcium intake (OSE-Calcium); and initiating and 
maintaining exercise habits (OSE-Exercise) (Horan, Kim, Gendler, Froman, & Patel, 
1998). The internal consistency of each subscales were r = 0.93 (for OSE-Calcium) and r 
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= 0.94 (OSE-Exercise) (Horan et al., 1998), and the reliability coefficient of the OSES was 
ɑ = 0.9 (C. A. Sedlak, Doheny, & Estok, 2000). The Osteoporosis Health Belief Scale 
(OHBS) was designed with the Health Belief Model as a framework and measures 
perceived seriousness, perceived susceptibility, perceived benefits, and perceived barriers 
related to healthy bone behaviors (see Appendix VI). This 42-item tool is divided into six 
subscales measuring the aforementioned constructs (benefits and barriers measured 
separately for calcium and exercise) and general health motivation. The responses were 
recorded on a five-point scale, from “strongly disagree” to “strongly agree”, that were 
awarded a numerical score in increasing order (from 1 to 5). The possible range for each 
subscale was six to 30, with higher scores meaning higher perceived susceptibility, 
seriousness, benefits from exercise, benefits from calcium, barriers to exercise, barriers to 
calcium, and health motivation. The reliability of the OHBS has been tested in a wide 
range of gender and groups, revealing acceptable levels of reliability (Crobach’s ɑ = 0.7 - 
0.9) (Shanthi Johnson, McLeod, Kennedy, & McLeod, 2008). 
 
Health and anthropometric measures 
The outcomes of interest for the present study were collected during a structured interview 
and included prostate cancer characteristics and treatments, bone health and osteoporosis 
status, health behaviors such as smoking, and FRAX® score. Participants with a FRAX® 
10-year probability risk < 20% for major fractures were classified as needing osteoporosis 
intervention (Kanis, Johnell, Odén, Johansson, & McCloskey, 2008). Height was measured 
to the nearest 0.1 cm using a stadiometer and body mass was measured to the nearest 
0.1 kg using electronic stand-on scales (A&D Mercury Load Cell Digitizer; A&D Weighting, 
Melbourne, Australia). Body mass index (BMI) was calculated as weight in kilograms 
divided by the square of height in metres (kg/m2). Calcium and dairy intake were derived 
from detailed structured diet histories (using the validated Wollongong diet history form 
(Martin, 2004) see Appendix VII) collected by an Accredited Practicing Dietitian. Calcium 
intake was compared with Australian Recommended Dietary Intakes (RDIs) (1000mg for 
men <70yrs and 1200mg for men >70yrs; (National Health and Medical Research Council, 
2005)). Blood tests were taken after an overnight fast in two 10-mL Vacutainers via vein 
phlebotomy. One Vacutainer was left to clot at room temperature for 20-30 minutes, while 
the remaining Vacutainer containing anti-coagulants was placed on ice. Both samples 
were centrifuged at 2,500 rpm for 10 minutes at 4o C, then plasma and serum were 
separated into aliquots and stored at -80o C until further processing. Samples were 
thawed on ice and the following biomarkers were tested using the automated Elecsys® 
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2010/cobas e411 analyser (Roche Diagnostics): serum C-terminal telopeptide of type 1 
collagen (CTx; CV of assay 3.0%), plasma osteocalcin (coefficient of variation [CV] of 
assay 1.5%), plasma procollagen type 1 N propeptide (P1NP; CV of assay 1.5%), plasma 
free testosterone (CV of assay 2.0%), and plasma total prostate specific antigen (PSA; CV 
of assay 3.6%). Serum bone-specific alkaline phosphatase (bone ALP) was measured by 
immunoenzymetric assay (CV assay 4.2%, Immunodiagnostic System [IDS] Ltd.). Plasma 
vitamin D was measured, with < 50 nmol/L considered as Vitamin D insufficiency, and < 25 
nmol/L as Vitamin D deficiency (World Health Organization Group on the Prevention and 
Management of Osteoporosis, 2003). Body composition and bone mineral density (BMD; 
at lumbar spine and right femoral neck) were measured using dual-energy X-ray 
absorptiometry (DXA; Hologic QDR 4500w) and the World Health Organization definition 
for osteoporosis was used (low bone mass: -1 < T-score > -2.5; osteoporosis: T-score ≤ -
2.5) (Kanis & Kanis, 1994).  
 
Statistical analyses 
This study was statistically powered for descriptive purposes. All normally distributed 
outcome variables were reported using means and standard deviations, while non-
parametric outcome variables were reported using medians and interquartile range (IQR). 
Because of the primarily non-parametric nature of the outcome variables, Kendall’s Tau (τ) 
was used to identify correlations between the psycho-behavioural and psycho-social 
constructs and the health behaviors. Statistical significance was defined as p-value ≤ 0.05. 
All analyses were completed using the Statistical Package for the Social Sciences (SPSS) 
software (version 22, IBM). 
 
Results 
Disease and participants characteristics 
Fifty-four men with prostate cancer and survivors were invited to participate in this study. A 
total of 41 men with prostate cancer and survivors were included, as 12 declined to 
participate and one was ineligible to participate. The characteristics of the study 
participants are presented in Table 3.1. Most of the participants were classified as prostate 
cancer survivors no longer undergoing active treatment, while 26.8% (n = 11) were 
currently undergoing ADT. All men reported on their prostate cancer stage (past or 
present), with 58.5% (n = 24) reporting localized disease, 17% (n = 7) reporting advanced 
disease, and 24.4% (n = 10) could not recall their disease stage. Radical prostatectomy 
(48.8%, n = 20) and radiation therapy (34.1%, n = 14) were the most common forms of 
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interventions reported by the study participants, and the other treatment modalities are 
presented in Table 3.1. The majority of the men in this study were overweight or obese 
based on their BMI. Body composition assessment, via DXA, revealed that this sample 
was obese because the mean fat mass percentage exceeded 30% (30.8 ± 5.1%) 
(Gallagher et al., 2000). Total PSA was negatively skewed, because two participants had 
active advanced disease. Testosterone levels varied, as expected, from castrate levels to 
normal levels (0.03 – 14.4 ng/mL) as this sample comprises a mix of hormone-naïve men 
and men on ADT.  
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Table 3.1 Characteristics of men with prostate cancer (n = 41) 
Variable Mean (sd) or Median (IQR) 
Age, years
a
 70 (7.5) 
Weight, kg 82.6 (10.3) 
Height, cm 176.5 (5.6) 
BMI, kg/m
2
 26.5 (3.2) 
BMI classification 
Normal weight (< 25 kg/m
2
), % (n) 
Overweight (25 - 30  kg/m
2
), % (n) 
Obese (> 30 kg/m
2
), % (n) 
 
26.6 (15) 
46.3 (19) 
17.1 (7) 
Current smoker, % (n) 2.4 (1) 
Gleason score (possible range 2-10)
a
 7 (1) 
Total PSA, ng/mL
a
 0.04 (0.6) 
Time since prostate cancer diagnosis, years
a
 4 (6.5) 
Previous or current ADT
b
, % (n) 41.5 (17) 
Prostate cancer treatment 
Radical prostatectomy, % (n) 
Radiation therapy, % (n) 
Brachytherapy, % (n) 
Radical prostatectomy & Radiation therapy, % (n) 
Chemotherapy & Radiation therapy, % (n) 
 
48.8 (20) 
34.1 (14) 
2.4 (1) 
9.8 (4) 
2.4 (1) 
Body fat percentage 30.8 (5.1) 
Lean body mass percentage 66.1 (5.0) 
Lumbar spine 
BMD, g/cm
2 a
 
T-score
a
 
Z-score
a
 
 
1.1 (0.2) 
-0.1 (2.0) 
0.8 (2.1) 
Right femoral neck 
BMD, g/cm
2
 
T-score 
Z-score 
 
0. 8 (0.1) 
-1.1 (0.6) 
0.1 (0.7) 
Bone health (at any ROI) 
Normal bone mass, % (n) 
Osteopenia, % (n) 
Osteoporosis, % (n) 
 
26.8 (11) 
63.4 (26) 
9.8 (4) 
Previous fracture, % (n) 61 (25) 
FRAX
®
 score for major fractures
a 
 4.30 (3.2) 
Calcium supplementation, % (n) 19.5 (8) 
Calcium intake, mg/day
a
,
c
 875 (495) 
Meeting calcium requirements, % (n)
d
 22 (9) 
Vitamin D supplementation, % (n) 26.8 (11) 
Plasma vitamin D, nmol/L 101.3 (25.6) 
Free Testosterone, ng/mL
a
 3.6 (5.3) 
SHBG, nmol/L
a
 47.9 (41.8) 
CTx, ng/mL 0.4 (0.2) 
Osteocalcin, μg/L 21.6 (8.1) 
P1NP, ng/mL
a
 44.5 (29.4) 
Bone ALP, μg/L
a
 17.2 (8.0) 
Note: IQR, interquartile range; BMI, body mass index; PSA, prostate specific antigen; ADT, androgen 
deprivation therapy; BMD, bone mineral density; ROI, region of interest; SHBG, sex hormone binding 
globulin; CTx, C-terminal telopeptide; P1NP, procollagen type 1 N-telopeptide; ALP, alkaline phosphatase. 
All values for continuous variable are presented as mean (sd), unless otherwise specified. 
a
The values for these variables are presented as median (IQR). 
b
Current and past treatment with ADT. 
cIntake including calcium from supplementation. dBased on calcium intake including calcium 
supplementation and the age appropriate RDI.  
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Bone health and related health behaviors 
Over 70% of men with prostate cancer and survivors in this study had low bone mass or 
osteoporosis. According to the FRAX® intervention threshold for major fractures, only 
2.5% (n = 1) needed re-assessment of bone health in 5 years and the rest of the sample 
did not need any intervention. Applying the FRAX® intervention threshold for hip fractures 
revealed that 2.5% (n = 1) of the sample met the criteria for pharmacological intervention, 
7.5% (n = 3) needed re-assessment of bone health in 5 years, and the rest of the sample 
did not need further interventions. (Kanis, McCloskey, et al., 2008). Bisphosphonates were 
prescribed to 9.8% (n = 4) of the sample, of which only 1 participant met the FRAX® 
threshold for osteoporosis intervention. All of the study participants currently taking 
bisphosphonates were either currently treated with or previously treated with ADT. 
Intake of dairy products, such as milk, cheese and yoghurt, ranged from 0 - 840 g per day 
(median 225 g/day, IQR 210 g/day). While intake of dairy products varied greatly only 
2.4% (n = 1) consumed no dairy at all and 9.8 % (n = 4) consumed more than 500 g of 
dairy products. The rest of the sample consumed between 20 g and 450 g of dairy 
products per day (56.1% consumed 0 – 250 g dairy products per day and 31.7% 
consumed 250 – 500 g dairy products per day). Milk was the main type of dairy products 
consumed (50.7% of dairy intake) followed by yoghurt (23.2% of dairy intake) and cheese 
(10.4% of dairy intake). Calcium supplementation was reported by 19.5% (n = 8) of men 
and vitamin D supplementation in 26.8% (n = 11). Calcium intake from dietary sources 
ranged from 440 mg to 1645 mg per day (median 865 mg/day, IQR 310 mg/day). Total 
calcium intake, which is the sum of dietary calcium intake and calcium from supplements, 
ranged from 550 mg to 1970 mg per day (median 875 mg/day, IQR 495 mg/day). Because 
of these wide ranges of calcium intake and the varying calcium requirements based on 
different ages, men in this sample were stratified based on whether they met their calcium 
requirements or not. We found that less than a quarter of men with prostate cancer and 
survivors (22%) met their calcium requirements, even when taking calcium 
supplementation into account. 
 
Osteoporosis knowledge, health beliefs and self-efficacy 
FOOQ: The majority of men with prostate cancer and survivors had inadequate 
osteoporosis knowledge, with an average FOOQ score of 43.3% (SD 18%). Most of the 
participants knew that “osteoporosis affects men and women” as 95.2% (n = 40) answered 
this question correctly. About three quarters (71.4%, n = 30) of men with prostate cancer 
and survivors correctly recognised “bone loss increases in men after the age of 70” but 
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scored poorly (7.2 - 33.3%) on the remaining osteoporosis questions specific to men. For 
instance only 33.3% were aware of their calcium requirement and 28.6% were aware that 
low testosterone level (as seen during ADT) is a risk factor for osteoporosis. More 
worryingly only 7.1% (n = 3) of participants knew that hormone treatment for prostate 
cancer increases the risks of osteoporosis. Few men (7.1%, n= 3) were aware that body 
weight affects bone health and 11.9% (n = 5) knew of the elevated risks (notably fractures) 
associated with osteoporosis. 
 
 
Figure 3.1 Median score on the seven subscales of the Osteoporosis Health Belief 
Score. Minimum possible score=6 and maximum possible score=30 
 
OHBS and OSES: The OHBS subscale measuring barriers to exercise scored the lowest 
(median = 11; IQR 6.5), indicating these participants reported minimal barriers to exercise; 
and the subscale measuring the benefits of exercise scored the highest (median = 24; IQR 
3.5) compared with the other subscales. A similar pattern was observed for the perceived 
barriers and benefits of calcium intake. Participants had a moderate perception of the 
seriousness of and their susceptibility to osteoporosis (Figure 3.1). Men with prostate 
cancer and survivors scored highly on the perceived health motivation subscale (median = 
24; IQR 5). Men with prostate cancer and survivors showed high confidence on the OSE-
Exercise and OSE-Calcium (83.0%, IQR 24.0% and 85.7%, IQR 27.0% respectively). 
Upon further examination of these subscales, we found that 26.8% (n = 11) and 36.6% (n 
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= 15) of the study participants were poorly to moderately confident (score < 75% on the 
visual analogue scale) in their exercise and calcium intake self-efficacy.  
 
Table 3.2 summarizes the correlations between the bone healthy behaviors and the 
psycho-behavioural and psycho-social factors. The correlations were small to moderate 
(Cohen, 2003) but similar to previous studies investigating osteoporosis knowledge and 
health beliefs (Jean M. Gaines & Marx, 2011; McLeod & Johnson, 2011). We found that 
osteoporosis knowledge was positively correlated with general health motivation (τ = 0.26, 
p = 0.05) and perceived benefits of exercise (τ = 0.26, p = 0.05), and negatively correlated 
with perceived barriers to calcium intake (τ = -0.47, p < 0.001). There was a positive 
correlation between the perceived benefits of exercise and the perceived benefits of 
calcium intake (τ = 0.41, p = 0.003). 
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Table 3.2 Correlation coefficient (τ) for associations between osteoporosis knowledge, health beliefs and self-efficacy, and 
osteoporosis behaviors and biomarkers of bone health. Correlation coefficients are highlighted if p ≤ 0.05, with p-values 
presented in brackets. 
n = 33 
τ 
(p-value) 
Osteoporosis 
knowledge 
Perceived 
Susceptibility 
Perceived 
Seriousne
ss 
Perceived 
Benefits 
Exercise 
Perceived 
Benefits 
Calcium 
Perceived 
Barriers 
Exercise 
Perceived 
Barriers 
Calcium 
Health 
Motivation 
Exercise 
Self-
efficacy 
Calcium 
Self-
efficacy 
Calcium intake 
0.03 
(0.80) 
-0.11 
(0.39) 
0.21 
(0.09) 
0.28 
(0.03) 
0.14 
(0.27) 
-0.21 
(0.10) 
-0.06 
(0.62) 
0.05 
(0.72) 
0.13 
(0.29) 
0.02 
(0.90) 
Dairy intake 
0 
(1.00) 
0.12 
(0.34) 
0.11 
(0.38) 
0.01 
(0.91) 
0.04 
(0.74) 
-0.09 
(0.50) 
0.04 
(0.78) 
0.13 
(0.31) 
0.05 
(0.71) 
-0.04 
(0.73) 
Number of 
alcoholic 
drinks/week 
-0.14 
(0.27) 
0.16 
(0.23) 
0.09 
(0.77) 
-0.05 
(0.70) 
-0.18 
(0.18) 
0.03 
(0.84) 
0.27 
(0.04) 
0.04 
(0.75) 
-0.01 
(0.96) 
-0.04 
(0.74) 
BMI 
-0.13 
(0.31) 
0.03 
(0.79) 
0.02 
(0.88) 
-0.05 
(0.69) 
0.07 
(0.60) 
0.24 
(0.06) 
0.26 
(0.04) 
-0.20 
(0.11) 
-0.30 
(0.02) 
-0.17 
(0.16) 
FRAX® for 
major fractures 
-0.02 
(0.90) 
0.17 
(0.18) 
-0.23 
(0.06) 
-0.18 
(0.16) 
-0.28 
(0.03) 
-0.12 
(0.36) 
0.05 
(0.67) 
-0.06 
(0.65) 
0.03 
(0.83) 
0.04 
(0.76) 
Right  Femoral 
Neck T-score 
-0.04 
(0.76) 
-0.05 
(0.68) 
0.34 
(0.01) 
0.02 
(0.86) 
0.03 
(0.80) 
0.10 
(0.46) 
0.15 
(0.23) 
.013 
(0.31) 
-0.21 
(0.09) 
-0.15 
(0.24) 
Right  Femoral 
Neck Z-score 
-0.11 
(0.37) 
-0.03 
(0.84) 
0.30 
(0.02) 
-0.08 
(0.55) 
0.13 
(0.34) 
0.11 
(0.42) 
0.17 
(0.18) 
0.21 
(0.11) 
-0.17 
(0.18) 
-0.13 
(0.31) 
Lumbar Spine 
T-score 
0.07 
(0.55) 
-0.11 
(0.41) 
0.23 
(0.07) 
0.01 
(0.96) 
0.10 
(0.43) 
-0.05 
(0.68) 
-0.18 
(0.17) 
-0.02 
(0.88) 
-0.22 
(0.07) 
0.06 
(0.61) 
Lumbar Spine 
T-score 
0.06 
(0.64) 
-0.11 
(0.37) 
0.18 
(0.16) 
-0.06 
(0.65) 
0.05 
(0.68) 
0.01 
(0.96) 
-0.11 
(0.38) 
-0.03 
(0.83) 
-0.25 
(0.04) 
0 
(1.00) 
CTx 
(ng/mL) 
0.05 
(0.70) 
0.17 
(0.19) 
-0.17 
(0.17) 
-0.29 
(0.02) 
-0.14 
(0.29) 
0.10 
(0.44) 
-0.04 
(0.73) 
-0.01 
(0.95) 
0.04 
(0.72) 
0.06 
(0.61) 
OC 
(ng/mL) 
0.08 
(0.51) 
0.07 
(0.61) 
-0.15 
(0.23) 
-0.23 
(0.07) 
-0.08 
(0.56) 
0.14 
(0.25) 
-0.09 
(0.49) 
0.03 
(0.84) 
0 
(1.00) 
0.09 
(0.46) 
Testosterone 
(ng/mL) 
0 
(1.00) 
-0.37 
(0.01) 
0.22 
(0.09) 
0.26 
(0.05) 
0.21 
(0.11) 
-0.01 
(0.91) 
0 
(0.98) 
-0.03 
(0.81) 
0.10 
(0.42) 
-0.07 
(0.60) 
P1NP 
(ng/mL) 
0.07 
(0.56) 
0.13 
(0.31) 
-0.17 
(0.18) 
-0.29 
(0.03) 
-0.12 
(0.35) 
0.15 
(0.24) 
-0.06 
(0.64) 
< 0.00 
(0.99) 
-0.01 
(0.95) 
0.10 
(0.44) 
BMI, body mass index; CTx, C-terminal telopeptide; OC, osteocalcin; P1NP, procollagen type 1 N-telopeptide. 
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Discussion 
Osteoporosis knowledge, health beliefs and prostate cancer 
This is the first study to investigate the extent of osteoporosis knowledge, health beliefs, 
and self-efficacy and their associations with health behaviors in a well-characterised group 
of prostate cancer survivors. Our sample, although small, was well-characterised in terms 
of disease profile, bone biomarkers, health behaviors, and behavioural and psycho-social 
constructs. The significant conclusions for men with prostate cancer and survivors were: (i) 
over 70% had poor bone health, (ii) they did not consume enough calcium, which is 
essential to bone health, (iii) the have inadequate osteoporosis knowledge, and (iv) did not 
perceive they were susceptible to osteoporosis or that it was a serious disease. According 
to the Health Belief Model (Rosenstock, Strecher, & Becker, 1988) these constructs are 
important to initiate and maintain health behaviour change. Such change, especially 
healthy bone behaviors, are important in men with prostate cancer, who have a high 
prevalence of poor bone health regardless of ADT status (A. C. Lassemillante et al., 2014; 
A. C. Lassemillante, Doi, Hooper, Prins, & Wright, 2015). Our findings support the idea 
that osteoporosis is a “silent disease” (Nguyen, Center, & Eisman, 2004) and reflects a 
lack of osteoporosis education, patient empowerment and bone health monitoring for men 
with prostate cancer (S. M. Alibhai et al., 2006; Shabbir MH Alibhai, Yun, Cheung, & 
Paszat, 2012; Tanvetyanon, 2005). On the other hand, the negative statistically significant 
correlation between testosterone levels and perceived susceptibility to osteoporosis 
reported here, suggests that hypogonadism may be associated with this health belief. 
Therefore our results indicate that only those at greatest risk of fractures and osteoporosis 
are informed of this bone condition, hence neglecting prostate cancer survivors and those 
not on ADT. Clinical guidelines recommend bone health monitoring and calcium 
supplementation in prostate cancer patients on ADT (National comprehensive cancer 
network, 2014), therefore explaining why they may feel more susceptible to poor bone 
health. Prostate cancer survivors and those not on ADT should not be neglected in terms 
of bone health education and empowerment as they experience a higher prevalence of 
osteoporosis and low bone mass than healthy older men (A. C. Lassemillante et al., 2015), 
likely due to other cancer treatments such as radiation therapy (Daniell et al., 2001). 
Osteoporosis education focussing on health beliefs alone does not incite behaviour 
change (Rizzoli, Abraham, & Brandi, 2014), therefore justifying the need for practical 
information on how to tackle barriers to behaviour change.  
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Osteoporosis knowledge, health beliefs and dietary behaviors 
This study is in line with previous research (A. C. Lassemillante et al., 2015) whereby men 
with prostate cancer do not meet their calcium requirements despite being at risk of 
osteoporosis, for example secondary to ADT. We showed this can be in part due to poor 
osteoporosis knowledge that led to greater barriers to calcium intake. In this study, trends 
in the results indicated calcium intake was not associated with calcium intake self-efficacy 
or knowledge, but was more closely linked with perceived exercise benefits. This finding 
demonstrates the importance of multiple disciplines in osteoporosis education and specific 
bone healthy behaviors. Despite the positive association between perceived exercise 
benefits and perceived calcium benefits, this did not equate to adequate calcium intake, 
highlighting the gap between health beliefs and actual health behaviors. We report here 
that men with prostate cancer and survivors are not aware of their calcium requirements 
and this may also help in explaining why they do not meet their requirements. The majority 
of this sample consumed less than the equivalent of 1 cup of milk per day, which is short 
of the current recommendations of 2.5 cups per day (National Health and Medical 
Research Council, 2013). Even those taking calcium supplements fell short of their 
requirements, likely due to low dietary calcium intake. The positive correlation between 
confidence in calcium intake self-efficacy and calcium intake suggests that promoting 
awareness on how to implement healthy bone strategies is more likely to contribute to 
calcium intake. A recent review of osteoporosis interventions (Ryan et al., 2013) reported 
that programs that included skills training were more successful at increasing calcium 
intake than those that did not include such component. Similarly, self-efficacy remained 
unchanged after many osteoporosis intervention programs (Francis, Matthews, Van 
Mechelen, Bennell, & Osborne, 2009; Carol A. Sedlak, Doheny, & Jones, 1998; Tung & 
Lee, 2006) despite improvements in osteoporosis knowledge and health beliefs. Therefore 
to affect behaviour change we need to go beyond traditional osteoporosis education 
programs by incorporating other behavioural change theoretical models in the 
interventions, including social contact, providing longer interventions (over a few months), 
and be multi-dimensional (Ryan et al., 2013). Rizzoli et al. (2014) discuss such novel 
approaches that are being implemented in new osteoporosis intervention programs 
(Gianoudis et al., 2012), but we also believe that dietary interventions need to include 
individualized care. As a result, the dietary preventative behaviors will be tailored to one’s 
social, family, and financial circumstances. Because men often survive many years after 
being diagnosed and treated for prostate cancer, it is important to educate them about 
other aspects of their health, especially those that could have been impacted by cancer 
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treatments. More osteoporosis intervention studies are needed but these also need to be 
sex specific. They also need to take into consideration the health behaviors of men with 
prostate cancer and survivors in providing practical guidance on how to maintain healthy 
bone behaviors. 
 
Some of the results reported here, such as osteoporosis knowledge, are in accordance 
with those reported in a cross-sectional study by Nadler et al. (2013); however some 
results such as calcium adequacy are markedly different. This can be explained by a lower 
proportion of men taking calcium supplements in the present study (19.5% versus 60% 
(Nadler et al., 2013)). While both studies present different findings, attributed to differences 
between the study populations, they both outline the gaps in the bone health (related 
behaviors and determinants) of men with prostate cancer. A recent intervention by Nadler, 
Alibhai, Catton, Catton, and Jones (2014), providing written education material on 
osteoporosis, resulted in increased calcium intake among men with prostate cancer who 
did not meet their requirements. While this intervention was simple, it was based on 
established behaviour change models; therefore it suggests that more comprehensive 
interventions, incorporating allied health professionals and behaviour changed models, 
may lead to additional health behaviour changes. 
 
Strengths and limitations 
Because the study participants were recruited from an exercise clinic, their confidence in 
exercise self-efficacy and other related exercise health beliefs measured here will differ 
from the rest of the prostate cancer population. This study reports on men with prostate 
cancer on ADT as well as under-represented groups in prostate cancer research, i.e., 
prostate cancer survivors and hormone-naïve men with prostate cancer. Given the 
association between hypogonadism and perceived susceptibility to osteoporosis, we 
anticipate that investigating hormone-naïve men with prostate cancer and survivors will 
result in poorer psycho-behavioural and psycho-social scores than reported here. The tool 
measuring calcium and exercise self-efficacy specifies what exercise means (“activities 
such as walking, swimming, golfing, biking, aerobic dancing”) but does not give examples 
of the terminology “calcium-rich foods”, which is used throughout this questionnaire. As a 
result the calcium intake self-efficacy responses might be biased for men who may not be 
aware of examples of calcium-rich foods; unfortunately, such bias could not be controlled 
for as we did not collect data on their osteoporosis-specific dietary knowledge. Although 
the sample is small, hence associated statistical analyses problematic, it offers a glimpse 
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of the gap in osteoporosis education in men with prostate cancer and survivors while 
raising further questions for research and practice. The present findings are not likely to be 
unique to men with prostate cancer, but this conclusion cannot be made due to the 
absence of a control group, such as healthy men. A strength of this study is the robust 
dietary methodology used to measure calcium intake that is more accurate than the 
methods used in similar studies (Nadler et al., 2013; Ryan et al., 2013) that have used 
calcium questionnaires or food frequency questionnaire to gather such data.  
 
Conclusion 
We can conclude that men with prostate cancer and survivors have inadequate 
osteoporosis knowledge, regardless of ADT status. It is concerning as one would expect 
that men on ADT would have better knowledge of this bone condition and subsequent 
bone healthy behaviors since it is a side-effect of their treatment. Intervention program 
designed for men with prostate cancer and survivors are required to address treatment-
related bone loss and health behaviors that they may have adopted to manage their 
cancer. Our findings support the complementary role of the multi-discipline approach to the 
management of bone health post-prostate cancer treatment. This approach should also be 
individually tailored, while being innovative to effect sustainable behaviour change.  
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3.2 Dietary intake of men with prostate cancer: a food group 
analysis. 
This section describes the dietary intake of men with prostate cancer and survivors using a 
novel dietary method analysis. While the manuscript presented here assesses overall 
dietary intake, rather than osteoporosis-preventative dietary behaviours, this methodology 
was used to report on dairy products intake in section 3.1. This method was based on the 
food grouping system used to report on the diets of Australians in the National Nutrition 
and Physical Activity Survey (NNPAS) from the Australian Health Survey (AHS) (2011 - 
2013). While food group analysis is not novel, the method and grouping system used to 
group the foods and comparison with the Australian population is novel. This is also new to 
the prostate cancer literature. 
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Abstract 
A reductionist approach, such as nutrient analysis, has been in dietary research, but it fails 
to acknowledge the multi-dimensional nature of diets. Food group analysis focuses on 
whole foods rather than specific nutrients. Aim: This pilot study aims to assess the food 
group intake of men with prostate cancer, and to compare this with the broader Australian 
population of men. Method: Diet history was collected from 41 men with prostate cancer. 
Foods were categorised using the Australian Health Survey (AHS) food categorisation 
system. The median weight of food group intake was compared between men with 
prostate cancer (n=41) and age-matched men from the National Nutrition Physical and 
Activity Survey (NNPAS). Results: Men with prostate cancer consumed 21 major food 
groups with “cereals and cereal products” contributing most to overall energy (20%; IQR 3-
36%). “Meat, poultry, and game products and dishes” comprised 10% of overall energy 
and provided 12g/day of total fat intake (IQR 11g/day). The prostate cancer group 
consumed more “vegetable products and dishes” (303g/day vs 175g/day, p<0.001), less 
“alcoholic beverages” (107g/day vs 379g/day, p<0.001), “meat, poultry, and game 
products and dishes” (106g/day vs 150g/day, p=0.007), and “legumes and pulse products 
and dishes” (0g/day vs 161g/day, p<0.001) than their NNPAS counterparts. Conclusion: 
This methodology allowed to identify a range of eating behaviours that differed between 
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men with prostate cancer and Australian men, therefore highlighting the advantage of food 
group analysis over the reductionist approach. These findings combined with the current 
evidence can be used to guide nutrition advice in this group. 
 
Keywords 
Food; Food analysis; Nutrition assessment; Prostatic neoplasm 
 
Introduction 
The role of diet in prostate cancer risk and progression has been investigated in both 
clinical and epidemiological studies using a range of dietary analysis techniques;1 
however, findings are largely inconclusive.1 Diet analysis has long used a reductionist 
approach in focussing on single nutrient intakes while ignoring the fact that diets are more 
complex and multi-dimensional.2 Extensive studies in the prostate cancer field have also 
adopted this approach,1, 3 but the results have been meagre. Such dietary analysis 
approach has allowed to identify the association of high saturated fat consumption with a 
greater risk of hormone-dependent cancer development and/or progression.4 On the other 
hand, studies of lycopene from tomatoes have shown better outcomes on specific prostate 
cancer biomarkers when consumed as part of whole tomatoes or tomato paste, rather than 
lycopene supplements.5 
 
Nutrient analysis is a valued part of nutrition research hierarchy, which also includes other 
global dietary assessments such as food group and dietary pattern analyses.6, 7 
Epidemiological studies have revealed the Mediterranean dietary pattern 8 may be 
protective against prostate cancer progression as a result of (i) its poly- and 
monounsaturated fat content,9 and (ii) the synergy of all the nutrients and phytochemicals 
that form part of this diet.10 This dietary pattern has also been extensively used in clinical 
trials, with positive results on disease outcomes.11 
 
Food group analysis is valid, reliable, and detailed; and focuses on whole foods rather 
than specific nutrients.6, 12 This method has an intuitive appeal because people primarily 
consume foods and dishes, which incidentally are sources of nutrients. Various methods of 
food group analyses have been used in research.13, 14 Food groups can be devised using a 
theoretical approach;15 a statistical approach, such as cluster analysis;16 or by using an 
existing food grouping classification system. Depending on the patient population involved, 
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findings can be directly compared with a food guidance system, such as the Australian 
Dietary Guidelines (ADG)17, to determine diet adequacy. 
 
The majority of large studies investigating nutrition and prostate cancer prevention or 
survivorship rely on dietary data collection tools that are limited in their ability to capture 
the qualitative and quantitative complexity of diets through detailed and structured 
questioning of the study participants.18 The food frequency questionnaire (FFQ) is often 
used to collect data on participants’ intake of foods/nutrients thought to benefit cancer 
prevention or ameliorate its progression.18 Studies using this dietary assessment tool often 
report precise amounts of food and/or nutrients and their relationship with disease,19 which 
is not the intended use of the FFQ and compromises the validity of the findings.20 Large 
population studies, such as the National Nutrition and Physical Activity Survey (NNPAS) 21 
and NHANES 2013-201422, now prefer to collect dietary data at multiple time points using 
more detailed tools (for example, the 24-hour recall). There is, therefore, a need for valid 
and reliable diet analysis methods where extensive information can be drawn from the rich 
dietary data collected.7 
 
This paper presents the results of a pilot study using an alternative food group analysis 
methodology. This post-hoc food group analysis was applied to a study in men with 
prostate cancer, originally designed to explore relationships between chronic health, diet, 
and bone health. The aim of this pilot study was to assess the detailed food group intake 
of a sample of men with prostate cancer utilising the same food group classification 
system as the NNPAS. These data were compared with the results for age-matched men 
from the NNPAS to identify their dietary similarities or differences. The methodology is 
different from previous dietary analysis methods as it takes into account the dietary habits 
and meal composition of Australians. This food grouping system has not previously been 
used in scholarly research and the results from such analysis can be directly compared 
with the wider Australian population to identify typical or atypical dietary behaviours. 
 
Methods 
Study participants: Participants for this pilot cross-sectional study were recruited from a 
student-led exercise program at The University of Queensland, Australia from September 
2013 to June 2014. Eligible participants were: prostate cancer survivors or men with a 
current prostate cancer diagnosis; aged over 60 years; either currently undergoing active 
treatment or not previously treated; not diagnosed with metastatic bone disease; free of 
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cardiovascular, musculoskeletal or metabolic disorders that would have prevented safe 
participation in exercise; and a body mass less than 150 kg. The study was approved by 
The University of Queensland Medical Research Ethics Committee (2013001160). All 
participants provided written informed consent before commencing the study. 
 
Background data: Personal information, detailed medical and prostate cancer history, 
nutritional supplementation, and medication use were obtained via an interviewer-
administered questionnaire. 
 
Anthropometry and body composition: Height and body mass were measured using 
standard procedures to the nearest 0.1 cm and 0.1 kg, respectively. Waist and hip girth 
were measured using an anthropometric tape (Lufkin W606PM retractable steel tape; 
Cooper Tools), to the nearest 0.1 cm, while participants were wearing light clothing. These 
were measured according to the procedures outlined by the International Society for the 
Advancement of Kinanthropometry23. Body mass index (BMI; kg/m2) and waist-to-hip ratio 
(WHR) were derived from these measurements. Percentage lean body mass and 
percentage fat mass were measured by dual-energy x-ray absorptiometry (DXA; Hologic 
QDR 4500w). 
 
Dietary assessment: An Accredited Practising Dietitian collected participant usual dietary 
intake using a validated open-ended diet history questionnaire (see Appendix VII).24 
During this structured interview participants were asked to recall their diet over the 
previous week to collect detailed dietary data about usual meals, snacks, and beverages. 
The Dietitian used neutral probes to aid in recall. Food preparation and cooking practices, 
product types, brands, accompaniments, and serving sizes were also recorded. Life-size 
images of foods25 were used to assist in quantifying serving sizes. Participants were 
probed for take-away and restaurant meals consumed over the past fortnight. This was 
followed by completion of a food checklist to ensure dietary details were not missed. A 
similar approach was used in NNPAS. Data were analysed using the dietary analysis 
program Foodworks 7 (version 7.0, Xyris Software, Australia) to calculate mean daily 
nutrient intakes. The food-nutrient database used was AUSNUT 2007 as the new 
database, AUSNUT 2011-13, had not yet been incorporated in the dietary analysis 
software at time of data entry. The ratio of energy intake (EI) to basal metabolic rate (BMR; 
EI:BMR)26 was used to identify energy under-reporters, which was defined as an EI:BMR 
ratio < 0.9. The same cut-off value has been used in NNPAS27.  
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Food groups: Food group analysis was performed for the diets of each participant and 
compared to the national medians, as reported in NNPAS, AHS.28 This national survey 
used the AUSNUT 2011-13 food-nutrient database to code the foods consumed. This 
database was developed to reflect the current Australian food supply, and contains 5,740 
foods and beverages each with a unique 8-digit code.29 The first 2 digits of this code 
determine the major food group to which a food belongs, and the first 3 digits determine 
the sub-major group. Based on this coding convention there are 24 major food groups and 
132 sub-major food groups that are collectively called the AHS food classification.30 The 
diets of the current study participants were also analysed using AUSNUT 2011-13, where 
each food was coded accordingly using Microsoft Excel 2010 (version 14.0, Microsoft 
Corporation). These foods were then grouped into major and sub-major food groups 
according to the NNPAS/AHS coding convention, for each study participant. The total 
weight of each food group (major and sub-major) was calculated as well as its energy 
contribution (kilojoules [kJ] and percentage of total energy intake). Table 3.3 outlines the 
major and sub-major food groups investigated and consumed by men with prostate cancer 
(see Appendix VIII for examples of foods in major and sub-major food groups). Cereal-type 
foods are grouped into two different categories, (i) “cereals and cereal products”, which 
includes wholemeal and refined breads, breakfast cereals, flours, and dry pasta; and (ii) 
“cereal based products and dishes”, which includes processed cereal products such as 
cakes, pies, and other baked products. The complete list of the constituents of the AHS 
food groups can be found elsewhere.30 One serve of “alcoholic beverages” was defined as 
containing 10 g of alcohol31 and compared to the alcohol intake recommendations outlined 
in the ADG.17 
 
Statistical analysis: A minimum of 31 participants were needed to estimate the mean 
energy intake (kJ/day) of this sample (SD 2100 kJ/day32 and marginal error 750 kJ/day).33 
Normally distributed variables (as per Shapiro-Wilks test) were reported as mean ± SD, 
and variables not normally distributed were reported as median (interquartile range [IQR]). 
Food group intake and their macro-nutrients contribution were reported as median (range) 
to demonstrate the true intake of this sample. Independent samples t-tests and Mann-
Whitney tests were used to compare food group intake between energy under-reporters 
and the rest of the sample. Wilcoxon signed rank tests were used to determine whether 
the median food group intake of men with prostate cancer differed to the national 
population medians reported in the NNPAS. Statistical analyses were completed using 
Statistical Package for the Social Sciences (SPSS) software (version 22, IBM).  
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Table 3.3 Major and sub-major food groups consumed by men with prostate cancer 
Major food group Sub-major food groups 
Non-alcoholic 
beverages 
Tea  
Coffee and coffee substitutes  
Fruit and vegetable juices, and drinks  
Cordials 
Soft drinks, and flavoured mineral waters 
Other beverage flavourings and prepared beverages 
Cereals and cereal 
products  
Flours and other cereal grains and starches  
Regular breads, and bread rolls (plain/unfilled/untopped varieties)  
English-style muffins, flat breads, and savoury and sweet breads  
Pasta and pasta products (without sauce) 
Breakfast cereals, ready to eat 
Breakfast cereals, hot porridge style 
Cereal based 
products and dishes 
Sweet biscuits 
Savoury biscuits 
Cakes, muffins, scones, cake-type desserts  
Pastries  
Mixed dishes where cereal is the major ingredient  
Batter-based products  
Fats and oils  Butters 
Dairy blends 
Margarine and table spreads 
Plant oils 
Fish and seafood 
products and dishes  
Fin fish (excluding commercially sterile)  
Crustacea and molluscs (excluding commercially sterile)  
Packed (commercially sterile) fish and seafood  
Fish and seafood products (homemade and takeaway) 
Mixed dishes with fish or seafood as the major component  
Fruit products and 
dishes  
Pome fruit  
Berry fruit  
Citrus fruit  
Stone fruit  
Tropical and subtropical fruit  
Other fruit  
Mixtures of two or more groups of fruit  
Dried fruit, preserved fruit  
Egg products and 
dishes  
Eggs  
Dishes where egg is the major ingredient  
Meat, poultry and 
game products and 
dishes  
Beef, sheep and pork, unprocessed 
Poultry and feathered game  
Sausages, frankfurts and saveloys  
Processed meat  
135 
 
Mixed dishes where beef, sheep, pork or mammalian game is the 
major component 
Mixed dishes where poultry or feathered game is the major 
component  
Milk products and 
dishes  
Dairy milk (cow, sheep and goat) 
Yoghurt  
Cream  
Cheese  
Frozen milk products  
Custards 
Other dishes where milk or a milk product is the major component 
Flavoured milks  and milkshakes 
Dairy and meat 
substitutes 
Dairy milk substitutes, unflavoured 
Soy-based yoghurts 
Soup  Soup, homemade from basic ingredients 
Canned condensed soup (unprepared) 
Soup, commercially sterile, prepared from condensed or sold ready to 
heat 
Seed and nut 
products and dishes  
Seeds and seed products  
Nuts and nut products  
Savoury sauces and 
condiments  
Gravies and savoury sauces  
Pickles, chutneys and relishes  
Salad dressings  
Dips 
Vegetable products 
and dishes  
Potatoes  
Cabbage, cauliflower and similar brassica vegetables  
Carrot and similar root vegetables  
Leaf and stalk vegetables  
Peas and beans  
Tomato and tomato products  
Other fruiting vegetables  
Other vegetables and vegetable combinations  
Dishes where vegetable is the major component  
Legume and pulse 
products and dishes  
Mature legumes and pulses  
Mature legume and pulse products and dishes  
Snack foods  Potato snacks  
Corn snacks  
Other snacks  
Sugar products and 
dishes  
Sugar, honey and syrups  
Jam and lemon spreads, chocolate spreads, sauces  
Dishes and products other than confectionery where sugar is the 
major component  
Confectionery and 
cereal/nut/fruit/seed 
bars  
Chocolate and chocolate-based confectionery  
Fruit, nut and seed-bars  
Muesli or cereal style bars 
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Other confectionery  
Alcoholic beverages  Beers  
Wines  
Spirits  
Cider and perry 
Special dietary foods  Formula dietary foods  
Miscellaneous  Yeast, and yeast vegetable or meat extracts  
 
Results 
Fifty-four men with prostate cancer were invited to participate in this study. A total of 41 
men with prostate cancer and survivors were included, 12 declined to participate, and one 
was excluded as he did not meet the inclusion criteria. The characteristics of the study 
participants are presented in Table 3.4. 
 
Disease and treatment characteristics 
The sample comprised prostate cancer survivors and men currently undergoing treatment 
(26.8%, n = 11). All the men reported on their prostate cancer stage (past or present), with 
58.5% (n = 24) reporting localised disease, 17% (n = 7) reporting advanced disease, and 
the remaining 10 participants could not recall their disease stage. Radical prostatectomy 
was common (58.5%, n = 24), and was either used in conjunction with other treatments 
(9.8%, n = 4) or used in isolation (48.8%, n = 20). Twenty study participants (48.8%) 
reported a form of radiation therapy as part of their prostate cancer treatment, including 
12.2% (n = 5) receiving adjuvant radiotherapy. 
 
Dietary characteristics 
The EI:BMR ratio revealed that 9.8% (n = 4) of the study sample were energy under-
reporters, which was lower than in NNPAS (19%)34. Energy under-reporters had a higher 
BMI (P < 0.05), hip circumference (P < 0.05), and body fat percentage (P < 0.05) than the 
rest of the sample. Dietary protein (P < 0.05), fat (P < 0.05) and carbohydrate intakes (P < 
0.05) were lower in energy under-reporters. The intake of “sugar products and dishes” was 
also lower in this subset of the study participants. Energy under-reporters were not 
excluded from the analyses presented here to maintain consistency with the NNPAS 
results, which also did not exclude energy under-reporters.  
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Table 3.4 Participant characteristics and average macro-nutrients intake 
Variable All (n = 41) 
95% 
confidence 
interval 
Age, years 70.5 ± 5.3 68.8 – 72.2 
Body mass, kg 82.6 ± 10.3 79.2 – 85.9 
Height, cm 176 ± 5.57 174.6 – 178.2 
BMI, kg/m
2
 26.5 ± 3.2 25.5 – 27.5 
BMI 
<25 kg/m
2
, % (n) 
25-30 kg/m
2
, % (n) 
>30 kg/m
2
, % (n) 
 
36.6 (15) 
46.3 (19) 
17.1 (7) 
- 
Time since diagnosis, years 4.0 (6.5) 1 - 18
a
 
Waist-to-hip ratio 0.98 (0.11) 0.8 – 1.9
a
 
Percent fat mass 30.8 ± 5.1 29.3 – 32.5 
Percent lean body mass 66.1 ± 5.0 64.4 – 67.6 
Average energy intake, kJ/day 9100 ± 2300 8330 – 9840 
Average protein intake, g/day 
% energy intake 
95 ± 22 
17.9 ± 2.7 
87 – 102 
17 – 18 
Average carbohydrates intake, g/day 
% energy intake 
210 ± 125 
40.7 ± 7.6 
201 – 253 
38 – 42 
Average fat intake, g/day 
% energy intake 
75 ± 30 
32.1 ± 8.6 
71 – 91 
30 – 35 
Average fibre intake, g/day 30 ± 11 27 – 34 
All values for continuous variables are presented as mean ± SD or presented as 
 
Food group classification, energy, and macro-nutrients contribution 
The complete AHS food grouping classification system includes culturally and age 
appropriate foods, for example “reptiles, amphibia, and insects” and “infant formulae and 
foods”; however, these were not consumed by men in this sample. Our study sample 
consumed 21 major food groups, with “cereals and cereal products” contributing the most 
to their energy intake (see Table 3.5). Daily energy intake ranged from (8200kJ/day and 14 
800 kJ/day), with carbohydrates providing the greatest proportion of energy. The average 
fat, and protein intakes of the study participants were within the acceptable macro-
nutrients distribution ranges;35 however, carbohydrate intake was below or at the lower 
end of the recommended range. Given the association between fat, particularly saturated 
fat,4 with the development and progression of hormone-related cancers, results for this 
macro-nutrient are presented in more detail here. The “Vegetable products and dishes” 
and “fruit products and dishes” groups are also described in detail due to their association 
with reduced rates of prostate cancer development and progression.36, 37 
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Table 3.5 Average daily macro-nutrients contribution from major food groups (and 
intake of sub-major food groups), ordered by energy contribution and contributing ≥ 
5% of energy, consumed by men with prostate cancer. 
 
Percent 
energy 
Carbohydrates 
(g/day) 
Total fat 
(g/day) 
Protein 
(g/day) 
Cereals and cereal products 
20 
(3 - 36) 
72 
(0 – 155) 
6 
(0 - 18) 
13 
(0 - 30) 
Regular breads, and bread rolls 
(plain/unfilled/untopped varieties)  
32 
(0 - 90) 
3 
(0 - 15) 
7 
(0 - 17) 
Breakfast cereals, ready to eat 
 
19 
(0 - 66) 
1 
(0 - 14) 
3 
(0 - 11) 
Flours and other cereal grains and 
starches  
4 
(0 - 86) 
<1 
(0 - 12) 
<1 
(0 - 16) 
Meat, poultry and game products 
and dishes 
10 
(2 - 22) 
<1 
(0 - 38) 
12 
(3 - 38) 
22 
(5 - 56) 
Poultry and feathered game 
 
- 
3 
(0 - 19) 
7 
(0 - 25) 
Beef, sheep and pork, unprocessed 
 
- 
4 
(0 - 20) 
9 
(0 - 33) 
Processed meat 
 
0 
(0 - 3) 
1 
(0 - 8) 
2 
(0 - 28) 
Milk products and dishes 
9 
(0 - 32) 
12 
(0 - 85) 
10 
(0 - 41) 
12 
(0 - 42) 
Dairy milk (cow, sheep and goat) 
 
7 
(0 - 36) 
2 
(0 - 19) 
5 
(0 - 28) 
Cheese 
 
- 
5 
(0 - 24) 
4 
(0 - 34) 
Yoghurt 
 
2 
(0 -11) 
<1 
(0 - 7) 
1 
(0 - 10) 
Cereal based products and dishes 
9 
(0 - 37) 
20 
(0 - 140) 
5 
(0 - 43) 
4 
(0 - 76) 
Sweet biscuits 
 
1 
(0 - 116) 
<1 
(0 - 35) 
<1 
(0 - 10) 
Savoury biscuits 
 
1 
(0 - 20) 
<1 
(0 - 4) 
<1 
(0 - 3) 
Fruit products and dishes 
7 
(0 - 20) 
34 
(0 - 100) 
<1 
(0 – 3) 
2 
(0 - 79) 
Vegetable products and dishes 
7 
(2 - 24) 
16 
(4 - 54) 
3 
(0 – 24) 
5 
(1 - 18) 
Other fruiting vegetables 
 
2 
(0 - 12) 
<1 
(0 - 23) 
1 
(0 - 11) 
Potatoes 
 
7 
(0 - 30) 
<1 
(0 - 6) 
1 
(0 - 7) 
Tomato and tomato products 
 
1 
(0 - 4) 
<1 
(0 – 1) 
<1 
(0 - 2) 
Carrot and similar root vegetables 
 
2 
(0 - 29) 
<1 
(0 – 3) 
<1 
(0 - 5) 
Cabbage, cauliflower and similar 
brassica vegetables  
<1 
(0 - 3) 
<1 
(0 – 3) 
1 
(0 - 6) 
Leaf and stalk vegetables 
 
<1 
(0 – 1s) 
- 
<1 
(0 – 2) 
Peas and beans 
 
<1 
(0 - 5) 
- 
<1 
(0 - 4) 
All values for continuous variables are presented as median (range).  
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Fat 
“Fats and oils”, consumed mostly in the form of “butters”, contributed to 2% of their overall 
energy intake (range 0 – 31%) and provided 3 g/day of total fat intake (0 - 85 g/day). 
“Meat, poultry, and game products and dishes” contributed to 10% of their overall energy 
intake (range 2 - 22%) but provided 12g/day of total fat intake (range 3 - 38 g/day); 
therefore this food group was also a major source of saturated fats. “Milk products and 
dishes” was a significant source of fat (median total fat intake 10 g/day [range 0 - 41 
g/day]), which was driven by the consumption of “cheese” (median total fat intake 5 g/day 
[range 0 – 24 g/day]). Further analyses revealed that about half of “dairy milk (cow, sheep 
and goat)” and “yoghurt” were either reduced or low in fat. 
 
Men with prostate cancer consumed little “fish and seafood products and dishes” (median 
weight 23 g/day [range 0 - 129 g/day]), which contributed to 3 g/day of total fat (range 0 - 
24 g/day). This major food group was further analysed to identify the intake of oily fish by 
men with prostate cancer. The median proportion of oily fish consumed by this sample was 
83.9% (range 0 - 100%). 
 
Vegetables and fruits 
“Vegetable products and dishes” contributed to 7% (range 2 - 24%) of energy intake and 
was the second most consumed major food group, after “non-alcoholic beverages” 
(median weight 303 g/day [range 73 - 553 g/day] v/s 875 g/day [range 0 – 2557 g/day]). 
Analysis of sub-major food groups revealed that the proportion of “vegetable products and 
dishes” consumed as “other fruiting vegetables” (e.g. pumpkin) was 20.0% (range 0 - 38%) 
followed by “potatoes” 18.6% (range 0 - 58%), “tomato and tomato products”, “carrots and 
similar root vegetables”, and “cabbage, cauliflower, and other brassica vegetables”. 
Overall “fruit products and dishes” was the fourth most consumed major food group, and 
consisted of 33.3% (range 0 – 90.5%) “pome fruits” and 17.8% (range 0 - 100%) “tropical 
and sub-tropical fruits”. 
 
Comparison of food group intake with the Australian population 
Figure 3.2 depicts the intakes of selected major food groups by men with prostate cancer 
in comparison with AHS age-matched counterparts (see Appendix IX for actual intakes). 
Men with prostate cancer consumed more “vegetable products and dishes” than the 
national average (303 g/day for men with prostate cancer vs 175 g/day for AHS men). Men 
in this study consumed less “potatoes” than men in the AHS group (40 g/day vs 126 g/day, 
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p < 0.001). This sample also consumed less “carrots and similar root vegetables” than the 
AHS men (25 g/day vs 60 g/day, p=0.012), while no differences in consumption of “tomato 
and tomato products” and “cabbage, cauliflower, and similar brassica vegetables” were 
observed (30 g/day vs 30 g/day, p = 0.183; and 22 g/day vs 38 g/day, p = 0.149 and 
respectively). 
 
The three animal protein food groups such as “egg products and dishes”, “fish and 
seafood products and dishes”, and “meat, poultry and game products and dishes” were 
consumed in lesser amounts by men with prostate cancer than AHS group of men. Men 
with prostate cancer also consumed less “processed meat” than AHS men (11 g/day vs 25 
g/day, P = 0.001). 
 
Figure 3.2 Intake of selected major food groups by men with prostate cancer in 
comparison with elderly men from the Australian Health Survey. 
 
Statistically significant difference **P ≤ 0.01, or ***P ≤ 0.001 when both groups are compared. 
 
The difference in “non-alcoholic beverages” intake between men with prostate cancer 
(median consumption 875 g/day) and the AHS men (median consumption 1250 g/day) can 
be explained by “water” not included in the total “non-alcoholic beverages” intake of the 
men with prostate cancer. The men in this study also consumed less “alcoholic beverages” 
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than their AHS counterparts (107 vs 379 g/day, P < 0.001). Men with prostate cancer 
consumed a median of 1 standard drinks per day (range 0 – 8 standard drinks per day), 
which are within the ADGs recommendation to reduce risk of chronic disease from alcohol 
intake.17 It is important to note that participants above the 50th percentile are likely to 
exceed these recommendations. 
 
Discussion 
This is the first study to pilot the use of the AHS food classification in dietary analysis 
research, and to analyse the diets of men with prostate cancer. It is also the first study to 
use the existing AHS food intake data to serve as a control for a study sample. No 
previous studies have profiled the food intake of men with prostate cancer and survivors in 
this level of detail. 
 
We report that a sample of men with prostate cancer generally have healthier eating 
behaviours than an age-matched sample of AHS elderly men. This methodology has 
allowed for a detailed description of the diets of men with prostate cancer beyond macro-
nutrient intakes. We identified differences in major food groups but also differences in sub-
major food groups that illustrate how this methodology can be used in nutrition research. 
Men with prostate cancer consumed significantly more vegetables (major food group) than 
their AHS counterparts, which could be a result of modification to healthier dietary habits 
after cancer diagnosis.38 The AHS classification system allowed a more detailed 
exploration of vegetable intake based on their nutritional properties (at the sub-major food  
group level),30 for example grouping based on health-enhancing phytochemicals. This is 
demonstrated by the fact that “cabbage, cauliflower and similar brassica vegetables” are 
rich in glucosinolates, which have been associated with reducing prostate cancer risk and 
progression39-41. Meaningful inferences can therefore be drawn when using this food group 
analysis compared to the generic five food groups traditionally used in Australia to assess 
diet quality and adequacy.17 As a result of the high phytochemical nutrient density of 
brassica vegetables,42 we may have expected to see differences in the intake of this sub-
major food group between men with prostate cancer and AHS men, but this was not 
observed. 
 
Educating patients and the wider population about the diet-disease relationship is central 
to dietetic practice; however, the reductionist approach that dominates nutrition research 
only addresses the nutrient-disease relationship. Food group analysis allows a broader 
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investigation of food-disease relationships, therefore assisting practitioners to make 
judgements about diet quality and how it may be associated with the disease of interest, 
thereby encompassing a more practical and holistic approach to dietetic practice. Layering 
nutrient intakes on top of food group intake provides another dimension to this analysis. It 
is valuable to know the sources of certain nutrients either for hypothesis formulation or 
developing recommendations. 
 
When looking at the energy intake of our sample we can conclude that they are not 
consuming excess energy; but some of their dietary habits could be detrimental to their 
health. For example, food group analysis of our pilot study participants revealed that 
“meat, poultry, and game products and dishes” was the second major source of energy 
and contributed the most to total fat intake. This shows the fat profile of our sample was 
not optimal with regard to poly- and monounsaturated fats and reveals an area for dietary 
intervention to promote cardiovascular health, which may already be compromised due to 
prostate cancer treatment. 43 Men in our sample consumed more “vegetable products and 
dishes” than their AHS counterparts, but did not meet the ADG recommendations17 (~3 
serves [289 g/day] instead of 5 serves [375 g/day]), nor did they meet the Mediterranean 
diet recommendations of more than 2 serves per meal.44 This is a concern for men with 
prostate cancer as they are at elevated risk of being diagnosed with metabolic syndrome 
because of cancer treatment43 and older age.45 Comparisons between the diets of men 
with prostate cancer and the Mediterranean diet pattern are more appropriate than 
comparisons with the ADGs. This is because the latter recommendations are for chronic 
disease prevention17 while the Mediterranean diet has been proven to be effective chronic 
disease management,11 which is prevalent in men with prostate cancer and survivors.43 
Therefore by looking at their diets more globally we can make the recommendation to 
decrease “meat, poultry and game products and dishes” intake while increasing “vegetable 
products and dishes” , and “fish and seafood products and dishes” to be in line with the 
Mediterranean pattern of eating which is known to reduce the risk of metabolic 
syndrome.46 
 
One shortfall of the AUSNUT 2011-13 database is that foods are not classified by their fat 
type or content, for example low fat dairy products and oily fish groups are not included. 
This can be overcome by analysing the respective major or sub-major food groups for 
specific nutrient content as illustrated in our analysis of the intake of oily “fish and seafood 
products and dishes”, and low and reduced fat “milk products and dishes”. This additional 
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analysis would be important for studies examining conditions where substantial evidence 
suggests a link between a specific nutrient and health/food (for example unsaturated fats 
and chronic health).47 A limitation of this study was the low consumption of “soups” and 
“legume pulse products and dishes” that resulted in significant differences between the 
AHS group of men, and could have been a result of seasonality. The use of two different 
food-nutrient databases to report on the macro-nutrient intake and food group intake is a 
limitation of this study, but is likely to be resolved with updated versions of Foodworks, 
which will include AUSNUT11-13 hence streamlining food group analysis. The sample size 
of this study is small, and may include some bias due to inherent flaws associated with 
research volunteers; hence the results presented here cannot be generalised to the 
prostate cancer population. 
 
A strength of this study protocol is that the diet history was collected by a Dietitian who 
was able to gather vital information about composite dishes consumed by the study 
participants. These dishes were then disaggregated into ingredients that were grouped 
accordingly, hence providing more accurate information about nutrient contributions for 
each food group.48 The accuracy of the dietary data collected is limited by the recall ability 
of the current study participants, but this is common to all dietary methods.20 This is 
pertinent to men with prostate cancer, who might have some cognitive impairments 
secondary to advanced age and treatment-related side-effects.49 Despite these limitations, 
the dietary data collection method used here remains more reliable than the majority of 
others used in this patient population, which rely on recall of food intake over the past 
year.50 We implemented many safeguards to maximise recall, and these include use of 
neutral probes and visual aids. Many significant differences in major and sub-major food 
groups intake observed between AHS men and men with prostate cancer could be a 
product of the lack of cultural diversity in our sample. Although the sample size was small 
and cannot be generalised to the prostate cancer population, it does not undermine the 
illustrative and descriptive purposes of this paper. Future research into dietary behaviours 
of men with prostate cancer should therefore include men at different stage on the 
prostatic disease continuum (prostate cancer and men with BPH) and healthy controls. 
The comparison of such findings with population data will reveal the dietary similarities 
between men with diseased prostates and healthy controls, thus indicating whether 
healthy diet messages should be targeted or universal. 
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Food grouping analyses are labour-intensive and time-consuming. Using food groups from 
an existing national database such as AUSNUT11-13, which can then be incorporated in 
food analysis software, will facilitate this process.51 Focussing on intakes of food groups, 
rather than the reductionist approach, acknowledges the multi-dimensional aspects of 
diets. Food group analysis is versatile in that it can be applied to a range of studies, from 
epidemiologic to randomised controlled trials. Most importantly research on food groups, 
dietary patterns, and nutrient profiles complement each other; therefore, facilitating the 
translation to practical recommendations in medical nutrition therapy. This pilot study 
serves as a guide for further studies across all areas of dietetics practice to strengthen 
understanding of food behaviours in the context of whole diets. 
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CHAPTER 4 DISCUSSION AND IMPLICATIONS FOR FUTURE 
RESEARCH 
4.1 Discussion 
Bone health on the prostate cancer continuum 
Throughout this thesis, the poor bone health of men with prostate cancer and men with 
BPH was discussed. The prevalence of poor bone health is presented on the prostate 
cancer continuum [Figure 4.1], with men affected by this condition regardless of where 
they are on that continuum. Osteoporosis is highly prevalent in this population but also 
varies greatly (between 9% and 53% for men on ADT, and 4% and 38% for hormone-
naïve men with prostate cancer) (75, 76). While a high prevalence of poor bone health was 
expected in men on ADT, the wide spread prevalence was unexpected. The meta-
analyses summarised such spread, with results from DOES and the pilot cross-sectional 
study further supporting this conclusion. The latter study was small (n=41) but was not 
unlike many studies investigating the bone health of men with prostate cancer (35, 104-
110). The variation in the prevalence of osteoporosis has been discussed in both meta-
analyses (see CHAPTER 1). The sensitivity analyses revealed that ethnicity, disease 
stage, and age were responsible for some of this variation. It is also possible that the 
different DXA machines used across the studies would account for some of the variance. 
The differences between the two most common DXA machines, Prodigy and Hologic, are 
known (111) and can range from 8.2% to 21.0%, with the largest difference seen at the 
femoral neck (112). The ROI used to assess overall bone health also impacts on the 
diagnosis of osteoporosis, which is likely due to the presence of osteo-dense regions at 
the lumbar spine, called osteophytes, leading to erroneously high BMDs (48, 113). 
Osteophytes are seen in elderly men with osteoarthritis of the lumbar spine (48, 114), 
which is a common degenerative condition in this gender. Lumbar spine BMD can be 
further elevated in men with prostate cancer from osteoblastic metastases (115, 116). The 
high frequency of spinal metastases in men with prostate cancer (115) can be explained 
by the venous circulation from the pelvic region to the vena cava through the vertebral 
venous system (117-119). The proximity of the vertebrae to this circulation system 
provides an ideal environment (the “soil” (6)) for circulating prostate cancer cells to home 
to. Therefore lumbar spine is not representative of overall bone health in elderly men and 
should be excluded from bone health examination protocols. This is of particular 
importance in men with prostate cancer who can have both osteophytes and osteoblastic 
metastases, therefore greatly affecting the validity of the lumbar spine in assessing their 
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bone health. The challenges of measuring BMD at the lumbar spine in men have not 
stopped this ROI from being used both in research (36, 104, 109, 120-123) and in practice 
(124, 125). It is therefore evident that osteoporosis diagnosis methods are tailored to 
women, and still need to be altered for accurate diagnosis in men. The forearm BMD has 
been shown to be representative of overall bone health in men (124), and it provides an 
alternative in assessing bone health in elderly men and those with prostate cancer. 
Unfortunately organisations such as the WHO and prostate cancer clinical guidelines do 
not recommend using the forearm instead of the lumbar spine (125, 126). Many studies 
investigating the bone health of men with prostate cancer exclude those with metastases 
at the lumbar spine (107, 123, 127) and fail to use an alternative ROI. This is not a 
solution-based practice that also excludes a potentially important prostate cancer 
population from being investigated. This suggests that more high quality research needs to 
be undertaken using ROIs other than the lumbar spine to provide strong evidence, which 
can be used in guidelines development. 
 
While Figure 4.1 is a simplification of prostate cancer progression, it summarises the 
findings of this research program and evidence to date. Only a few studies have reported 
on the bone health of men at both ends of the continuum; therefore these numbers are 
anticipated to change with the release of new evidence. The number of prostate cancer 
survivors has increased (128) because of early detection (129) and improved treatment 
(130) but the rate of osteoporosis is expected to increase with more men potentially 
treated with ADT. New pharmacological approaches, such as intermittent-ADT, that lessen 
the severity of traditional ADT prescriptions may mitigate some of this deterioration in bone 
health (131). Consistent bone health monitoring in association with these novel treatments 
would be valuable to estimate whether they have fewer negative effects on bone health. 
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Figure 4.1 The prevalence of poor bone health (osteoporosis + low bone mass) on 
the prostate cancer continuum, regardless of bone site. 
Osteoporosis and low bone mass have been combined for clinical relevance as risk of fractures increases 
with low bone mass in elderly men (132). 
 
Implications of bone health management in men with prostate cancer 
The release of new clinical guidelines in the USA and UK (94, 126) that include more 
comprehensive bone health management recommendations could positively impact the 
future bone health of men with prostate cancer and survivors. This impact is dependent on 
whether or not these guidelines are fully implemented by medical practitioners; hence 
future investigations into the extent of guideline implementation alongside specific clinical 
outcomes will provide information on their effectiveness. It is important to implement 
guidelines using theoretical frameworks to effect sustainable behaviour change (133, 134). 
The results from the cross-sectional study outline the role of psycho-behavioural and –
social factors (individual theoretical constructs) in bone healthy behaviours among men 
with prostate cancer. Therefore future investigations using theoretical frameworks in 
guideline implementation will help to measure the translation of recommendations into 
behaviour change and clinical outcomes. 
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Prostate cancer survivors are a hormonally heterogeneous group comprising both men 
previously treated with ADT and not previously treated with ADT, but in this thesis they are 
considered to be past ADT-users. The bone health of men with prostate cancer is driven 
by treatment (75), possible disease pathophysiology (135-137), genes (138), and lifestyle 
(139). The mechanism underlying bone loss in men with prostate cancer has been 
discussed in section 1.3. In clinical practice, survivors are also likely to have poorer bone 
health than men with a current prostate cancer diagnosis due to bone loss associated with 
age (prostate cancer survivors are older) and treatment (including radiotherapy and ADT). 
Of all these different aetiologies, bone loss in men with prostate cancer on ADT is 
expected and is managed better when compared with the bone health of men with 
prostate cancer who are not on ADT (140, 141). The findings presented in this research 
program support the need to manage the bone health of all men with diseased prostates 
rather than focussing only on men being treated with ADT. There are two main advantages 
to implementing health promotion strategies for bones at every point on the prostate 
cancer continuum. These include: 
 
 There is strong evidence that dietary calcium and supplemental calcium (65) reduce 
bone loss; therefore early intervention (prior to ADT initiation) will minimise bone 
loss in men with prostate cancer (mainly age-related bone loss). This strategy 
means men would start ADT with less depleted bones, which may help minimise 
the consequences associated with ADT. An example of a measurable outcome of 
this strategy is extending the time to fracture in this population (142), although more 
studies are needed this area. Men would have also formed long-term bone healthy 
habits, which will therefore be easier to maintain over time (143). 
 
 Early intervention may reduce the economic burden of osteoporosis in men with 
prostate cancer. In 2011-2012, 40 289 claims for ADT (Goserelin and bicalutamide; 
and leuprolide) were made under the Pharmaceutical Benefits Schedule in Australia 
compared with 38 400 on 2008-2009 (24). Given this increase in the number of 
patients on ADT and that up to 85% of men on ADT have osteoporosis or 
osteopenia (76), there will be will be an increase in osteoporosis and/or fractures 
related costs, especially if bone health management strategies remain unchanged. 
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Health behaviours: the clinician’s perspective 
The results from the cross-sectional study describe some lifestyle aspects, notably diet, 
that affects this population. Men with prostate cancer and survivors, regardless of 
hormonal status, are not meeting their calcium requirements or consuming adequate 
amounts of dairy for optimum health. The NH&MRC osteoporosis guidelines/algorithm, 
recommends increasing dietary calcium intake to reduce bone loss (Grade A 
recommendation) (144); verifying the strong evidence to support the bone protective 
effects of dietary calcium (145). The combination of this poor dietary behaviour and the 
failure by medical practitioners to recognise that men with prostate cancer are at risk of 
osteoporosis (146) is concerning. Additionally, these men do not believe that osteoporosis 
is a serious disease as demonstrated in this research program. This has previously been 
summarised by Gaines and Marx (147), who also reported that men have a limited 
understanding of the osteoporosis disease process, risk factors, and prevention. Men in 
the cross-sectional study, presented in this thesis, had poor knowledge of the relationship 
between osteoporosis and men’s health, as was seen in Gaines’s review of the literature 
(147). These authors also found that men knew more about the female-osteoporosis 
relationship than they knew about the male-osteoporosis relationship (147). 
 
Deficits in bone health knowledge, beliefs and perceptions, and bone health protective 
behaviours can be due to the treating doctor not discussing/recognising bone health 
issues with/in their patients (77, 146). A review of osteoporosis-specific knowledge among 
doctors (and other health professionals) revealed that they have good knowledge of 
osteoporosis diagnosis and management but poor knowledge on calcium-containing foods 
and recommended intake (86). The recently reviewed clinical guidelines on the 
management of prostate cancer (94, 126) provide details on bone health monitoring 
strategies as well as bone health management recommendations. These include specific 
calcium and vitamin D recommendations through supplementation and are likely to 
improve this aspect of care in men with prostate cancer. These recommendations 
emphasise the need for Dietitians to be included in bone health management efforts to 
bridge this gap in specific health behaviours knowledge and the implementation of dietary 
behaviour change. It is imperative that these guidelines be adopted in practice as the 
number of men with prostate cancer treated with ADT is increasing (24), thereby 
increasing the proportion of men with poor bone health and at increased risks for fractures. 
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Health behaviours: the importance of behavioural change theoretical frameworks 
Understanding the reasons for the gap between knowledge and health behaviour and 
health status (among patients) is important as it will lead to the development of strategies 
to increase uptake of bone healthy behaviours among men with prostate cancer. 
Inadequate osteoporosis knowledge could play a role in the high prevalence of poor bone 
health in men with prostate cancer. According to Orem’s Self-Care theory, one’s 
knowledge of potential disease is a prerequisite for participating in health behaviours (88); 
therefore the lack of information on the deleterious effects of ADT on bone health, may 
result in poor participation in bone healthy behaviours. Education alone is not the solution 
to the osteoporosis problem as it may not be sufficient to change behaviour (148), 
therefore bone health education programs need to go beyond traditional osteoporosis 
interventions. These need to provide practical information that can be easily applied by 
men with prostate cancer as demonstrated in a study by Plawecki and Chapman-
Novakofski (149). These authors (149) designed an eight-week group education program, 
whereby participants were educated on nutrition label reading, meal planning, and serving 
size estimation. This intervention led to increased calcium intake by the end of the study 
period, thus demonstrating the importance of providing such practical information.  A 
recent osteoporosis intervention program in men with prostate cancer showed that 
increased osteoporosis knowledge and perceived susceptibility significantly improved 
intake of calcium and vitamin D (150). This intervention was one of the few among men 
with prostate cancer on ADT, and provided detailed written information including calcium-
containing foods with practical information on how to incorporate them in their diets (150). 
While most of the bone healthy messages are targeted at men with prostate cancer on 
ADT, for obvious reasons, these messages should also reach hormone-naïve men with 
prostate cancer and men with BPH. Men not on ADT are also potential ADT candidates; 
therefore, encouraging implementation of behaviour change early at the time of diagnosis 
may reduce future risk for osteoporosis and fracture. Further studies are required to 
examine the impact of diet behaviour change from diagnosis on future risk of fracture in 
prostate cancer patients. 
 
Educational Framework for Dietitians 
Bone health management is shared between the nurse, medical team, allied health team, 
carer, and the patient (Figure 4.2). The findings presented here support the need for 
multidisciplinary management of bone health in men with prostate cancer; this is because 
behaviour change and enhanced self-efficacy in one type of health behaviour drive 
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behaviour and self-efficacy in another health behaviour. There is also evidence to suggest 
that a multidisciplinary education program enhances osteoporosis knowledge (151). Allied 
health professionals, such as Dietitians and Exercise Physiologists, therefore need to be 
familiar with the (i) iatrogenic effects of prostate cancer treatments, like the effects of ADT 
on chronic health and bone health, (ii) the management strategies of such side-effects, 
and (iii) the current fads (dietary) and health misinformation in the prostate cancer 
community. The multi-modal osteoporosis education intervention designed by Tussing and 
Chapman-Novakofski (152), demonstrates that Dietitians can deliver successful programs 
that lead to increased dietary calcium intake. This program was theory-based (Health 
Belief Model and Theory of Reasoned Action), thus suggesting the importance of such 
framework when designing and delivering education programs. Dietitians are trained in 
such theories, and use them to assess patient’s current dietary behaviours and to tailor 
dietary intervention to the patient’s circumstances and preferences (153). 
 
Results from this research program and the literature support the lack of knowledge and 
perceived seriousness related to osteoporosis in men with prostate cancer. Reports on 
these constructs are common in the literature as the Health Belief Model is the most 
frequent theoretical framework used to investigate osteoporosis and health behaviours 
(83). In dietetic practice, the prostate cancer patient is likely to present with multiple 
comorbidities (e.g. metabolic syndrome and osteoporosis secondary to ADT); therefore 
Medical Nutrition Therapy needs to be carefully planned in order to address these many 
conditions. Because of the burden of prostate cancer, (uncertainty associated with active 
surveillance and devastating effects of ADT) men with prostate cancer can (i) partake in 
many food fads in an attempt to fight the cancer (154), or (ii) be overwhelmed by their 
diagnosis and have/gain insufficient knowledge about disease and diet. The Nutrition Care 
Process is a systematic approach used by Dietitians to provide Medical Nutrition Therapy 
(155). The findings presented in this thesis are used to design a framework, which is 
based in the Nutrition Care Process, for the management of bone health in men with 
prostate cancer and survivors. The assessment and diagnosis will differ between patients 
and it will guide the content of the intervention. This should be based on a counselling 
theoretical approach such as the Health Belief Model, which is ideal for osteoporosis 
counselling in men with prostate cancer as it is successful in group interventions (152). 
Table 4.1 presents a modified table from the Nutrition Care Process (156) to assist in 
osteoporosis counselling using the Health Belief Model. Information on metabolic 
syndrome can be added to this table for a holistic intervention on the side-effects of ADT.  
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Figure 4.2 Theoretical framework mapping the involvement of the dietitian (and all 
involved in prostate cancer care) in behaviour change for the management of bone 
health in men with prostate cancer. 
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Table 4.1 How to apply the Health Belief Model in nutrition counselling of osteoporosis in men with prostate cancer. 
This table is based on (156).
Construct Definition Strategies 
Perceived 
Susceptibility 
Client’s belief or opinion of the personal 
threat osteoporosis represents for 
them; client opinion regarding whether 
they have osteoporosis or their chance 
of getting osteoporosis 
 Educate on osteoporosis risk factors, e.g., low calcium intake, low dairy intake, excessive alcohol 
intake… 
 Tailor information to the client, more specifically to men and ADT (if applicable) 
 Ask client if they think they are at risk or have the osteoporosis or poor bone health 
 Guided discussions 
 Motivational interviewing (express empathy, open-ended questions, reflective listening, affirming, 
summarizing, and eliciting self-motivation statements) 
Perceived 
Severity 
Client’s belief about the impact 
osteoporosis threat will have on them 
and their lifestyle 
 Educate on consequences osteoporosis or low bone mass; show graphs and statistics of 
fractures and their impact on quality of life 
 Elicit client response 
 Discuss potential impact of fractures on client’s lifestyle 
 Motivational interviewing 
Perceived 
Benefits and 
Barriers 
Client’s belief regarding benefits they 
will derive from taking nutrition-related 
action (increase vitamin D, calcium 
and/or dairy intake); perceived 
benefits versus barriers - client’s 
perception of whether benefits will 
outweigh the sacrifices and efforts 
involved in behaviour change 
 Clearly define benefits of nutrition therapy and physical activity, e.g. reducing bone loss and 
reduction in risk of fractures 
 Role models, testimonials 
 Explore ambivalence and barriers 
 Imagine the future 
 Explore successes 
 Summarize and affirm the positive 
Cues to 
Action 
Internal or external triggers that 
motivate or stimulate action 
 How-to education 
 Link current symptoms to osteoporosis 
 Discuss media information and fallacy that osteoporosis only affects women 
 Social support, e.g. prostate cancer support groups, osteoporosis support groups 
Self-Efficacy Client confidence in their ability to 
successfully accomplish the necessary 
action 
 Skill training/demonstration, e.g., on how to incorporate more dairy in the diet and how to 
increase calcium and vitamin D intake 
 Introduce alternatives and choices, e.g., calcium and vitamin D supplements (brands, types and 
dosage) 
 Behaviour contracting; small, incremental goals 
 Coaching, verbal reinforcement 
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Table 4.2 Summary of research findings reported in this research program. 
Research question/Aim Outcome 
To explore the literature on the prevalence of osteoporosis 
and/or low bone mass (osteopenia) in men with prostate 
cancer, whether treated with ADT or not on ADT 
Up to 85% of men with prostate cancer on ADT and up to 80% of hormone-naïve men with 
prostate cancer experience poor bone health. 
What are the bone-health management recommendations 
made in evidence-based guidelines for the management of 
prostate cancer? 
Inconsistent recommendations across 4 evidence-based guidelines documents: all 
mention deleterious effects of ADT on bone health and most recommend bone health 
monitoring post ADT initiation. 
Do the recommendations include lifestyle management 
strategies, such as increasing dietary calcium and 
exercise/physical activity?  
3 out of 4 guidelines documents recommend 
 exercise for the management of osteoporosis in men with prostate cancer on ADT. 
 calcium and vitamin D for osteoporosis management. 
If such recommendations are made, how detailed and 
comprehensive are they? 
Only 1 guidelines document provided strong emphasis on osteoporosis preventative 
measures, including the involvement of a Nutritionists. 
2 out of 4 refer to Osteoporosis Guidelines for detailed recommendations. 
Specific calcium and vitamin D dosages and exercise prescriptions were only included in 1 
guidelines document. 
What is the post-diagnostic incidence of osteoporosis 
and/or low bone mass in men with BPH, men with prostate 
cancer on ADT, and hormone-naïve men with prostate 
cancer? 
Post-diagnostic incidence of osteoporosis in: 
 men with BPH was 20.8% (at lumbar spine) and 59.2% (at femoral neck) 
 hormone-naïve men with prostate cancer was 23.1% (at lumbar spine) and 50.0% 
(at femoral neck) 
 men with prostate cancer on ADT was 44.4% (at lumbar spine) and 51.9% (at 
femoral neck) 
The odds of having LS osteoporosis/osteopenia are 3.2 times lower in men with BPH than 
men with prostate cancer on ADT (p = 0.035). 
What is the rate of post-diagnostic fractures in the population 
mentioned above? 
Hazard ratio of post-diagnostic fractures lower in men with BPH when compared with men 
with prostate cancer on ADT (HR: 0.284, 95% CI = 0.091 - 0.892; p = 0.031). 
What is the extent of osteoporosis knowledge, osteoporosis-
related health beliefs, and self-efficacy in men with prostate 
cancer and survivors? 
The majority of men with prostate cancer and survivors had inadequate osteoporosis 
knowledge, with an average FOOQ score of 43.3% (SD 18%). 
Men with prostate cancer and survivors did not perceive they were susceptible to 
osteoporosis or that it was a serious disease. 
Participants reported minimal barriers to exercise (in osteoporosis management) and rated 
the benefits of exercise (in osteoporosis management) highly. 
What are the health behaviours, notably dietary behaviours, 
that men with prostate cancer and survivors participate in? 
Calcium supplementation was reported by 19.5% (n = 8) of men and vitamin D 
supplementation in 26.8% (n = 11). 
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And are they adequate for optimum bone health? 22% of men with prostate cancer and survivors met their calcium requirements, even when 
taking calcium supplementation into account. 
What is the association between determinants of health 
behaviours (psycho-behavioural and psycho–social 
factors), and bone health; and dietary behaviours in men 
with prostate cancer and survivors? 
Osteoporosis knowledge was positively correlated with general health motivation (τ = 0.26, 
p = 0.05) and perceived benefits of exercise (τ = 0.26, p = 0.05), and negatively correlated 
with perceived barriers to calcium intake (τ = -0.47, p < 0.001). 
There was a positive correlation between the perceived benefits of exercise and the 
perceived benefits of calcium intake (τ = 0.41, p = 0.003). 
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4.2 Implications for future research and conclusion 
Calcium and vitamin D supplementation are routinely recommended in conjunction with 
bisphosphonates in the bone health management of bone loss secondary to osteoporosis 
(126). Although this is routine practice (and is recommended in clinical guidelines) there is 
no evidence that these supplements alone reduce bone loss or osteoporotic fractures in 
men with prostate cancer on ADT (157). The lack of evidence in the form of clinical trials 
demonstrates a gap in nutrition intervention in men with prostate cancer, whether on ADT 
or not. It is hypothesised that the bone-related outcomes of a nutrition intervention would 
be different between men with prostate cancer on ADT and not on ADT due to the different 
bone loss mechanisms in each group. Because of this difference, bone-related nutrition 
intervention studies need to target all men on the prostate cancer continuum but divide 
them into well-characterised groups for each stage along the continuum. This will assist in 
clarifying individualisation of bone health management strategies in each prostate cancer 
patient group. Time will be a challenge for such studies as the clinical outcome of 
osteoporosis, fractures, takes years to occur. 
 
Prior to investing time and money in long-term nutrition and lifestyle interventions in men 
with prostate cancer, smaller investigations in behaviour change are needed. Such 
interventions may include group education programs, which have been successful in 
increasing osteoporosis knowledge, medication adherence, and calcium intake in women 
(158, 159). The educational framework presented in the discussion can also be used in 
smaller scale intervention studies (one-on-one or small group intervention) to assess how 
lifestyle recommendations, delivered using a specific theoretical framework, are 
implemented by men with prostate cancer. Such findings can then be used for larger scale 
studies or longer duration. 
 
Osteoporosis research in men with prostate cancer is still in its infancy, especially 
osteoporosis education and intervention. Although ADT is known to negatively impact the 
bone health of men with prostate cancer, few lifestyle intervention studies have been 
undertaken on this population. More studies are therefore warranted, and the interventions 
need to (i) be based on health behaviour theoretical frameworks, (ii) use a multidisciplinary 
approach, (iii) include men early on the prostate cancer continuum as well as survivors, 
(iv) use tools targeted at a male audience, and (v) provide practical information such as 
specific strategies on how to increase the calcium content of a meal. Nadler, Alibhaiet al. 
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(150) are one of the few authors who have implemented an osteoporosis education 
program in men with prostate cancer on ADT, but the program did not address most of the 
points mentioned above. This intervention was not tailored to each patient nor did it 
include different allied health professionals, hence these limitations can be used as 
learning opportunities when developing future intervention studies. Davison, Wiens et al. 
(160) have also implemented an education program to increase the dietary calcium intake 
of men with prostate cancer on ADT, which only included a few of the above-mentioned 
recommendations. The dietary intervention in this study was delivered by a Dietitian, but it 
was not based on a behaviour change theoretical framework (160). While this intervention 
did not result in increased dietary calcium intake, the authors reported on higher calcium 
intakes in men on ADT for less than one year compared to those on ADT for more than 
one year (160). This finding support the recommendations made in this thesis, where bone 
health preventative strategies need to be implemented early on the prostate cancer 
continuum. Both of these studies (150, 160) include valuable elements of osteoporosis 
education but the lack of effect observed support the importance of a holistic approach. 
Although more research is needed to identify the most effective health behaviour change 
strategies, current osteoporosis population health messages and programs, which are 
targeted at women, can be expanded to also include men. The findings from this research 
program (i) have contributed to increasing the understanding of various aspects of bone in 
men with diseased prostates, and (ii) interpretation in conjunction with findings from 
previous intervention studies (such as (150) and (160)), will help improve bone health and 
side-effect management in men with prostate cancer. This thesis also demonstrates that 
there is more to osteoporosis management than prescribing calcium and vitamin D 
supplements. Behaviour change is challenging for the patient, health practitioner, and 
researcher; therefore there is no “one size fits all” solution, instead interdisciplinary 
involvement is crucial in research and in practice. 
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APPENDIX I Medicare pharmaceutical benefits scheme 
claims for Androgen Deprivation Therapy (2003 to 2015) 
 
Table A 1 Medicare Pharmaceutical Benefits Scheme claims for ADT for the financial 
years from 2003 to 2015. 
 
Gosereline and 
bicalutamide 
Leuprorelin Degarelix Total 
2003/04 0 205 0 205 
2004/05 0 2493 0 2493 
2005/06 0 4740 0 4740 
2006/07 111 29044 0 29155 
2007/08 1762 32755 0 34517 
2008/09 2885 35523 0 38408 
2009/10 3556 35544 0 39100 
2010/11 4369 34723 0 39092 
2011/12 4824 35465 0 40289 
2012/13 5280 34790 0 40070 
2013/14 5491 36107 1751 43349 
YTD 2014/2015 2852 18707 3915 25474 
Total 31130 300096 5666 336892 
YTD; year to date; Medicare Pharmaceutical Benefits Scheme item number for Gosereline and bicalutamide 
9064C, 9066E, 9065D; Medicare Pharmaceutical Benefits Scheme item number for Leuprorelin 8875D, 
8859G, 8877F, 8709J, 8707G, 8708H, 8876E; Medicare Pharmaceutical Benefits Scheme item number for 
Degarelix 2785N, 2784M. 
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APPENDIX II FRAX
®
 algorithm 
 
 
Figure A 1 Example of the FRAX algorithm, specific to Australia. 
Sourced from (51). 
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APPENDIX III Literature search strategy for meta-analyses of 
osteoporosis in men with prostate cancer 
 
Database: PUBMED 
Osteoporosis[Mesh] OR osteoporosis OR Osteoporoses OR “Osteoporosis, Post-
Traumatic” OR “Osteoporosis, Post Traumatic” OR “Post-Traumatic Osteoporoses” OR 
“Post-Traumatic Osteoporosis” OR “Osteoporosis, Senile” OR “Osteoporoses, Senile” OR 
“Senile Osteoporoses” OR “Senile Osteoporosis” OR “Osteoporosis, Age-Related” OR 
“Osteoporosis, Age Related” OR “Bone Loss, Age-Related” OR “Age-Related Bone Loss” 
OR “Age-Related Bone Losses” OR “Bone Loss, Age Related” OR “Bone Losses, Age-
Related” OR “Age-Related Osteoporosis” OR “Age Related Osteoporosis” OR “Age-
Related Osteoporoses” OR “Osteoporoses, Age-Related” 
AND 
"Prostatic Neoplasms"[Mesh] OR “Prostate Neoplasms” OR “Prostate Neoplasm” OR 
“Prostatic Neoplasm” OR “Prostate Cancer” OR “Prostate Cancers” OR “Cancer of the 
Prostate” OR “Prostatic Cancer” OR “Cancer of Prostate” OR “prostate tumor” OR 
“prostate tumors” OR “prostate tumour” OR “prostate tumours” OR “prostate carcinoma” 
OR “prostate carcinomas” OR “prostatic carcinoma” OR “prostatic carcinomas” OR 
“carcinoma of the prostate” OR “carcinoma of prostate” 
 
Database: EMBASE 
‘OSTEOPOROSIS’/EXP OR osteoporosis OR osteoporoses OR 'osteoporosis, post-
traumatic' OR 'osteoporosis, post traumatic' OR 'post-traumatic osteoporoses' OR 'post-
traumatic osteoporosis' OR 'osteoporosis, senile' OR 'osteoporoses, senile' OR 'senile 
osteoporoses' OR 'senile osteoporosis' OR 'osteoporosis, age-related' OR 'osteoporosis, 
age related' OR 'bone loss, age-related' OR 'age-related bone loss' OR 'age-related bone 
losses' OR 'bone loss, age related' OR 'bone losses, age-related' OR 'age-related 
osteoporosis' OR 'age related osteoporosis' OR 'age-related osteoporoses' OR 
'osteoporoses, age-related' 
AND 
‘Prostate cancer’/exp OR “Prostate Neoplasms” OR “Prostate Neoplasm” OR “Prostatic 
Neoplasm” OR “Prostate Cancer” OR “Prostate Cancers” OR “Cancer of the Prostate” OR 
“Prostatic Cancer” OR “Cancer of Prostate” OR “prostate tumor” OR “prostate tumors” OR 
“prostate tumour” OR “prostate tumours” OR “prostate carcinoma” OR “prostate 
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carcinomas” OR “prostatic carcinoma” OR “prostatic carcinomas” OR “carcinoma of the 
prostate” OR “carcinoma of prostate” 
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APPENDIX IV Facts On Osteoporosis Quiz (FOOQ) with Men’s 
Osteoporosis Knowledge Questionnaire (MOKQ) 
Facts on Osteoporosis Quiz 
Osteoporosis refers to weakened bone strength. It is commonly called “brittle bones” 
because this disease increases the risk of bone fractures. 
Completely fill in the circle of the appropriate answer. 
 True False 
Don’t 
Know 
1. Physical activity increases the risk of 
osteoporosis. 
Ⓣ Ⓕ Ⓓ 
2. High impact exercise (weight training) 
improves bone health. 
Ⓣ Ⓕ Ⓓ 
3. Most people gain bone mass after 30 
years of age. 
Ⓣ Ⓕ Ⓓ 
4. Low-weight women have osteoporosis 
more than heavy women. 
Ⓣ Ⓕ Ⓓ 
5. Alcoholism is not linked to the occurrence 
of osteoporosis. 
Ⓣ Ⓕ Ⓓ 
6. The most important time to build bone 
strength is between 9 and 17 years of age. 
Ⓣ Ⓕ Ⓓ 
7. Normally, bone loss speeds up after 
menopause. 
Ⓣ Ⓕ Ⓓ 
8. High caffeine combined with low calcium 
intake increases the risk of osteoporosis. 
Ⓣ Ⓕ Ⓓ 
9. There are many ways to prevent 
osteoporosis. 
Ⓣ Ⓕ Ⓓ 
10. Without preventative measures 20% of 
women older than 50 years will have a 
fracture due to osteoporosis in their 
lifetime. 
Ⓣ Ⓕ Ⓓ 
11. There are treatments for osteoporosis 
after it develops. 
Ⓣ Ⓕ Ⓓ 
12. A lifetime of low intake of calcium and 
vitamin D does not increase the risk of 
osteoporosis. 
Ⓣ Ⓕ Ⓓ 
13. Smoking does not increase the risk of 
osteoporosis. 
Ⓣ Ⓕ Ⓓ 
14. Walking has a great effect on bone health. Ⓣ Ⓕ Ⓓ 
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 True False 
Don’t 
Know 
15. After menopause, women not on estrogen 
need about 1500mg of calcium (for 
example, 5 glasses of milk) daily. 
Ⓣ Ⓕ Ⓓ 
16. Osteoporosis affects men and women. Ⓣ Ⓕ Ⓓ 
17. Early menopause is not a risk factor for 
osteoporosis. 
Ⓣ Ⓕ Ⓓ 
18. Replacing hormones after menopause 
cannot slow down bone loss. 
Ⓣ Ⓕ Ⓓ 
19. Children 9 to 17 years of age get enough 
calcium from one glass of milk each day to 
prevent osteoporosis. 
Ⓣ Ⓕ Ⓓ 
20. Family history of osteoporosis is not a risk 
factor for osteoporosis. 
Ⓣ Ⓕ Ⓓ 
 
 
Men’s Osteoporosis Knowledge Questionnaire 
 True False 
Don’t 
Know 
21. Small frame/low weight men have 
osteoporosis more than larger 
framed/heavier men. 
Ⓣ Ⓕ Ⓓ 
22. Bone loss increases in men after the age 
of 70 years. 
Ⓣ Ⓕ Ⓓ 
23. Without preventative measures 25% of 
men older than 50 years will have a 
fracture because of osteoporosis in their 
lifetime. 
Ⓣ Ⓕ Ⓓ 
24. After the age of 50 years, men need about 
1,200mg of calcium daily. 
Ⓣ Ⓕ Ⓓ 
25. Low testosterone levels are not a risk 
factor for osteoporosis. 
Ⓣ Ⓕ Ⓓ 
26. Hormone treatment for prostate cancer 
decreases the risk of osteoporosis. 
Ⓣ Ⓕ Ⓓ 
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APPENDIX V Osteoporosis Self-Efficacy Scale 
Osteoporosis Self-Efficacy Scale 
We are interested in learning how confident you feel about doing the following activities. 
Everyone has different experiences which will make each person more or less confident in 
doing the following things. Thus, there are no right or wrong answers to this questionnaire. 
It is your opinion that is important. In this questionnaire, EXERCISE means activities such 
as walking, swimming, golfing, biking, aerobic dancing. 
 
Place your "X" anywhere on the answer line that you feel best describes your confidence 
level. 
 
If it were recommended that you do any of the following THIS WEEK, how confident or 
certain would you be that you could: 
 
Begin a new or different exercise program 
 
Not at all  Very   
confident         confident 
 
Change your exercise habits 
 
Not at all  Very   
confident         confident 
 
Put forth the effort required to exercise 
 
Not at all  Very   
confident         confident 
 
Do exercises even if they are difficult 
 
Not at all  Very   
confident         confident 
 
Maintain a regular exercise program 
 
Not at all  Very   
confident         confident 
 
Exercise for the appropriate length of time 
 
Not at all  Very   
confident         confident 
 
Do exercises even if they are tiring 
 
Not at all  Very   
confident         confident  
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Stick to your exercise program 
 
Not at all  Very   
confident         confident 
 
Exercise at least 3 times a week 
 
Not at all  Very   
confident         confident 
 
Do the type of exercise that you are supposed to do 
 
Not at all  Very   
confident         confident 
 
Begin to eat more calcium rich foods 
 
Not at all  Very   
confident         confident 
 
Increase your calcium intake 
 
Not at all  Very   
confident         confident 
 
Consume adequate amount of calcium rich foods 
 
Not at all  Very   
confident         confident 
 
Eat calcium rich foods on a regular basis 
 
Not at all  Very   
confident         confident 
 
Change your diet to include more calcium rich foods 
 
Not at all  Very   
confident         confident 
 
Eat calcium rich foods as often as you are supposed to do 
 
Not at all  Very   
confident         confident 
 
Select appropriate foods to increase your calcium intake 
 
Not at all  Very   
confident         confident  
183 
 
Stick to a diet which gives an adequate amount of calcium 
 
Not at all  Very   
confident         confident 
 
Obtain foods that give an adequate amount of calcium 
 
Not at all  Very   
confident         confident 
 
Remember to eat calcium rich foods 
 
Not at all  Very   
confident         confident 
 
Take calcium supplements if you don’t get enough calcium from your diet 
 
Not at all  Very   
confident         confident 
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APPENDIX VI Osteoporosis Health Belief Scale 
Osteoporosis Health Belief Scale 
(Interviewer: Read the following instructions slowly) 
Osteoporosis is a condition in which the bones become excessively thin (porous) and 
weak so that they are fracture prone (they break easily). 
 
I  am going to ask you some questions about your beliefs about osteoporosis. There are 
no right or wrong answers. Everyone has different experiences which will influence how 
they feel. After I read each statement, tell me if you STRONGLY DISAGREE, DISAGREE, 
are NEUTRAL, AGREE, or STRONGLY AGREE with each statement. 
 
It is important that you answer according to your actual beliefs and not according to how 
you feel you should believe or how you think we want you to believe. We need the 
answers that best explain how you feel. 
 
 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
1. Your chances of getting 
osteoporosis are high. 
 
 
 
 
 
 
 
 
 
 
2. Because of your body build, you 
are more likely to develop 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
3. It is extremely likely that you will 
get osteoporosis. 
 
 
 
 
 
 
 
 
 
 
4. There is a good chance that you 
will get osteoporosis. 
 
 
 
 
 
 
 
 
 
 
5. You are more likely than the 
average person to get 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
6. Your family history makes it more 
likely that you will get 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
7. The thought of having 
osteoporosis scares you. 
 
 
 
 
 
 
 
 
 
 
8. If you had osteoporosis you 
would be crippled. 
 
 
 
 
 
 
 
 
 
 
9. Your feelings about yourself 
would change if you got 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
10. It would be very costly if you got      
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 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
osteoporosis.      
11. When you think about 
osteoporosis you get depressed. 
 
 
 
 
 
 
 
 
 
 
12. It would be very serious if you got 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
13. Regular exercise prevents 
problems that would happen from 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
14. You feel better when you exercise 
to prevent osteoporosis. 
 
 
 
 
 
 
 
 
 
 
15. Regular exercise helps to build 
strong bones. 
 
 
 
 
 
 
 
 
 
 
16. Exercising to prevent 
osteoporosis also improves the 
way your body looks. 
 
 
 
 
 
 
 
 
 
 
17. Regular exercise cuts down the 
chances of broken bones. 
 
 
 
 
 
 
 
 
 
 
18. You feel good about yourself 
when you exercise to prevent 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
For the following questions, when I say "taking in enough calcium" it means taking enough 
calcium by eating calcium rich foods and/or taking calcium supplements. 
19. Taking in enough calcium 
prevents problems from 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
20. You have lots to gain from taking 
in enough calcium to prevent 
osteoporosis. 
 
 
 
 
 
 
 
 
 
 
21. Taking in enough calcium 
prevents painful osteoporosis. 
 
 
 
 
 
 
 
 
 
 
22. You would not worry as much 
about osteoporosis if you took in 
enough calcium. 
 
 
 
 
 
 
 
 
 
 
23. Taking in enough calcium cuts 
down on your chances of broken 
bones. 
 
 
 
 
 
 
 
 
 
 
24. You feel good about yourself 
when you take in enough calcium 
to prevent osteoporosis. 
 
 
 
 
 
 
 
 
 
 
25. You feel like you are not strong 
enough to exercise regularly. 
 
 
 
 
 
 
 
 
 
 
 
26. You have no place where you can 
exercise. 
 
 
 
 
 
 
 
 
 
 
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 Strongly 
Disagree 
Disagree Neutral Agree Strongly 
Agree 
27. Your spouse or family 
discourages you from exercising. 
 
 
 
 
 
 
 
 
 
 
28. Exercising regularly would mean 
starting a new habit which is hard 
for you to do. 
 
 
 
 
 
 
 
 
 
 
29. Exercising regularly makes you 
uncomfortable. 
 
 
 
 
 
 
 
 
 
 
30. Exercising regularly upsets your 
every day routine. 
 
 
 
 
 
 
 
 
 
 
31. Calcium rich foods cost too much.      
32. Calcium rich foods do not agree 
with you. 
 
 
 
 
 
 
 
 
 
 
33. You do not like calcium rich 
foods. 
     
34. Eating calcium rich foods means 
changing your diet which is hard 
to do. 
 
 
 
 
 
 
 
 
 
 
35. In order to eat more calcium rich 
foods you have to give up other 
foods that you like. 
 
 
 
 
 
 
 
 
 
 
36. Calcium rich foods have too much 
cholesterol. 
 
 
 
 
 
 
 
 
 
 
37. You eat a well-balanced diet.      
38. You look for new information 
related to health. 
 
 
 
 
 
 
 
 
 
 
39. Keeping healthy is very important 
for you. 
 
 
 
 
 
 
 
 
 
 
40. You try to discover health 
problems early. 
 
 
 
 
 
 
 
 
 
 
41. You have a regular health check-
up even when you are not sick. 
 
 
 
 
 
 
 
 
 
 
42. You follow recommendations to 
keep you healthy. 
 
 
 
 
 
 
 
 
 
 
 
  
Date:    Participant Name.:    Participant Initials:   
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APPENDIX VII Diet History Form 
Instructions: 
- Think about what you usually eat on a weekly basis. 
- Please note down these foods and drinks with as much detail as possible, inclu. type of food (eg toast with jam), amount of food (use 
cups, teaspoon, tablespoon measures where possible), and how often the food is consumed (eg frequency - 3 out of 7 days in a wk).   
- Count any snacks or meals eaten at least an hour apart as separate eating occasions. 
- To give you an idea of how to fill this booklet in, please see the sample. 
- Key – Tb = Tablespoon; tsp = teaspoon; sl = slice. 
Sample of how to fill in the diet history: 
Prompts  Type and amount Frequency 
Breakfast 
 
2 sl toast - wholemeal 
1 Tb margarine 
2 Tb jam 
1 cup coffee with 20mL full cream milk and 1 tsp sugar 
2 rashers bacon cooked in 1 Tb olive oil 
1 boiled egg 
½ tomato cooked in 1 tsp olive oil 
1 slice (sl) toast 
 
5 days out of 7 (or 5/7) 
5/7 
 
2 days out of 7 (or 2/7) 
2/7 
 
Part 0: Anything consumed before breakfast (please note any differences for weekends) 
How many times a week do you eat something before breakfast? _______________ What time do you usually do this? ___________ 
Prompts  Tick Type and amount Frequency 
Tea / Coffee 
Milk  
Sugar 
   
Toast 
Biscuit 
Other 
Date:    Participant Name.:    Participant Initials:   
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Part 1: Breakfast (please note any differences for weekends) 
How many times a week do you eat breakfast? __________________ What time do you usually eat breakfast? _________________ 
Prompts  Tick Type and amount Frequency 
Breakfast cereal    
Muesli / Oats 
Cereal bars 
Bread / Toast spreads 
eg margarine, butter, 
jam etc. 
Muffins Crumpets 
Croissants 
Pancakes 
Yoghurt 
Fruit Salad 
Protein shakes/powders 
Eggs (boiled scrambled, 
fried, poached,) 
Bacon 
Baked beans 
Sausages 
Hash browns 
Sauce/s 
Oil / Fat 
Other 
 
Drinks: Tea, coffee, juice and others (hot chocolate, fruit juice, smoothie, alcohol) with sugar/sweetener 
 
Type & amount: ______________________________________________________________________ Frequency:_____________ 
 
Type & amount:  ______________________________________________________________________ Frequency:_____________ 
 
Type & amount:  ______________________________________________________________________ Frequency:_____________ 
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Part 2: Morning Tea (please note any differences for weekends)  
How many times a week do you eat morning tea? _______________ What time do you usually eat morning tea? ___________ 
Prompts Tick Type and Amount Frequency  
Tea 
Coffee 
Sugar / 
Sweetener 
Milk 
Juice 
Flavoured milk 
Alcohol 
Smoothie 
Hot Chocolate 
   
Yoghurt 
Fruit 
Cereal bars 
Biscuits 
Cake 
Muffins 
Chocolate 
Other 
 
Date:    Participant Name.:    Participant Initials:   
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Part 3: Lunch (please note any differences for weekends) 
How many times a week do you eat lunch? _______________ What time do you usually eat lunch? ______________________ 
Prompts Tick Type and amount Frequency  
Sandwich  
bread  
fillings eg -  
salad, meat  
cheese  
spreads eg – 
jam, margarine  
sauces eg – 
tomato, mustard, 
mayonnaise 
Salads 
dressing 
ingredients 
Soups 
Hot Meals  
eg spaghetti 
Bolognese, pasta 
Takeaway foods 
pizzas 
pies 
hamburgers 
hot chips 
Other 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***SALT*** 
 
 
Drinks: Tea, coffee, juice, soft drink, cordial, alcohol etc   
Type & amount: _________________________________________________________ Frequency: ______________________ 
 
Type & amount: _________________________________________________________ Frequency:  ______________________ 
Date:    Participant Name.:    Participant Initials:   
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Part 4: Afternoon Tea (please note any differences for weekends) 
How many times a week do you eat afternoon tea? ________________  What time do you usually eat afternoon tea?   
Prompts Tick Type and amount Frequency 
Tea 
Coffee 
Sugar / 
Sweetener 
Milk 
Juice 
Flavoured milk 
Alcohol 
Smoothie 
Hot Chocolate 
Yoghurt 
Fruit 
Biscuits 
Cake 
Cereal bars 
Muffins 
Chocolate 
Other 
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Part 5: Dinner (please note any differences for weekends) 
How many times a week do you eat dinner? ____________________ What time do you usually eat dinner? _________________ 
Prompts  Tick Type and amount & cooking method Frequency 
Meat – grilled,  
roasted, crumbed, 
fried 
Chicken 
Fish 
Pasta 
Spaghetti Bol 
Lasagne  
Stir fries 
Casseroles 
Stews 
Soups 
Quiche 
Accompaniments 
Potato 
Vegetables  
Mash 
Wedges 
Rice 
Cous cous 
Salads 
Potato chips 
Gravies 
Sauce/s 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***SALT*** 
 
Drinks: Tea, coffee, alcohol, juice, soft drink, cordial, etc   
 
Type: ___________________________________________________________________ Frequency:_______________________ 
 
Type: ___________________________________________________________________ Frequency:_______________________ 
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Desserts eaten directly after dinner 
How many times a week do you eat dessert? __________________________ What time do you usually eat this? ___________ 
Prompts  Tick Type & amount Frequency  
Ice cream 
Fruit 
Pies 
Crumbles 
Cake 
Pudding 
Lamingtons 
Cookies 
Biscuits 
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Part 6: Takeaway/Restaurant Meals/ Eating Out (please note any differences for weekends) 
How many times a week do you eat takeaway? __________________________ What time do you usually eat this? ___________ 
Prompts  Tick Type and amount Frequency  
McDonald’s 
burger 
fries 
shake/drink 
Kentucky Fried Chicken 
fried chicken 
nuggets 
fries/chips 
Pizza 
pan 
thin-based 
toppings 
soft drink 
Asian food 
Chinese 
Japanese 
Thai 
Vietnamese 
Fish and chips 
battered or fried 
grilled 
potato scallops 
fries/chips 
Other  
soft drink 
Indian food 
Italian food 
Mexican food 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
***SALT*** 
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Part 7: Evening Snack Foods (please note any differences for weekends) 
How many times a week do you eat an evening snack? __________________________ What time do you usually eat this?______ 
Prompts Tick Type and amount Frequency  
Tea 
Coffee 
Sugar/ Sweetener 
Milk 
Juice 
Flavoured milk 
Smoothie 
Alcohol 
Yoghurt 
Fruit 
Biscuits 
Cake 
Cereal bars 
Muffins 
Chocolate 
Desserts 
mentioned above 
but eaten at least 
an hour after 
dinner. 
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Part 8: Food frequency checklist (only tick if accounted for) 
Type of food Serving size Frequency 
Milk (brand and fat %)   
Flavoured milk (Milo…)   
Fruit   
Fruit Juice   
Soft drinks/cordials/sports drinks   
Alcohol   
Yoghurt   
Cheese   
Ice creams   
Crispbreads/crackers   
Biscuits   
Cakes/scones   
Chocolate   
Chips   
Lollies   
Coffee/Lattés   
Cream   
Eggs   
Fish (type)   
Nuts (almonds, brazil nuts …)   
Tofu   
Beans/Pulses/Legumes   
Canned fish (with or without bones)   
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197 
 
Part 9: Food Preparation Practices 
 
9.1 Butter/Margarine How much would you have in a day or a week?__________________________________ 
 
What type do you usually use? (please circle) 
a)  Butter      d) margarine – regular fat 
b)  Dairy Blend – regular fat   e) margarine – reduced fat 
c)  Dairy Blend – reduced fat  
 
 
9.2 Oil/Fat in Cooking How much would you have in a day or a week?__________________________________ 
 
What type of oil/fat do you use in cooking? (please circle all that you use) 
a)  Butter        
b)  Dairy blend       
c)  Margarine    
d)  Lard or dripping   
e)  Olive oil  
f)  Canola oil   
g)  Other vegetable oil ____________________________________________ 
 
 
9.3 Fat on Meats/Chicken How much would you have in a day or a week?__________________________________ 
 
How much fat is trimmed from meat before cooking/eating? (please circle) 
a)  None 
b)  25% 
c)  50% 
d)  75% 
e)  All 
f)  Other, please specify:_____________________________ 
 
How much skin do you eat on chicken?  (please circle) 
a)  None 
b)  25% 
c)  50% 
d)  75% 
e)  All 
f)  Other, please specify:_____________________________ 
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Appendix VIII Examples of food groups (major, sub-major, and 
minor) used in the Australian Health Survey 
Table A 2 Examples of minor food groups included in the major and sub-major food 
groups used in the Australian Health Survey. 
Major food group Sub-major food groups Minor food groups and/or 
examples 
Non-alcoholic 
beverages 
Tea  Tea (caffeinated or 
decaffeinated); herbal tea 
Coffee and coffee substitutes  Coffee (caffeinated or 
decaffeinated), coffee 
substitutes 
Fruit and vegetable juices, and drinks  Fruit and vegetable juice (fresh 
of commercially prepared); fruit 
drinks 
Cordials Made from concentrate (incl. 
artificially sweetened) 
Soft drinks, and flavoured mineral waters Cola, non-cola and flavoured 
mineral waters (incl. intense 
sweetened) 
Other beverage flavourings and prepared 
beverages 
Fortified and unfortified 
beverages flavourings 
(including prepared with water 
or milk); breakfast cereal 
beverages 
Cereals and cereal 
products  
Flours and other cereal grains and starches  Grains, rice and cereal flours 
and starches 
Regular breads, and bread rolls 
(plain/unfilled/untopped varieties)  
Wheat based and non-wheat 
based breads (incl. gluten free) 
English-style muffins, flat breads, and 
savoury and sweet breads  
Sweet (filled or unfilled) and 
savoury breads 
Pasta and pasta products (without sauce) Wheat and non-wheat based 
pasta and noodles; filled pasta 
Breakfast cereals, ready to eat Sweetened and unsweetened 
breakfast cereals (wheat based 
and non-wheat based)  
Breakfast cereals, hot porridge style Porridge style (from oats or 
other cereals) 
Cereal based 
products and 
dishes 
Sweet biscuits Plain, filled, coated, uncoated 
and all flavours sweet biscuits 
Savoury biscuits Wheat-based and non-wheat 
based varieties 
Cakes, muffins, scones, cake-type desserts  Scones; cakes; cake mixes; 
cake-type desserts; slices; and 
other desserts containing 
cereals. 
Pastries  Filled or unfilled, sweet or 
savoury (incl. pies, rolls, 
quiches) 
Mixed dishes where cereal is the major Pizza; sandwiches; burgers; 
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ingredient  tortilla-based dishes; savoury 
pasta/noodles/rice dishes; 
dumplings; sushi  
Batter-based products  Pancakes; waffles; doughnuts 
Fats and oils  Butters Butter 
Dairy blends Regular or reduced fat varieties 
Margarine and table spreads Polyunsaturated, 
monounsaturated, cooking 
margarine (incl. with added 
phytosterols) 
Plant oils Polyunsaturated, 
monounsaturated and blended 
varieties 
Fish and seafood 
products and 
dishes  
Fin fish (excluding commercially sterile)  Fresh or smoked (flathead, 
snapper, salmon) 
Crustacea and molluscs (excluding 
commercially sterile)  
Prawn; octopus; scallop; squid 
Packed (commercially sterile) fish and 
seafood  
Fish patty; canned fish (incl. 
flavoured) 
Fish and seafood products (homemade and 
takeaway) 
All seafood battered or 
crumbed 
Mixed dishes with fish or seafood as the 
major component  
 
Fruit products and 
dishes  
Pome fruit  Apples and pears 
Berry fruit  All berry fruits 
Citrus fruit  Orange; lemons; and other 
citrus fruits 
Stone fruit  Peaches; nectarines; and other 
stone fruits 
Tropical and subtropical fruit  Bananas; pineapple; and other 
tropical fruits 
Other fruit  Grapes 
Mixtures of two or more groups of fruit  Fresh or canned 
Dried fruit, preserved fruit   
Egg products and 
dishes  
Eggs  Eggs (incl. fortified) from 
chicken or other 
Dishes where egg is the major ingredient  Sweet or savoury dishes 
(soufflé) 
Meat, poultry and 
game products and 
dishes  
Beef, sheep and pork, unprocessed Beef; lamb; mutton; pork; veal 
Poultry and feathered game  Chicken and other poultry 
Sausages, frankfurts and saveloys  Sausages 
Processed meat  Bacon; ham; salami; dried 
meats 
Mixed dishes where beef, sheep, pork or 
mammalian game is the major component 
Meat dishes with gravy, 
tomato-based sauce (incl. with 
added pasta or rice and/or 
vegetables); crumbed or 
battered or loaf meat dishes 
Mixed dishes where poultry or feathered 
game is the major component  
Poultry dishes with gravy, 
tomato-based sauce (incl. with 
added pasta or rice and/or 
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vegetables); crumbed or 
battered or loaf poultry dishes 
Milk products and 
dishes  
Dairy milk (cow, sheep and goat) Full, reduced or non-fat milk; 
powdered, evaporated milk; 
and non-bovine milk 
Yoghurt  Flavoured or unflavoured 
yoghurt; yoghurt-based drinks 
Cream  Regular or increased fat; sour 
cream; cream substitutes 
Cheese  Hard, unripened (incl. cream 
and cottage cheese), ripened 
(incl. camembert, brie) and 
processed cheese 
Frozen milk products  Ice cream; frozen yoghurts 
Custards  
Other dishes where milk or a milk product is 
the major component 
Dairy desserts; and milk, cream 
or cheese-based desserts 
Flavoured milks  and milkshakes Coffee, fruit and other flavours 
milk-based drinks 
Dairy and meat 
substitutes 
Dairy milk substitutes, unflavoured Soy-based, cereal-based and 
nut-based milk substitutes 
drinks 
Soy-based yoghurts  
Soup  Soup, homemade from basic ingredients Vegetable only or with meats 
Canned condensed soup (unprepared) Vegetable only or with meats 
Soup, commercially sterile, prepared from 
condensed or sold ready to heat 
Vegetable only or with meats 
Seed and nut 
products and 
dishes  
Seeds and seed products  Sunflower seeds (raw, roasted, 
salted and unsalted) 
Nuts and nut products  Peanuts; coconuts 
Savoury sauces 
and condiments  
Gravies and savoury sauces  Gravy (prepared and dry), 
tomato-based and dairy-based 
sauces (homemade or 
commercial) 
Pickles, chutneys and relishes  Fruit or vegetable based 
pickles and chutneys 
Salad dressings  Mayonnaise; cream-style 
dressing; vinegar; French or 
Italian dressings 
Dips Dairy-based, vegetable-based 
or legume-based 
Vegetable products 
and dishes  
Potatoes   
Cabbage, cauliflower and similar brassica 
vegetables  
 
Carrot and similar root vegetables   
Leaf and stalk vegetables  Artichoke; asparagus, Incl. 
herbs and seaweed 
Peas and beans  Incl. sprouts 
Tomato and tomato products   
Other fruiting vegetables  Pumpkin, squash, mushroom, 
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sweetcorn 
Other vegetables and vegetable 
combinations  
Incl. onion, leek, garlic 
Dishes where vegetable is the major 
component  
Salads (with to without added 
meats/eggs); stuffed or fried 
vegetables 
Legume and pulse 
products and 
dishes  
Mature legumes and pulses  Bean (red kidney; broad) raw 
or cooked 
Mature legume and pulse products and 
dishes  
Casserole dish with legumes 
and pulses 
Snack foods  Potato snacks  Potato crisps 
Corn snacks  Corn chips and popcorn 
Other snacks  Extruded snacks (pappadam, 
noodle snacks) 
Sugar products and 
dishes  
Sugar, honey and syrups   
Jam and lemon spreads, chocolate 
spreads, sauces  
 
Dishes and products other than 
confectionery where sugar is the major 
component  
Sugar-based desserts; gelato 
and sorbets; frosting 
Confectionery and 
cereal/nut/fruit/seed 
bars  
Chocolate and chocolate-based 
confectionery  
Plain; with nuts and other 
fillings; carob-based 
Fruit, nut and seed-bars   
Muesli or cereal style bars With or without fruits; with or 
without fruit paste or yoghurt 
topping 
Other confectionery  Lollies (incl. intense 
sweetened); chewing gum 
Alcoholic 
beverages  
Beers   
Wines  Red; white or fortified wines 
Spirits   
Cider and perry  
Special dietary 
foods  
Formula dietary foods  Meal replacement; sports 
protein powders; 
supplementary and medical 
beverages (dry or prepared) 
Miscellaneous  Yeast, and yeast vegetable or meat 
extracts  
Vegemite 
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Appendix IX Average daily intake of major food groups 
Table A 3 Average daily weights of major food groups (ordered by weight) 
consumed by men with prostate cancer in comparison with elderly men from the 
Australian Health Survey. 
 Weight consumed by 
men with prostate 
cancer (g/day) 
Weight consumed by 
elderly Australian men 
(g/day) 
P values 
Non-alcoholic beverages 875 (0 - 2557) 1250 0.003 
Vegetable products and dishes  303 (73 - 553) 175 < 0.001 
Milk products and dishes  225 (0 -841) 203 0.49 
Fruit products and dishes  215 (0 - 848) 214 0.23 
Cereals and cereal products  151 (30 - 321) 140 0.20 
Alcoholic beverages  107 (0 - 1997) 379 < 0.001 
Meat, poultry and game products 
and dishes  
106 (2 - 22) 150 0.007 
Cereal based products and dishes 47 (0 - 37) 105 0.002 
Fish and seafood products and 
dishes  
23 (0 – 129) 130 < 0.001 
Egg products and dishes  19 (0 - 102) 88 < 0.001 
Savoury sauces and condiments  19 (0 - 89) 21 0.80 
Confectionery and 
cereal/nut/fruit/seed bars  
6 (0 - 124) 23 0.002 
Fats and oils  5 (0 - 85) 10 0.002 
Seed and nut products and dishes  4 (0 - 164) 26 0.009 
Sugar products and dishes  1 (0 - 120) 17 < 0.001 
Dairy & meat substitutes 0 (0 - 534) 155 < 0.001 
Soup  0 (0 - 145) 309 < 0.001 
Legume and pulse products and 
dishes  
0 (0 - 100) 161 < 0.001 
Snack foods  0 (0 - 57) 18 < 0.001 
Special dietary foods  0 (0 - 14) - - 
Miscellaneous  < 1 (0 - 29) < 1 0.52 
Weight of food group consumed by men with prostate cancer presented as median (range), and for elderly 
Australian men presented as median. 
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